Pharmacy Enterprise Customization System (PECS)

User Guide



Version 2.2

March 2013

Department of Veterans Affairs Office of Information and Technology (OIT) Product Development

Document Control Section

Revision History

Date	Description of Change	Author Information
02/07/2013	Updated graphic on Page 53 to ensure caption remained with image; Updated TOC	B Holihan
02/07/2013	Updated Title Page to reflect Release month Updated Revision History order Updated Footer to include version number, release date.	B Holihan
06/26/2012	Updated title page to reflect the update month	Marella Colyvas
06/13/2012	Updated to address Sonia T, Joanne C comments.	B Holihan
06/12/2012	Updated to address Radu C comments of 06/11/12	B Holihan
05/31/2012	Entered nearly all of Joanne's comments re: FDB Comparison Reports.	Marella Colyvas
05/23/2012	Updated TOC; changed some heading levels; replaced screen shots for Requestor & Approver home pages; adjusted pagination and section breaks	Marella Colyvas
05/09/2012	Updated Quick Drug Pair selection.	B Holihan
05/08/2012	Added screen capture to Null Drug Pair section; Reduced size of Custom Update samples	B Holihan
5/07/2012	Added sentence at the end of the Null Drug Pair write-up to contain info about the date from the FDB update.	Marella Colyvas
05/04/2012	Added more information to Release Manager. Still needs better explanations of screen captures; added Null Drug Pairs write-up to Administrator Role (Julie's); added write-up on Quick Drug Pair Selection; added information about CCR5122 in User Guide in the Notification of Drug Pairs Needing Action for an Approved Drug-Drug Interaction section.	Marella Colyvas
5/04/2012	Clarified the "Also note: If you wish to put a Drug-Drug Interaction (DDI)" statement at the end of the Notification of Drug Pairs Needing Action for the Approved Drug-Drug Interaction section.	Joanne Callahan
05/03/2012	Added explanation of Custom Update File in Release Manager section; updated definition of Administrator on pages 2 and 62 (added fact they can initiate null drug pair removal). Updated write-up on Quick Drug Pair Selection	Marella Colyvas
4/27/2012	Added PBM feedback to Release Manager write-up; added short write-up on Quick Drug Pair Selection	Marella Colyvas
4/12/2012	More changes to Drug Pair Notification; added Release Manager write-up	Marella Colyvas
4/11/2012	More changes to Drug Pair Notification	Marella Colyvas
4/9/2012	Renamed the Title of the Drug Pair Notification Section (was "Working with Drug Pairs")	Marella Colyvas

Date	Description of Change	Author Information
4/6/2012	Edited and obtained new screen shots for Multiple DDI records to one FDB; attempted to write up Release Manager but need more information.	Marella Colyvas
3/23/2012	Drafted Drug Pair Notification	Marella Colyvas
3/15/2012	Cleaned up Record Locking; made edits from Sonia on Creating Multiple Custom DDIs to One FDB Record and Prevention of Duplicate DP on Single Record	Marella Colyvas
3/13/2012	Added information on Creating Multiple Custom DDIs to One FDB Record and Prevention of Duplicate DP on Single Record	Marella Colyvas
03/12/2012	Added data on Forward/Reverse Monographs and Multiple DDIs to one FDB; included Lynn Teague's changes	Marella Colyvas
02/17/2012	Completed Record Locking	Marella Colyvas
02/16/2012	Made a few additions to Record Locking	Marella Colyvas
02/10/2012	Made a few changes to the text on Edit panels	Marella Colyvas
1/26/2012	Created text for Not Editing Single Drug Pair window; added some screen shots; still have to add Sonia's changes.	Marella Colyvas
1/23/2012	Beginning of changes for PECS 2.2. Added new Read-Only screens for each concept; eliminated edit mode screen shots for now;	Marella Colyvas
11/05/11	Edited information from customer on Action Statuses, and added information on Saved Queries	Marella Colyvas
10/13/11	Added information on potential Easy Search/PECS Record discrepancy; changed a screen shot	Marella Colyvas, Wendy Cobb
10/7/11	Reviewed and provided feedback / comments	Hussain Kedwaii
10/6/2011	Added changes for 2.1	Marella Colyvas, Kristen Kriwox, Wendy Cobb
04/12/2011	Added edits from CPS.	Marella Colyvas
12/08/2010 CR 3520	Began changes for PECS v2.0, sprint 1, Professional Monograph and Historical Records	Marella Colyvas
11/18/2010 CR 3391	Edited changes requested by customer analyst prior to second (final) review by EIE	Marella Colyvas
10/12/2010 CR 3391	Updated elements found in Enterprise Infrastructure Engineering (EIE) review for Operational Readiness Testing (ORT)	Marella Colyvas
4/14/2010	Baseline	Russell Chachula & Marella Colyvas

Table of Contents

Pharmacy Enterprise Customization System (PECS)	
Overview	
Purpose	
PECS Advantage	
Security Roles	
Identity Management	
Process Flow	
Transaction Flow	
Customization Information	
Drug-Drug Interaction and Professional Monograph	
Duplicate Therapy	8
Dose Range	8
PECS Button List	8
Application Screens	10
Login	10
Instructions	10
Authentication Explanation	10
Home Page	11
Drug Pair Lookup Page	14
Advanced Query/Customization Page	18
Accessing the Advanced Query/Customization Page	18
The Query Builder Panel	19
How to Build a Query	19
And/Or Usage Example	22
Query Specifics	22
Save a Query	22
Run a Saved Query	23
Delete a Saved Query	24
Rename a Saved Query	24
Sort Query Results	25
Export Query Results	26

Query Errors	26
Special Dose Range Query Button	27
Panels You Can Modify	29
Single Drug Pair Page Modification Not Allowed	33
Notification of Drug Pairs Needing Action for an Approved Drug-Drug Interaction	35
Record Locking Feature	41
Creating Multiple VA Custom Drug-Drug Interactions to One FDB Reco	ord 47
Create Multiple DDIs per One FDB Record	
Prevention of Two Users Adding Identical Drug Pairs to the Same DDI	50
Quick Selection of Drug Pairs from the Selection List	52
Forward and Reverse Professional Monograph	53
Easy Search Query Page	54
Potential Discrepancy Between Easy Search Results and PECS Record	ds 57
Easy Search Dose Range	60
User Roles	61
Requestor	61
Approver	61
Release Manager Role	61
Update Files Explained	62
Administrator Role	65
Customize Settings	65
Approver User Settings	68
Null Drug Pair Removal Process	70
Sample Modification Scenarios	72
Duplicate Therapy Modification	72
Process Steps	72
Duplicate Therapy Approval	74
Process Steps	74
Drug Interaction Research	74
Process Steps for Severity Check, Case 1	74
Drug Interaction Severity Change	74

iv

March 2013

Process Steps for Editing Case 1	75
Drug Interaction Severity Change	76
Process Steps for Editing Case 2	76
Remove Drug Pair from Interaction	77
Process Steps	77
Create Professional Monograph	79
Process Steps	79
Reports	81
Customization Reports	
FDB Custom Dose Range Report	
FDB Custom Drug-Drug Interaction Report	
FDB Custom Duplicate Therapy Report	
FDB Custom Professional Monograph Report	
Deleted Monograph Customization Report	82
Null Drug Pairs Customization Report	82
FDB Comparison Reports	83
Structure of the FDB Comparison Report	
Drug-Drug Interaction/Drug Pair Report	
Duplicate Therapy Report	
Dose Range Report	

Pharmacy Enterprise Customization System (PECS) Overview

Purpose

The Pharmacy Enterprise Customization System (PECS) is a Graphical User Interface (GUI) application that currently allows users to customize the contents of the following five business concepts:

- Drug-Drug Interaction
- Drug Pair
- Duplicate Therapy
- Dose Range
- Professional Monograph

The purpose of this user guide is to provide a general overview of the PECS application, as well as more detailed working information. It also provides reference material and task-based instructions for entering and approving Drug-Drug Interaction, Drug Pair, Duplicate Therapy, Dose Range, or Professional Monograph Customization Requests.

PECS Advantage

- All customizations will be performed at the national level to provide consistent order checks between facilities
- Use of First DataBank for drug interaction, duplicate therapy, and dosing data.
- More specificity in drug interaction order checks with the ability to include or exclude dose routes.
- More specificity in duplicate therapy order checks with FDB data.
- Weekly FDB updates with monthly customization updates.
- More frequent customization updates when needed.

Security Roles

The PECS application is accessible only by users signed directly into the VA network, or by users signed into the VA network via the RESCUE client. User authentication into the VA network is a precondition of PECS application access. Application authentication and authorization will be controlled by the VA Kernel Authentication and Authorization for J2EE (KAAJEE) security Application Programming Interface (API).

In order to log in to the application, each user must have a valid VistA account at a local or national facility, since KAAJEE delegates user authentication to VistA. At the application's login screen, users are prompted for their access and verify codes and will be allowed to select the VistA institution which issued their credentials*

Identity Management

Authorization is handled through the use of specific VistA security keys. PECS doesn't assign individual permissions to users. Instead, it defines a number of roles for its users (requestor, approver, release manager and administrator) and associates a set of permissions with each of them. These roles are mapped to security keys as follows.

PECS Role	VistA Security Key
Requestor	PSS_CUSTOM_TABLES_REQUESTOR
Approver	PSS_CUSTOM_TABLES_APPROVER
Release Manager	PSS_CUSTOM_TABLES_REL_MAN
Administrator	PSS_CUSTOM_TABLES_ADMIN

Depending on the permissions needed by a user, the appropriate role is determined and the corresponding key assigned to their account. The user provisioning process is part of the VistA system and is thus not documented here. Password changes, account activation/inactivation, etc., must be performed through VistA. Refer to the appropriate documentation for details on user account management

Following is a list of roles available within the application, and a description of what each role can do:

Requestor: Create a customization request, modify their own requests, and run, save, and export queries.

<u>Approver</u>: Create, review, approve, modify, delete or reject customization requests; run, save, and export queries, and run reports. An approver can review but cannot approve their own requests.

<u>Release Manager</u>: Can run queries and view detail records. A Release Manager can generate an incremental or full Custom Update file, or download an existing Custom Update.

<u>Administrator</u>: Can run queries and view detail records. In addition, Administrators can modify field settings for each concept type, add or delete users to/from the approver role, and initiate the process to remove drug pairs that contain a null routed generic drug.

Process Flow

Here is a process diagram depicting the process life cycle. It depicts the high-level business process from the point at which a new interaction is created to when a file is available to be loaded to production.






Figure 1 shows the life cycle of a customization change from the Requestor entry to the point the record is ready to be sent to the production FDB Drug Information Framework (DIF) custom table. The updates and changes are made and maintained in a Staging Table. Records are not extracted until the Release Manager submits approved changes. Records are then formatted and placed in a directory where they will be updated to production. The process that updates these records uses software named DATUP.

Transaction Flow

The diagram below depicts the Action Statuses of a record's transition from creation to approval.




Figure 2: Action Statuses

Action Statuses

This list displays the different Action Statuses a VA customized record may go through as it steps through the approval workflow within PECS. Note that only seven of the following eleven states are displayed in the user interface - in other words, some of this information is "behind-the-scenes." It is included here as information only.

<u>New</u> - A new customization request has been created. If a user has the appropriate authority, they may modify the request (Modified) to be completed at a later point. Then, if they have the proper authority, they may submit the request as reviewed (Reviewed).

<u>Modified</u> - A user can make changes to their own New requests. The record will remain Modified until a user with the proper authority (Approver role) reviews the request and submits the request as Reviewed.

<u>Modified After Approve</u> - (displays as Modified) A user with the proper authority has requested a change in the Approved customization that requires another approval process.

<u>Modified After Delete</u> - (*displays as Modified*) A user with the proper authority has requested the deleted record be considered again for Approval with or without modifications. This requires another approval process.

<u>**Reviewed</u>** - This is the first stage of approval. A user with the proper authority (Approver role) reviews the new or modified customization request and submits it as Reviewed. The approver may also reject or modify the request. Note that an approver can review their own requests but not approve them.</u>

<u>Reviewed After Approve</u> - (*displays as Reviewed*) Modifications were made to an approved record. A user with the proper authority (Approver role) reviews the request and submits it as Reviewed. The Approver may also reject the request, in which case the record returns to the Approved state, or they may modify it.

<u>Reviewed After Delete</u> (displays as Reviewed)- Modifications were made to a deleted record. A user with the proper authority (Approver role) reviews the request and submits it as Reviewed. The Approver may also reject the request, in which case the record returns to Deleted state, or they may modify it.

<u>**Rejected</u>** - The customization request is in a Rejected state. At this point the user may make changes, resubmit, or keep the transaction in the rejected state. All records that are rejected or not approved will remain in that state and will be available to the user for any future changes.</u>

<u>Approved</u> – This is the second stage of approval. A user with the proper authority (Approver role) who did *not* submit the request as Reviewed will review the record and may approve, reject, or modify the request.

<u>**Delete**</u> <u>**Reviewed**</u>- The record remains active but a user with the proper authority (Approver role) has requested deletion of an existing approved customization.

<u>**Deleted**</u> – A user in the Approver role who did *not* submit the request for Deletion may delete the customization. If an Approver confirms the deletion, the record will remain active for potential future modifications.


Customization Information

Here is information on the basic types of customization that can be done with PECS.

Drug-Drug Interaction and Professional Monograph

This diagram displays how a drug interaction is tied to drug pairs and professional monographs:

Drug-Drug Interaction Relationship



Drug interaction now between routed generics within an interaction description that is also associated with a monograph.

Figure 3: Drug-Drug Interaction Relationship

FDB Drug-Drug interaction severity levels:

1 = Contraindicated

- 2 =Severe
- 3 = Moderate
- 9 = Undetermined severity Alternate therapy

Within the VA system, an FDB or VA Custom drug-drug interaction of severity level 1 will return a Critical order check and severity level 2 will return a Significant order check. Severity levels 3 and 9 will not return an order check.

Types of drug-drug interaction customizations include:

- Change in severity level
- Add or remove drug pairs
- Create drug interactions not found in FDB

Note: Due to the millions of possible drug pair combinations, you must be very specific on which two products are involved when reporting problems with the system.

Duplicate Therapy

The Duplicate Therapy concept allows you to specify the maximum number (0, 1, or 2) of duplicate therapy matches that can occur within a therapeutic class without creating an order check. A '0' duplicate allowance means only 1 medication from that therapeutic class can be on the patient profile without getting an order check (zero duplication). If a second drug from that class is added the provider gets the order check. If the allowance is '1', two drugs can be on the patient profile at once, the 3rd drug added would get the check (one duplication), etc.

The only type of Duplicate Therapy customization allowed is to increase or lower the duplicate therapy allowance for a therapeutic category.

Dose Range

Here is information about the Dose Range function:

- Dosing is based on the GCN Sequence Number (GCNSEQNO), a random number specific to all drug products with the same generic ingredient(s), route of administration, drug strength(s) and dosage form.
- Dosing is age-specific for most products. FDB has dosing for neonatal, infant, adolescent, adult, and geriatric. All ages are by days, for example, 18 years x 365= 6570 days.
- FDB also has indication-specific dosing, and dosing type. Examples of dosing type are loading, maintenance, single, initial.
- A typical product may have 30 or more dosing records when all variables are taken into consideration.
- The initial implementation of dosing order checks within VistA looks at the maximum single dose and daily dose range order checks using a common indicator.

PECS Button List

Here is a list of the buttons in PECS and their meanings. This list is alphabetical, not by window or function, as the buttons can display on many different windows and it depends upon user authority whether a button is visible.

- Active -- Displayed on the Query Result page. Opens an existing in-process request.
- Add Default DRC Query Found on the Dose Range Advanced Query page. When selected, Concept Type Equal to 6 AND Age High in Days Greater than or Equal to 6570 is added to the query builder.
- And Adds query criteria to a query that is being created for execution. This creates an "AND" clause with any other existing criteria.
- Approve Moves the request from the Reviewed status into the Approved status.
- **Cancel** Returns the user to the Home index page without saving any changes to the database for the request.
- Clear Query Clears the Query Builder form of any previously entered data.
- Customize Displayed on some pages to create a VA customization from an FDB record.

- Edit Displays on the detail pages of all concepts where the record is in Read-only mode. This button allows users to edit a particular detail page if it is not already in use by another user.
- Delete Moves the request from the Delete Reviewed status into the Deleted status.
- **Drug Pairs** Retrieves a list of possible drug pairs from the FDB DIF database that are eligible to be added to the VA Custom Drug Interaction, and lists any existing custom drug pairs that the Drug Interaction may have.
- **Export** Creates a file of the results of an executed query that can be downloaded and opened in the Microsoft Excel program.
- **Historical** Displayed on the query result page. Opens a historic record as read-only.
- **Modify** Moves a request from New, Modified, Rejected, Approved or Deleted into the Modified status. Writes any changes made to the request to the database, and leaves the status in the Modified status.
- **Open** Displayed on the query result page. Opens an FDB record.
- **Open Blank Form** Found under the FDB results when querying Both VA and FDB records in Drug-Drug Interaction, Professional Monograph or Dose Range. Navigates the user to a blank form.
- **Or** Adds query criteria to a query that is being created for execution. This will create an "OR" clause with any other existing criteria.
- **Print Page** Calls the browser's print page functionality.
- **Query** Allows the user to submit a query to the system. If there are records that match the query parameters, they will be displayed in the results table.
- **Reject** Moves the request from the New, Modified, or Reviewed status into the Rejected status. When records that are modified after approval or deletion are rejected, the record returns to the approved or deleted state.
- **Save Query** Allows the user to save the executed query with a user-friendly name, available to be executed in the future.
- Submit As Reviewed Moves the request from the New, Modified or Rejected status into the Reviewed status.
- **Submit For Delete** Moves the request from the Approved status into the Delete Reviewed status.

Application Screens

Login

Instructions

The purpose of this screen is to provide an authorized user access to the system. Each user needs to select their site, then enter their current VistA access and verify codes, which are their assigned/designated "user IDs" and passwords.

Note that authorization is handled through the use of specific VistA security keys. PECS doesn't assign individual permissions to users. Instead, it defines a number of roles for its users (requestor, approver, release manager and administrator) and associates a set of permissions with each of them. To see the list, refer to <u>Identity Management</u> on page <u>2</u>.

Authentication Explanation

Application authentication and authorization is controlled by KAAJEE. Refer to VistA documentation for details on the user account maintenance.

If the response from the authentication request is successful via the KAAJEE API, KAAJEE returns a user profile object, which is used by the application to determine the user's role and permissions. On successful login, the system transfers the user to the Home page of the application.

Here is the login window:

			-		
System Announcements:					
U.S. Government Computer System	ı				
limited personal use in accordance v	vith policy. Information from these systems		systems and networks funded by	explicitly authorized for official business and the government. All access or use constitutes	
		ensitive information protected by various Fe ccess to the data and records is on a need-		y Act, 5 U.S.C. Section 552a, and veterans'	
		of these terms and constitutes unconditiona ng, tracking, disclosing to authorized person			
		formation on this system, (2) modify this sys ts are subject to action that may result in cri		n, (4) accrue resources for unauthorized use lties.	
		Login: PECS			
	Healthe Vis Vis.A	Access Code:			
N	\circledast Sort by Station Number *	○ Sort by Station Name *			
45	Institution: SAN FRANCISCO VAN	MC (662)	~	*	
		Login			
	*:	Persistent Cookie Used (more information)).		
					<u> </u>

Figure 4: KAAJEE Login Screen

Home Page

The home page is the first page you see after logging in to the application. It provides information about when the last update to the First DataBank (FDB) database tables occurred and also when the last customization update file was created. The main purpose of the home page is to provide a count of the number of active customizations that you can access.

The Home page is organized into six panels. The display of a panel to the user is dependent upon the role of the user. Users in the "Requestor" role are shown only the "My Request History" panel. Users in the "Approver" role are shown all available panels.

The counts are organized by the action (Review/Approve/Delete) the user with the Approver role is assigned to perform on the customization records for each concept type (Drug-Drug Interaction, Professional Monograph, Duplicate Therapy, Dose Range, and Approved Drug-Drug Interactions with Pending Drug Pairs). The "Unassigned Requests" panel contains counts of records in the New, Modified, Reviewed, or Delete Reviewed status that are not assigned to a specific Approver, but need action taken to complete the request. Additionally, the Home page provides details on the status of any active customization records that the user may have entered into the system (My Request History). This allows the user to track their own requests through the approval process.

If you click the link to the number of records under each panel (if more than '0'), you are taken to the Advanced Query/Customization tab with the "Build a Query" panel displaying the fields, filters, and values that were queried against, in order to obtain the results showing in the "VA Table Results" panel. The 'VA Table Results' panel contains the active records that match the items for the count displayed on the Home page.

The bottom of the home page (and every page) also contains links to the various areas of the system, which are also accessible via the tabs at the top of every page.

The following window displays an example of what a user with the "Approver" role may see on the home page:

ose Range	<u>51</u>	<u>38</u>	<u>5</u>	<u>49</u>	<u>5</u>	<u>9</u>	157		
uplicate Therapy	<u>30</u>	<u>18</u>	<u>21</u>	<u>10</u>	5	9	93		
rofessional Monograph	<u>14</u>	<u>17</u>	<u>11</u>	<u>33</u>	<u>6</u>	<u>11</u>	92		
rug-Drug Interaction	<u>147</u>	<u>58</u>	<u>27</u>	<u>660</u>	<u>94</u>	<u>46</u>	1032		
oncept	New	Modified	Reviewed	Approved	Rejected	Deleted	All		
ll Requests									
ith Pending Drug Pairs								 	
proved Drug Drug Interactions	<u>14</u>								
ose Range	<u>87</u>								
uplicate Therapy	<u>58</u>								
rofessional Monograph	<u>29</u>								
rug-Drug Interaction	<u>205</u>								
oncept	Unassigned								
nassigned Requests									
ith Pending Drug Pairs	٤							 	
oproved Drug Drug Interactions	2								
ose Range	0								
uplicate Therapy	0								
ofessional Monograph	1								
rug-Drug Interaction	0								
oncept	Deletion								
	Awaiting								
ly Assigned Requests for Del	etion							 	
pproved Drug Drug Interactions ith Pending Drug Pairs	0								
ose Range	0								
uplicate Therapy	0								
rofessional Monograph	0								
rug-Drug Interaction	0								
oncept	Approval								
	Awaiting								
ly Assigned Requests for App	oroval	···						 	
oproved Drug Drug Interactions ith Pending Drug Pairs	<u>4</u>								
ose Range	2								
	1								
uplicate Therapy									
rofessional Monograph	0								
rug-Drug Interaction	Review 1								
oncept	Awaiting								
ly Assigned Requests for Rev	riew								
ose Range	<u>16</u>	<u>13</u>	1	1	1	2	<u>34</u>		
uplicate Therapy	<u>15</u>	8	<u>7</u>	3	1	5	<u>39</u>		
rofessional Monograph	<u>6</u>	<u>3</u>	2	1	2	<u>1</u>	<u>15</u>		
rug-Drug Interaction	<u>55</u>	<u>19</u>	<u>7</u>	<u>14</u>	<u>5</u>	2	<u>102</u>		
oncept	New	Modified	Reviewed	Approved	Rejected	Deleted	All		
ly Request History									
st customization update file creati	on occurred on:	05-15-2012							
st update to First DataBank DIF da	tabase occurre	d on: 05-25-2	012 version: 3.3	2					
elcome FIVE APPROVE	2								Page Hel
Advanced Query/Custo	mization Ea	sy Search	Drug Pair Lo	okup Repo	orts Help				
	RMACY ENT								

Figure 5: Home Page for Approver (All Available Panels)

This window displays an example of what a user with the "Requestor" role may see on the home page:

Home Advanced Query/C	ustomization	Easy Search	Drug Pall LO	okup Help				
Velcome ONE_REQUE	STOR							Page Hel
ast update to First DataBank D	IF database occu	urred on: 05-25-2	012 version: 3.2	2				
ast customization update file c				-				
ly Request History								
wy Request History								
Concept	New	Modified	Reviewed	Approved	Rejected	Deleted	All	
Drug-Drug Interaction	1	<u>1</u>	0	0	0	0	2	
	0	2	0	0	0	0	2	
Professional Monograph	0	1	0	0	0	0	1	
			0	1	0	0	<u>8</u>	
Duplicate Therapy	<u>4</u>	3	0					
Duplicate Therapy	4	3	U	-				
Professional Monograph Duplicate Therapy Dose Range	4	3	0					

Figure 6: Home Page for Requestor

Drug Pair Lookup Page

If you have the proper authority, you can access the Drug Pair page by clicking the Drug Pair Lookup tab. It allows you to perform a quick query search on the most common elements.

On this page, you can perform a simplified query where a record search is performed from the FDB DIF and VA Custom tables. Simply enter filter data in any or all of the four entry fields (Drug A, Drug B, Interaction, or Severity Level Code). The resulting data is displayed under the VA Table Results and FDB Table Results panels. These consist of active customized Drug Pair records from the VA custom database (DB), which are available for modification, as well as their related Drug Pair records from the FDB DB from which they were customized.

Field names are as follows:

- Drug A The name (or partial name) of one generic drug associated with an interaction.
- Drug B The name (or partial name) of a second generic drug associated with an interaction.
- Interaction An assigned drug interaction ID number or Description associated with the drug pair of Drug A and Drug B.
- Severity Level Code Drop down list of available severity codes.

ome Advanced Query/Cu		NTERPRISE ON SYSTEM Easy Search Drug Pair Lookup	Reports Help			
rug Pair Lookup	31011120001		перона пер			
lug i un Lookup						Page Help
gB, Interaction and/or select a	value for Severit	h for VA custom drug pairs and FDB drug y Level Code, an exact match is perform				
scription anywhere in the spec		eturned. of the fields below. Note that at least one	field must be specifier			
segin your search for drug par	ra, complete any	of the neids below. Note that at reast one	mera maar be apecinea			
g A (Generic):						
g B (Generic):						
raction:						
erity Level Code:						*
Query Home						
					Help	

Figure 7: Drug-Drug Pair Query Window

ζ,

DECC	TERANS AFFAIRS Welcome, THREE_REQUESTOR USTOMIZATION SYSTEM	Logout 📢
	USTOMIZATION SYSTEM ustomization Easy Search Drug Pair Lookup Help	
Drug Pair Lookup		
The Drug Pair Lookup page allo	ws users to search for VA custom drug pairs and FDB drug pairs based on the information provided in the form below. If you enter numeric values against DrugA, a value for Severity Level Code, an exact match is performed. If you enter description values against Drug A, Drug B, and/or Interaction, records that contain the given	<u>aqe Help</u>
To begin your search for drug pa	airs, complete any of the fields below. Note that at least one field must be specified.	1
Drug A (Generic):	Metyrapone oral	
Drug B (Generic):	Cyproheptadine hcl	
Interaction:		
Severity Level Code:		~ 1
Query Home		
Query Home		

Figure 8: Sample Data

F

Select	Routed Generic #1 Description	Routed Generic #2 Description	Interaction Description	Severity Level Code	Action Status	1
Active	METYRAPONE ORAL	CYPROHEPTADINE HCL MISCELLANEOUS	VA Custom: METYRAPONE/CYPROHEPTADINE	2	Modified	F
Active	METYRAPONE ORAL	CYPROHEPTADINE HCL/LYSINE/VITAMIN B COMPLEX/ZINC ORAL	VA Custom: METYRAPONE/CYPROHEPTADINE	2	Modified	F
Active	METYRAPONE ORAL	CYPROHEPTADINE HCL/VITAMIN B COMPLEX ORAL	VA Custom: METYRAPONE/CYPROHEPTADINE	2	Modified	F
<u>Active</u>	METYRAPONE ORAL	CYPROHEPTADINE HCL ORAL	VA Custom: METYRAPONE/CYPROHEPTADINE	2	Modified	F
	r∎ ⊳c Desuits					>
FDB Tabl	es Results					>
FDB Tabl	es Results Routed Generic #1 Description METYRAPONE ORAL	Routed Generic #2 Description	Interaction Description METYRAPONE/CYPROHEPTADINE	Severity Level Code	Interaction ID 234	
FDB Table Select <u>Open</u>	Routed Generic #1 Description METYRAPONE ORAL	CYPROHEPTADINE HCL/VITAMIN B COMPLEX ORAL	METYRAPONE/CYPROHEPTADINE	2	234	:
-2	Routed Generic #1 Description	CYPROHEPTADINE HCL/VITAMIN B		2		

Figure 9: Drug Pair Query Result

Note that in this example, both the FDB table and VA Custom table contain more information that is found via the horizontal scroll bar:

equest Sub	mitted By	Action Date		Action Perform	ned By	Request Assign	ned To	Interaction ID		Severity Level
IVE_APPRO	VER	2011-09-27 07:	20	ONE_APPROVE	ER	FIVE_APPROVE	ER	2020476		Severe Interacti
IVE_APPRO	VER	2011-09-27 07:	20	ONE_APPROVE	ER	FIVE_APPROVE	R	2020476		Severe Interacti
VE_APPRO	VER	2011-09-27 07:	20	ONE_APPROVE	ER	FIVE_APPROVE	R	2020476		Severe Interacti
VE_APPRO	VER	2011-09-27 07:	20	ONE_APPROVE	ER	FIVE_APPROVE	ER	2020476		Severe Interacti
	s Results						NO -			
DB Table	s Results Routed Generic #2	Description	Interaction Descripti	ion	Severity Level Code		Interaction ID		Severity Level D	
DB Table			Interaction Descripti METYRAPONE/CYPR				Interaction ID 234		Severity Level D Severe Interaction	
DB Table	Routed Generic #2 CYPROHEPTADINE COMPLEX ORAL CYPROHEPTADINE	HCL/VITAMIN B		ROHEPTADINE	2					Description
DB Table	Routed Generic #2 CYPROHEPTADINE COMPLEX ORAL	E HCL/VITAMIN B E HCL ORAL E IN B	METYRAPONE/CYPR		2		234		Severe Interaction	Description
EDB Tables	Routed Generic #2 CYPROHEPTADINE COMPLEX ORAL CYPROHEPTADINE CYPROHEPTADINE HCLL/YSINE/VITAMI	E HCL/VITAMIN B E HCL ORAL E IN B VAL	METYRAPONE/CYPR	ROHEPTADINE ROHEPTADINE ROHEPTADINE	2 2 2 2		234 234		Severe Interaction	Description on on

Figure 10: VA & FDB Tables, continued

E_APPROVER FIVE_APPROVER 2020476 Severe Interaction E_APPROVER FIVE_APPROVER 2020476 Severe Interaction	Action Performed By	Request Assigned To	Interaction ID	Severity Level Description	Reference Text
E_APPROVER FIVE_APPROVER 2020476 Severe Interaction	ONE_APPROVER	FIVE_APPROVER	2020476	Severe Interaction	
	ONE_APPROVER	FIVE_APPROVER	2020476	Severe Interaction	
	ONE_APPROVER	FIVE_APPROVER	2020476	Severe Interaction	
_APPROVER FIVE_APPROVER 2020476 Severe interaction	ONE_APPROVER	FIVE_APPROVER	2020476	Severe Interaction	



Note that you can move the columns in these tables and compare different fields side-by-side. Click the heading and drag and drop it:

VA Tables Results Default position for "Request Assigned To" column							
Action Status	Request Submitted By	Action Date	Action Performed By	Request Assigned To	Interaction ID		
Modified	FIVE_APPROVER	2011-09-27 07:20	ONE_APPROVER	FIVE_APPROVER	2020476		
Modified	FIVE_APPROVER	2011-09-27 07:20	ONE_APPROVER	FIVE_APPROVER	2020476		
lodified	FIVE_APPROVER	2011-09-27 07:20	ONE_APPROVER	FIVE_APPROVER	2020476		
lodified	FIVE_APPROVER	2011-09-27 07:20	ONE_APPROVER	FIVE_APPROVER	2020476		
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~					~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~		

#### Figure 12: Default Position of "Request Assigned To"

VA Tables Results		"Request Assigned To moved	" column		
Action Status	Request Assigned To	Request Submitted By	Action Date	Action Performed By	Interaction ID
Modified	FIVE_APPROVER	FIVE_APPROVER	2011-09-27 07:20	ONE_APPROVER	2020476
Modified	FIVE_APPROVER	FIVE_APPROVER	2011-09-27 07:20	ONE_APPROVER	2020476
Modified	FIVE_APPROVER	FIVE_APPROVER	2011-09-27 07:20	ONE_APPROVER	2020476
Modified	FIVE_APPROVER	FIVE_APPROVER	2011-09-27 07:20	ONE_APPROVER	2020476

Figure 13: Re-positioned "Request Assigned To" Column

# **Advanced Query/Customization Page**

The Advanced Query / Customization page is used to access customization records from either the FDB Standard table, the VA Custom tables, or both at the same time. This allows you to research existing records, make customizations, or export data.

### Accessing the Advanced Query/Customization Page

The Advanced Query/Customization page allows you to retrieve records from either the FDB standard tables, custom tables, or both to research, make customization changes, or export data. The Advanced Query / Customization page can is accessed in one of two ways.

• Click the Advanced Query/Customization tab on the navigation bar near the top of the page. This will open a blank query.



Figure 14: Accessing the Advanced Query / Customization Page

• Click a link from one of the summary tables displayed on the Home tab. This will generate a query appropriate to the context of the link that was clicked. In the example below, a query displaying criteria to display the unassigned Drug-Drug Interaction records will be produced.

	HARMACY	IRS	
PECS	USTOMIZAT	INTERPRISE	
Home Advanced Query/C	ustomization	Easy Search	Drug I
·			
Welcome TWO_APPRO	VER		
Last update to First DataBank D	IF database occu	urred on: 05-18-2	012 vers
			012 vers
			012 vers
Last customization update file c			012 vers
Last update to First DataBank D Last customization update file c My Request History			012 vers
Last customization update file c			1
Last customization update file contract My Request History	reation occurred	on: 05-15-2012	1
Last customization update file concept	reation occurred	on: 05-15-2012	1
Last customization update file of My Request History Concept Drug-Drug Interaction	reation occurred	on: 05-15-2012 Modified <u>4</u>	Revie

Figure 15: Access Advanced Query/Customization from the Home Tab

### The Query Builder Panel

The Query Builder Panel on the Advanced Query/Customization page allows you to retrieve a specified set of records the VA Custom Tables, the FDB standard tables or Both in order to perform research, make customization changes, or export data. You can use it to create a new query, load a query you have previously saved, or load a query saved by another user.

#### How to Build a Query

This is the Query Builder page, described above. From this page you can build your own query, run it, save it, run a saved query, or run another user's saved query.

To create a query

1. On the Advanced Query/Customization tab, select a Concept.

Build a Query					
Select Concept	<b>•</b>				
	Drug-Drug Interaction				
Run a Saved	Drug Pair Professional Monograph ³				
My Queries	Duplicate Therapy Dose Range				

2. Select what data you want to view-- VA, FDB, or Both.

Select VA, FDB, or Both	•	]
	VA records	
	FDB records 생 Both VA and FDB records	

3. In the "Enter a value to build a query" area, select the Field you want to use as a query criteria. The available field options will be determined by the Concept you selected earlier.

Enter a value to build a query

Fields		
Concept Type		•
Concept Type		*
Concept ID Number		
Concept ID Description		
Action Status	15	
Age Low In Days		
HITTYPE		
Age High In Days		_
Dose Route		=
Deep Doute Departmention	1	

4. Select the Filter you want to impose on the Field.

	Filter	
	Greater than 🔹	
	Contains Equal to	
	Less than or Equal to	
1	Greater than or Equal to	
	Begins with Ends with	егу
	Greater than	
	Less than 😼	
	Not Equal to	

5. Enter a Value to use as your query criteria. The Value must be appropriate for the Field and Filter or an error will be generated. See Query Specifics for additional information.

Value			
6	3		

6. To add additional criteria to the query, make a selection from the And/Or list.



- AND indicates the results must match the new criteria and all the AND-connected criteria above it
- OR indicates that the results must match either the new criteria or the AND-connected criteria above it. See And/Or Usage Examples for additional information.
- 7. To include Historical Records in the query, select the Include Historical Records check box.

8. When all criteria have been added, click the Query button. The results will display below the query panel.

9. To see details of the record, select the link in the Select column.

Export			
Select	Concept Type	Concept ID Number	Concept ID D
Active	6	15532	BCG LIVE IN (SDV,MDV OF
Active	6	22222222	
Historical	6	476	NITROGLYCI TABLET,SUB
Historical	6	1234	POTASSIUM BICARBONA CITRATE/CIT

### And/Or Usage Example

To see approved records with an interaction description equal to "anti" or "Lido", build the query as follows:

Field	Filter	Value	And/Or
Interaction description	Equals	anti	And
Status	Equals	approved	Or
Interaction description	Equals	Lido	And
Status	Equals	approved	

If you build the query below, you will get approved records with an interaction description = "Anti", but you will get all records with an interaction description of "Lido", regardless of status.

Field	Filter	Value	And/Or
Interaction description	Equals	anti	And
Status	Equals	approved	Or
Interaction description	Equals	Lido	

### **Query Specifics**

- Use the YYYY-MM-DD date format for searching date fields within a query
- Date values can only use the following filters::
  - o Equal to
  - o Less than or Equal to
  - o Greater than or Equal to
  - o Greater than
  - o Less than

#### Save a Query

PECS allows you to save a complete query so that you and other PECS users can run a specific query without having to re-build it every time. This feature is not available to users with the Requestor role.

Note: the state of the Historical Records check box will not be saved with the query; if desired, it must be re-selected after the query is loaded at run-time.

To save a query

- 1. Create a query in the Build A Query panel. See Build A Query for additional information.
- 2. Enter a name for the query in the Query Name field. The name must contain at least five characters and cannot be longer than 64 characters.
- 3. Click Save Query.



4. The saved query will appear in the My Queries list.

Run a Saveo	I Query
My Queries	Other Users' Queries
Oncept	6 - Rejected
O Dose Ro	ute Not ORAL
Ose Ro	ute Not ORAL, Rejected, Deleted
Concepte	6, Powder, Elixir
Approver	2 Requests Not Assigned
Aspirin D	RC
Load De	lete

#### **Run a Saved Query**

PECS allows you to run a previously saved query with the same Concept and content (VA, FDB, or Both). You can run queries that you have saved or those that other users have saved.

To run a saved query

- 1. On the Advanced Query/Customization tab, select a Concept.
- 2. Select what data you want to view-- VA, FDB, or Both.
- 3. In the Run a Saved Query sub-panel, select either My Queries or Other Users's Queries, then select the query you want to run.

4. Click the Load button. This will add the components of the saved query to the Build a Query panel.

My	Queries Other Users' Queries
۲	Concept 6 - Rejected
$\bigcirc$	Dose Route Not ORAL
$\bigcirc$	Dose Route Not ORAL, Rejected, Deleted
$\bigcirc$	Concept6, Powder, Elixir
$\bigcirc$	Approver 2 Requests Not Assigned
$\bigcirc$	Aspirin DRC

5. Click the Query button to run the query. You may also select additional criteria to alter or enhance the saved query.

#### **Delete a Saved Query**

You can delete queries you have created and saved. Note that the delete operation is immediate; you will not be warned that the query is about to be deleted and there is no undo option.

To delete a Saved Query

- 1. On the Advanced Query/Customization tab, select a Concept.
- 2. Select what data you want to view-- VA, FDB, or Both.
- 3. In the Run a Saved Query sub-panel, select My Queries; you cannot delete a query that was created by another user, then select the query you want to delete.
- 4. Click the Delete button. The query is deleted.

#### **Rename a Saved Query**

A saved query can be renamed by loading it then adding a different name in the Query Name field.

To rename a saved query

- 1. On the Advanced Query/Customization tab, select a Concept.
- 2. Select what data you want to view-- VA, FDB, or Both.
- 3. In the Run a Saved Query sub-panel, select My Queries; you cannot rename a saved query created by another user.
- 4. Enter a new the Query Name field.
- 5. Click Save Query. The new query name will appear in the My Queries list in place of the original query.

### **Sort Query Results**

You can change the sort order of results of your query by clicking on the column headings in the display grid. Clicking once will display the records in ascending order (A to Z, 1-2-3 etc.) based on the contents of the column of the header you clicked; clicking a second time display the records in descending order (Z to A, 3-2-1, etc.). A small arrow indicates the direction of the current sort.

Action Performed By	Action Date	- Reference Text
SIX_APPROVER	2012-05-10 13:39:25	Sort Direction
SIX_APPROVER	2012-05-10 13:30:32	Indicator
TWO_APPROVER	2012-05-10 13:12:57	
TWO_APPROVER	2012-05-10 13:09:47	
SIX_APPROVER	2012-05-10 10:38:44	
SIX_APPROVER	2012-05-10 10:35:22	
FOUR_APPROVER	2012-05-09 17:35:26	
TWO_APPROVER	2012-05-03 16:00:44	
		III III III

#### Figure 16: Sorting Query Results

For VA records, the default sort order is by the 'Action Date' value, from newest to oldest. This puts the VA Customizations that have been updated most recently at the top of the returned list. By default, FDB records are displayed in the order they appeared in the update file sent by FDB. However, they can be resorted by clicking a column header.

Note: Due to technical database restrictions, not all fields can be used to determine the sort order. For example, Concept ID Description on a Dose Range query cannot be used to sort the query results. Clicking these columns will have no result and the current sort order will be retained.

### **Export Query Results**

Query results for both VA and FDB records can be exported to an Excel spreadsheet file.

To export the query results

1. On the appropriate query results panel, click the Export button.

VA Tables	Results	
Export	Concent Turc	Canaart II
Select	Concept Type	Concept I
Active	6	15532
Active	6	22222222

- 2. Select one of the following options from the dialog box:
  - Click Open to open the exported query in Excel.
  - Click Save to save the exported query to a location on your hard drive.
  - Click Cancel to abandon the export operation.

#### **Query Errors**

Running a query will sometimes return an error message.



#### Figure 17: Query Error Message

In many cases, the error is caused by the query returning too many results which causes the database to time-out. Try re-writing the query with more specific criteria. For example, enter "Aspirin" as the Concept ID Description in a Dose Range query instead of "a" as the Concept ID Description. This will reduce the number of results and potentially prevent database time-outs. Rule of thumb: always be as specific as possible when creating a query.

An error may also appear if the selected Filter is not appropriate for the data type.

#### **Special Dose Range Query Button**

If you are performing a Dose Range Query, there is a special button that displays only on the Dose Range Query window for VA, FDB, or Both. It is a predefined search that enters a default Dose Range query. If you do not want to run the default, you can enter specific values yourself, then run your query.

Here are the predefined fields for this Dose Range Query:

- Concept type = 6 and
- AGEHIGHINDAYS >= (greater than or equal to) 6570

To run this query, simply press the Add Default DRC Query, then press Query. The results are shown below:




Figure 18: Default Dose Range Query Window

VA Tables						
Export						
Select	Concept Type	Concept ID Number	Concept ID Description	Action Status	Age Low In Days	1
			CALCIUM			<u>^</u>
<u>Active</u>			CARBONATE/MAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG 133 UNIT	Delete Reviewed	30	E
			CALCIUM			
<u>Historical</u>	6	63438	CARBONATE/MAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG 133 UNIT	Approved	30	
<u>Historical</u>	6	63438	CALCIUM CARBONATE/MAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG 133 UNIT	Reviewed	30	
	6	63438	CALCIUM CARBONATE/MAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG	New	30	-
• [	6 es Results	63438	CARBONATE/MAGNESIUM OXIDE/CHOLECALCIFEROL (VIT		30	-
< III FDB Table		63438	CARBONATE/MAGNESIUM OXIDE/CHOLECALCIFEROL (VIT		30	F
FDB Table	es Results		CARBONATEMAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG			•
<ul> <li>✓ Ⅲ</li> <li>FDB Table</li> <li>Export</li> <li>Select</li> </ul>	es Results Concept Type	Concept ID Number	CARBONATEMAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG	- Age Low In Days	НІТТҮРЕ	•
FDB Table Export Select Open	concept Type	Concept ID Number 1049183	CARBONATEMAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG Concept ID Description MAGNESIUM CHLORIDE ORAL	Age Low In Days	<b>НІТТҮРЕ</b> 3	
FDB Table Export Select Open Open	concept Type 5 5	Concept ID Number	CARBONATEMAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG Concept ID Description MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL	- Age Low In Days	НІТТҮРЕ	
FDB Table Export Select Open Open Open	Concept Type 5 5 5 5	Concept ID Number 1049183 1049183 1049183	CARBONATEMAGNESIUM OXIDE/CHOLECAL CIFEROL (WT D3) ORAL TABLET 400 MG-167 MG Concept ID Description MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL	Age Low In Days 6570 23726 4745	<b>НІТТҮРЕ</b> 3 3	
FDB Table Export Select Open Open Open	Concept Type 5 5 5 5 5 5	Concept ID Number 1049183 1049183 1049183 1049183 1049183	CARBONATEMAGNESIUM OXIDE/CHOLECAL/CIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG Concept ID Description MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL	- Age Low In Days 6570 23726 4745 4745	нттуре 3 3 1 1	
FDB Table Export Select Open Open Open Open Open Open Open Open	Concept Type 5 5 5 5 5 5 5 5 5	Concept ID Number 1049183 1049183 1049183 1049183 1049183 1049183	CARBONATEMAANESIUM OXIDE/CHOLECAL/IFEROL (VIT D3) ORAL TABLET 400 MG-167 MG Concept ID Description MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL	Age Low In Days 6570 23726 4745 4745 0	нгтүре 3 3 1 1 1 1	
FDB Table      FDB Table      Export      Select      Dpen      Dpen	S Concept Type 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	Concept ID Number 1049183 1049183 1049183 1049183 1049183 1049183 1049183	CARBONATEMAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG Concept ID Description MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL	- Age Low In Days 5570 23726 4745 4745 0 0	HITTYPE 3 3 1 1 1 1 1 1 1 1	
Compare la compar	S Results Concept Type 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	Concept ID Number 1049183 1049183 1049183 1049183 1049183 1049183 1049183 1049183	CARBONATEMAGNESIUM OXIDE/CHOLECALCIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG Concept ID Description MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL	- Age Low In Days 6570 23726 4745 4745 4745 0 0 0 180	HITTYPE 3 3 1 1 1 1 1 1 1 1 1 1	
FDB Table      FDB Table      Export      Select      Open      Open	Concept Type 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	Concept ID Number           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183	CARBONATEMAGNESIUM OXIDE/CHOLECAL/DEFROL_(WT D3) ORAL TABLET 400 MG-167 MG Concept ID Description MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL	Age Low In Days 6570 23726 4745 4745 0 0 180 180	HITTYPE 3 3 1 1 1 1 1 1 1 1 1 1 1 1	
FDB Table Export Select Open Open Open Open Open Open Open Open	Concept Type 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	Concept ID Number           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183	CARBONATEMAGNESIUM OXIDE/CHOLECAL/CIFEROL (WT D3) ORAL TABLET 400 MG-167 MG MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL	Age Low In Days 6570 23726 4745 4745 0 0 180 180 180 365	HITTYPE 3 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
FDB Table      Export      Select      Open      Op	Concept Type 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	Concept ID Number           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183	CARBONATEMAGNESIUM OXIDE/CHOLECAL/CIFEROL (VIT D3) ORAL TABLET 400 MG-167 MG MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL	- Age Low In Days 6570 23726 4745 4745 0 0 0 180 180 180 385 385	HITTYPE 3 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
FDB Table      FDB Table      Export      Select      Open      Open	Concept Type 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	Concept ID Number           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183           1049183	CARBONATEMAGNESIUM OXIDE/CHOLECAL/CIFEROL (WT D3) ORAL TABLET 400 MG-167 MG MAGNESIUM CHLORIDE ORAL MAGNESIUM CHLORIDE ORAL	Age Low In Days 6570 23726 4745 4745 0 0 180 180 180 365	HITTYPE 3 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	

Figure 19: Results from Building a Dose Range Query with Default DRC Query

•

## Panels You Can Modify

Following are example Dose Range, Professional Monographs, Duplicate Therapy, and Drug-Drug Interaction panels, shown in Read-Only mode, which is the default view. You can modify these panels only if:

- 1. You have the correct security permissions.
- 2. You have clicked the Edit button to bring up the record in Edit mode.
- 3. No other user is modifying the record at the same time (you will be notified if that is the case).

Note that shaded fields on any the detail pages in Edit mode cannot be modified.

#### **Dose Range**

Click the Edit Button to open the fields to edit the record. The view below is Read-Only.

PECS	RMACY ENTERPRISE TOMIZATION SYSTEM	Welcome, TWO_APPROVER   Logo
	mization Easy Search Drug Pair Lookup Reports Help	
lose Range		Page H
o update this record click on the edi	it button below.	
Edit		Print Page
oncept Type	6	
oncept ID Number (Required)	1974	
oncept ID Description	DEXTROSE 5 %-WATER INTRAVENOUS VIAL (SDV,MDV OR ADDITIVE) 5 %	
ction Status	Reviewed	
ge Low In Days (Required)	350	
ge High In Days (Required)	5000	
ction Effective Date	2012-06-01 01:29:56	
ose Route (Required)	007 - INTRAOSSEOUS	
ose Type (Required)	08 - INITIAL DOSE	
DBDX	999	
XID	4892	

#### Figure 20: Dose Range Panel - Read-Only

#### **Professional Monograph**

During customization, you can edit the professional monograph that is displayed. Below is an example in read-only mode. Click the Edit button to modify.




Figure 21: Professional Monograph Panel - Read Only

#### **Duplicate Therapy**

You may also edit the Duplicate Therapy panel if you have the authority and click the Edit button.

	MACY ENTERPRISE MIZATION SYSTEM	
Home Advanced Query/Customi	zation Easy Search Drug Pair Lookup Reports Help	
Duplicate Therapy		Page Hel
_		
dit		
		Print Page
toid	1200	
ustom Dup Allowance (Required)	0	
escription (Required)	Antibiotics with Anaerobic Coverage test	
tion Status	Modified	
tion Date	2011-11-15 05:18:18	
tion Effective Date	2011-11-15 05:18:18	
tion Performed By	SIX_APPROVER	
equest Assigned To	UNASSIGNED	
equest Submitted By	FIVE_APPROVER	
tion Reason History eference Text	2011/1/15 17:16:18 SIX_APPROVER: car 2011/1/15 17:17:39 SIX_APPROVER: car 2011/1/15 17:16:57 FIVE_APPROVER: car 2011/1/15 12:26:49 FIVE_APPROVER: car 2011/1/15 12:26:49 FIVE_APPROVER: submit as review 2011/10/26 13:39:49 UNE_APPROVER: reject t 2011/10/26 13:39:49 FIVE_APPROVER: reject t 2011/10/26 13:37:19 FIVE_APPROVER: reject t 2011/10/26 13:23:54 UNE_APPROVER: reject t 2011/10/26 13:23:54 UNE_APPROVER: reject t 2011/10/26 13:26:10 UNE_APPROVER: reject t 2011/10/26 13:26:10 UNE_APPROVER: reject t 2011/10/26 13:26:10 UNE_APPROVER: reject t 2011/10/26 13:26:10 UNE_APPROVER: reject t 2011/10/26 13:26:21 UNE_APPR	
urrent Action Reason (Required)		Print Page

Figure 22: Duplicate Therapy Panel - Read-Only

#### **Drug-Drug Interaction**

The Drug-Drug Interaction Panel can be edited only if you have the proper authority and after you click the Edit button.




Figure 23: Drug-Drug Interaction Panel - Read Only

## Single Drug Pair Page Modification Not Allowed

You cannot modify or customize a drug pair if you display a single drug pair from a query on the Drug Pair concept, as shown below:

1. Pick the Drug Pair concept, as shown below, and select one of the drug pairs displayed.

d Query/Customization erv pt Drug Pair v f to build a query	elect VA, FDB, or Both VA records			Page Help	
pt Drug Peir	elect VA, FDB, or Both VA records				
	elect VA, FDB, or Both VA records				
		~			
to build a query					
	Filter	Value	And/Or		
neric#1 Description 🛩	Contains 💌	asp	V Query		
listorical Records					
istorical Records		_			
	Save Query Clear Quer	У			
ed Query					
Others Manager Councilian					
enes. Build a query.					
Results					
The Solido					
Routed Generic #1 Description					
	Deuted Connels #3 Description	Interaction Description	Emmilted mail Code	Action Status 1	
METHOTREXATE ORAL	Routed Generic #2 Description ASPIRIN/ACETAMINOPHEN ORAL	Interaction Description METHOTREXATE/SALICYLATES	Severity Level Code	Action Status	
METHOTREXATE ORAL ASPIRIN/SALICYLAMIDE IACETAMINOPHEN/CAFFEINE	ASPIRIN/ACETAMINOPHEN ORAL	METHOTREXATE/SALICYLATES	3	New	
METHOTREXATE ORAL ASPIRINISALICYLAMIDE IACETAMINOPHENICAFFEINE ORAL ASPIRINICALCIUM	ASPIRIN/ACETAMINOPHEN ORAL	METHOTREXATE/SALICYLATES	3	New ^	
METHOTREDATE ORAL ASPIRINISALICYLAMIDE IACCETAMINOPHENICAFFEINE ORAL ASPIRINICALCIUM CARBONATE/MAGNESIUM ORAL	ASPIRINACETAMINOPHEN ORAL CELECOMB ORAL CELECOMB ORAL	METHOTREVATE/SALICYLATES ASPIRINCELECOXB ASPIRINCELECOXB	3 2 2	New A	
METHOTREXATE ORAL ASPIRINSALICYLAMIDE IACETAMINOPHENICAFEINE ORAL ASPIRINICALCIUM CARBONATEMAGNESTUM ORAL ASPIRINACETAMINOPHEN ORAL ASPIRINACETAMINOPHEN	ASPIRINACETAMINOPHEN ORAL CELECOXIB ORAL CELECOXIB ORAL CELECOXIB ORAL	METHOTREXATE/SALICYLATES ASPIRINCELECOXB ASPIRINCELECOXB ASPIRINCELECOXB	3 2 2 2	New A	
METHOTREXATE ORAL ASPERINSALICYLAMIDE ACETAMINOHENICAFEINE ORAL ASPERINACELAMINOPHEN ORAL ASPERINACETAMINOPHEN ORAL ASPERINACETAMINOPHEN MYTRILAMINE ORAL ASPERINACETAMINOPHEN ASPERINALOYLAMIDE	ASPRINACETAMINOPHEN ORAL CELECOXIB ORAL CELECOXIB ORAL CELECOXIB ORAL CELECOXIB ORAL	METHOTREXATE/SALICYLATES ASPIRINCELECOMB ASPIRINCELECOMB ASPIRINCELECOMB ASPIRINCELECOMB	3 2 2 2 2 2	New Colored Deleted Deleted Deleted Deleted	
METHOTREXATE ORAL ASPIRINSALIC'LAMIDE ACETAMINOPHICASFEINE ORAL ASPIRINACA CIUM CARBONATEMAGNEBUM ORAL ASPIRINACETAMINOPHEN PYTRILAMINEO IGNAL ASPIRINSALIC'LAMIDE ACETAMINOPHIN ORAL	ASPIRINACETAMINOPHEN ORAL CELECOXIB ORAL CELECOXIB ORAL CELECOXIB ORAL CELECOXIB ORAL CELECOXIB ORAL	METHOTREXATE/SALICYLATES ASPIRINCELECOMB ASPIRINCELECOMB ASPIRINCELECOMB ASPIRINCELECOMB ASPIRINCELECOMB	2 2 2 2 2 2 2 2	New A	
METHOTRECATE ORAL ASPIRINSALICILANDE ACETAMINOPHENCATEINE ORAL ASPIRINCALCIUM CARBONITEMUNHESUM ORAL ASPIRINUCETAMINOPHEN ORAL ASPIRINUCETAMINOPHEN ORAL ASPIRINSALICILAMDE ACETAMINOPHEN ORAL ASPIRINSALICILAMDE ASPIRINSALICILAMDE	ASPIRENACETAMINOPHEN ORAL CELECOXIB ORAL CELECOXIB ORAL CELECOXIB ORAL CELECOXIB ORAL CELECOXIB ORAL CELECOXIB ORAL	METHOTREXATE/SALICYLATES ASPIRINCELECOMB ASPIRINCELECOMB ASPIRINCELECOMB ASPIRINCELECOMB ASPIRINCELECOMB	3 2 2 2 2 2 2 2 2	New A	
		Save Query Clear Quer ed Cuery Other User's 'Quertes rels. Build a query.	Save Query Clear Query ed Cuery Other Users' Overlies nes. Build a gowy.	Save Query Clear Query ed Query Other User's Overles miss. Build a query.	ed Guery ed Guery Other Vaenes res. Build a query.

2. The page that displays is the single drug pair, and an information message is displayed: "Further customization or deletion of this drug pair can be done only through the VA custom Drug-Drug Interaction detail page."

	RMACY ENTERPRISE OMIZATION SYSTEM mizdon Eavy Search Drug Par Lookup Reports Help		
Drug Pairs (Active read-only		Page Help	
bright and (near or rodd-only			
		Print Page	
Informational Messages:			
Further customization or deletion of t	iis drug pair can only be done through the VA custom Drug-Drug Interaction detail page.		
Action Status	New .		
Corresponding FDB Interaction ID	74		
Request Submitted By	TVI0_APPROVER		
Action Effective Date			
Action Date	2011-12-19 11:26:36		
Action Performed By	TWI0_APPROVER		
RequestAssigned To	TWIO_APPROVER		
Interaction ID (Required)	2020697 - METHOTREXATE/SALICYLATES	×	
Severity Level Description	Moderate Interaction		
Routed Generic#1 (Required)	METHOTREXATE ORAL	v	
Routed Generic #2 (Required)	ASPIRIN/ACETAMINOPHEN ORAL		
Reference Text	references		
Action Reason History	2011/12/19 23:26:36 TWO_APPROVER: customizing this drug pair		
Current Action Reason (Required)			
		Print Page	

3. The easiest way to get to the custom Drug-Drug Interaction detail page is to use the Easy Search tab. See the section "Easy Search Query Page."

# Notification of Drug Pairs Needing Action for an Approved Drug-Drug Interaction

The drug pairs that are associated with a Drug-Drug Interaction (DDI) need to go through the approval/state change process themselves (be approved, rejected, modified, or deleted), separately from the DDI. If the drug pairs are acted upon at the same time as the DDI is acted upon, there is no problem in an approver knowing that the drug pair needs to be acted upon. However, drug pairs may be added or have their status changed even after a DDI has been acted upon. The way an approver will know if they need to act on a drug pair associated with an already-approved DDI is by the row on each of the home page tables that displays "Approved Drug-Drug Interaction with Pending Drug Pairs."

Home Advanced Query/Cus	ARMACY EN STOMIZATIO			skup Repo	rts Help								
Welcome SIX_APPROVE	2									Page Help	a.		
Last update to First DataBank DIF Last customization update file creater	database occurre ation occurred on	ed on: 04-13-0 : 04-11-2012	2012 version: 3.	2									
My Request History													
Concept	New	Modified	Reviewed	Approved	Rejected	Deleted	All						
Drug-Drug Interaction	5	0	1	1	0	0	Z						
Professional Monograph	0	0	0	0	0	0	0						
Duplicate Therapy	0	0	1	0	0	0	1						
Dose Range	5	0	0	0	0	0	5						
My Assigned Requests for R	eview												
Concept	Awaiting												
Drug-Drug Interaction	Review 0												
Professional Monograph	0												
Duplicate Therapy	0			Annes	ed Drug Dr	un Interacti	ions with Pe	ding					
Dose Range	0			Drug P	airs for sign	ed-in user	(awaiting re	iew)					
Approved Drug Drug Interactions	2 2			_									
With Pending Drug Pairs													
My Assigned Requests for Ap	pproval												
Concept	Awaiting												
Drug-Drug Interaction	Approval 0			d Doug Doug	- let - continue	a with Daw	fee Deve D	in the					
Professional Monograph	0		signed-i	a Drug-Drug 1 user (awai	ting revew)	- in this cas	ding Drug Pa se, there are	none.					
Duplicate Therapy	0												
Dose Range	0												
My Assigned Requests for D		_											
Concept	Awaiting Deletion												
Drug-Drug Interaction	0		App	oved Drug- ned-in user	Urug Interati (awaiting de	ons with P eletion) - in	ending Drug this case, th	Pairs for	)				
Professional Monograph	0		U 318	ilea-ili aser	(awalong de	ione.	uno caoe, u	cie die					
Duplicate Therapy	0						-		-				
Dose Range	0												
Approved Drug Drug Interactions With Pending Drug Pairs	0												
Unassigned Requests													
Concept	Unassigned	1											
Drug-Drug Interaction	177												
Professional Monograph	25												
Duplicate Therapy	53	6	All the D	rug-Drug Int	eractions wi	th Pending	Drug						
Dose Range	74		Pairs the	It have been ate of the Dr	not yet bee rug Pairs on	n assigne	3, or if ed						
Approved Drug Drug Interactions With Pending Drug Pairs	39		ar	proved DD	DI has been	changed.		1					
All Requests													
	New	Modified	Reviewed	Approved	Rejected	Deleted	All						
Concept	125	<u>49</u>	24	664	24	45	1001						
Drug-Drug Interaction	11	16	2	31	6	2	82						
Drug-Drug Interaction Professional Monograph		18	18	8	6	5	83						
Drug-Drug Interaction Professional Monograph Duplicate Therapy	26												
Drug-Drug Interaction Professional Monograph		35	2	<u>47</u>	2	2	137						

Figure 24: Home Page with Approved DDIs with Pending Drug Pairs

On the screen above in the application, if you select the link "My Assigned Drug Pairs Associated with Approved Drug-Drug Interactions" for one of the states listed that has actual counts (not zero), you are taken to the Advanced Query/Customization page, shown below, that displays the results for all approved Drug-Drug Interactions with associated Drug Pairs assigned to you in that state.

Build a Quer	uery/Customization					
					Page Help	
Select Concept						
	Drug-Drug Interaction	Select VA, FDB, or Both VA records	8 🔽			
Enter a value to	build a query					
Fields Interaction ID	v	Filter Equal to	Value 2020737	And/Or OR ¥		
Fields		Filter	Value	And/Or		
Interaction ID	v	Equal to	2020738	Query		
Query Name:	storical Records					
		Save Query Clear Query				
Run a Saved	a query					
My Queries	Other Users' Queries	(				
No saved querie	es. Build a query.		List of Drug-Drug Interactions f user that have drug pairs need			
VA Tables R	esults		user triat nave drug pairs need	action		
_						
Export	Interaction Description	Honograph ID	Action Status	Corresponding EDB Interaction ID	Interaction ID	
Export Select	VA Custom	Honograph ID	Action Status Approved	Corresponding FDB Interaction ID	Interaction ID : 2020738 ;	
Export Select	VA Custom AMINOGLYCOSIDES/PENICILLINS	45	Approved	Corresponding FDB Interaction ID 45 45		
Export Select	VA Custom	45		45	2020738 :	
Export Select	VA Custom AMINOGLYCOSIDES/PENICILLINS	45	Approved	45	2020738 :	
Export Select	VA Custom AMINOGLYCOSIDES/PENICILLINS	45	Approved	45	2020738 :	
Export Select	VA Custom AMINOGLYCOSIDES/PENICILLINS	45	Approved	45	2020738 :	
Export Select Active	VA Custom AMINOGLYCOSIDES/PENICILLINS	45	Approved	45	2020738 :	
Export Selast Active	VA Custom AMINOGLYCOSIDES/PENICILLINS	45	Approved	45	2020738 :	
Export Selast Active	VA Custom AMINOGLYCOSIDES/PENICILLINS	45	Approved	45	2020738 :	
Export Selast Active	VA Custom AMINOGLYCOSIDES/PENICILLINS	45	Approved	45	2020738 :	
Export Selast Active	VA Custom AMINOGLYCOSIDES/PENICILLINS	45	Approved	45	2020738 :	

Figure 25: My Assigned DDIs with Pending Drug Pairs List

Here is the Interaction window shown after the link is clicked from the Advanced Query Page (previous screen shot). On the Interaction window you can act on the drug pairs -- to do so, click the Drug Pairs button:

	ARMACY ENTERPRISE			Welcome, SIX_APPROVER   Logout
Home Advanced Query/Custo	omization Easy Search I	Drug Pair Lookup Reports Help		
Drug-Drug Interaction				Page Help
o update this record click on the ed	dit button below.			
Edit Drug Pairs				Print Page
formational Messages:				
-				
The associated drug pairs are no Following additional VA custom r	ot all noviewed yet. To submit this ecord(s) exist for the correspondi	interaction as reviewed, you must review all as ng FDB Drug-Drug Interaction.	issociated drug pairs. First click on the Drug F	Pairs button and then, take appropriate action.
	teraction ID	Interaction Description	Interaction Severity 3	Interaction Action Status
DB Interaction 45 A Interaction 20207		IDES/PENICILLINS	3	Approved
		IDES/PENICILLINS	3	New
				Approved
A Interaction 20207	39 AMINOGLYCOS	IDES/PENICILLINS	2	Approved
A Interaction 20207 A Interaction 20208 A Interaction 20207	39         AMINOGLYCOS           80         AMINOGLYCOS           40         AMINOGLYCOS	IDES/PENICILLINS IDES/PENICILLINS IDES/PENICILLINS - Test 1		Approved New Approved
A Interaction 20207 A Interaction 20208	39         AMINOGLYCOS           80         AMINOGLYCOS           40         AMINOGLYCOS	IDES/PENICILLINS IDES/PENICILLINS IDES/PENICILLINS IDES/PENICILLINS s - 45 Here is one of the was selected from with Pending D	2 9 1 Drug-Drug Interactions that n the list of Approved DDIs Drug Pairs. To review or	New
A Interaction 20207 A Interaction 20208 teraction Description (Required) onograph ID ction Status orresponding EDB Interaction ID.	39         AMINOGLYCOS           80         AMINOGLYCOS           40         AMINOGLYCOS           VA Custem AMINOGLYCOS         Aminoglycosides/Penicillin           Approved         Approved	IDES/PENICILLINS IDES/PENICILLINS IDES/PENICILLINS IDES/PENICILLINS s - 45 Here is one of the was selected from with Pending D otherwise act on th	2 9 1 Drug-Drug Interactions that n the list of Approved DDIs	New
A Interaction 20207 A Interaction 20208 A Interaction 202007 teraction Description (Required) anoaraph ID. ction Status arresponding FDB Interaction ID. teraction ID 4	39         AMINOGLYCOS           80         AMINOGLYCOS           40         AMINOGLYCOS           VA Custem AMINOGLYCOS         Aminoglycosides/Penicillin           Approved         45	IDES/PENICILLINS IDES/PENICILLINS IDES/PENICILLINS IDES/PENICILLINS s - 45 Here is one of the was selected from with Pending D otherwise act on th	2 9 1 Drug-Drug Interactions that n the list of Approved DDIs Drug Pairs. To review or te drug pairs, click the Drug	New
A Interaction 20207 A Interaction 20208 teraction Description (Required) onograph ID ction Status orresponding EDB Interaction ID teraction ID ( evertly Level Code (Required)	39         AMINOGLYCOS           80         AMINOGLYCOS           40         AMINOGLYCOS           VA Custem AMINOGLYCOS           Aminoglycosides/Penicillin           Approved           45           2020738	IDES/PENICILLINS IDES/PENICILLINS IDES/PENICILLINS IDES/PENICILLINS s - 45 Here is one of the was selected from with Pending D otherwise act on th	2 9 1 Drug-Drug Interactions that n the list of Approved DDIs Drug Pairs. To review or te drug pairs, click the Drug	New
A Interaction 20207 A Interaction 20208 teraction Description (Required) onograph ID tion Status orresponding EDB Interaction ID teraction ID ( everify Level Code (Required) tion Date	39         AMINOGLYCOS           80         AMINOGLYCOS           40         AMINOGLYCOS           VA Custem AMINOGLYCOS         Aminoglycosides/Penicillin           Approved         45           2020738         2 - Severe Interaction	IDES/PENICILLINS IDES/PENICILLINS IDES/PENICILLINS IDES/PENICILLINS s - 45 Here is one of the was selected from with Pending D otherwise act on th	2 9 1 Drug-Drug Interactions that n the list of Approved DDIs Drug Pairs. To review or te drug pairs, click the Drug	New
A Interaction 20207 A Interaction 20208 A Interaction 202007 teraction Description (Required) anoaraph ID ction Status orresponding FDB Interaction ID feraction ID 4 everity Level Code (Required) ction Date ction Performed By	39         AMINOGLYCOS           80         AMINOGLYCOS           40         AMINOGLYCOS           40         AMINOGLYCOS           40         AMINOGLYCOS           40         AMINOGLYCOS           40         AMINOGLYCOS           41         AMINOGLYCOS           42         AMINOGLYCOS           43         AMINOGLYCOS           45         2020738           2 - Severe Interaction         2012-02-23 12:52:05	IDES/PENICILLINS IDES/PENICILLINS IDES/PENICILLINS IDES/PENICILLINS s - 45 Here is one of the was selected from with Pending D otherwise act on th	2 9 1 Drug-Drug Interactions that n the list of Approved DDIs Drug Pairs. To review or te drug pairs, click the Drug	New
A Interaction 20207 A Interaction 20208 A Interaction 20200 teraction Description (Required) onograph ID ction Status orresponding FDB Interaction ID feraction ID ( everity Level Code (Required) ction Date ction Performed By equest Submitted By	39         AMINOGLYCOS           80         AMINOGLYCOS           40         AMINOGLYCOS           40         AMINOGLYCOS           40         AMINOGLYCOS           40         AMINOGLYCOS           40         AMINOGLYCOS           41         AMINOGLYCOS           42         AMINOGLYCOS           43         Zo20738           2 - Severe Interaction         2012-02-23 12:52:05           ONE_APPROVER         ONE_APPROVER	IDES/PENICILLINS IDES/PENICILLINS IDES/PENICILLINS IDES/PENICILLINS s - 45 Here is one of the was selected from with Pending D otherwise act on th	2 9 1 Drug-Drug Interactions that n the list of Approved DDIs Drug Pairs. To review or te drug pairs, click the Drug	New
A Interaction 20207 A Interaction 20208 A Interaction 202007 teraction Description (Required) oncorraph ID ction Status	39         AMINOGLYCOS           30         AMINOGLYCOS           30         AMINOGLYCOS           40         AMINOGLYCOS           40         AMINOGLYCOS           40         AMINOGLYCOS           40         AMINOGLYCOS           40         AMINOGLYCOS           40         AMINOGLYCOS           41         Aminoglycosides/Penicillin           Approved         45           2020738         2 - Severe Interaction           2012-02-23 12:52:05         ONE_APPROVER           FIVE_APPROVER         FIVE_APPROVER	IDES/PENICILLINS IDES/PENICILLINS IDES/PENICILLINS IDES/PENICILLINS s - 45 Here is one of the was selected from with Pending D otherwise act on th	2 9 1 Drug-Drug Interactions that n the list of Approved DDIs Drug Pairs. To review or te drug pairs, click the Drug	New

Figure 26: Drug-Drug Interaction Window

After you click the Drug Pairs button, you see a window similar to the one below. After you click the Edit button, you can act on the drug pairs.

rug Dair O	ustamization								D	
ug Pair C	ustomization								<u>Page H</u>	elp
ancel Edit	I									
Interactio		raction ID	Interaction Descrip	tion			ion Severity		Action Status	
Interaction B Interaction	1 <u>45</u>		AMINOGLYCOSIDES/PENICILLINS COSIDES/PENICILLINS			2 3		Approved N/A		
- Eviation (	(A. Ourstean Descent/o									
Interaction	/A Custom Record(s on Type In	) teraction ID	Interaction Descript	ion		Interaction	n Severity	Interaction	Action Status	
Interaction	20207	37 AMINOGL	LYCOSIDES/PENICILLINS		1		Ap	proved		
Interaction	20207		LYCOSIDES/PENICILLINS		3			ew		
Interaction Interaction	20207		LYCOSIDES/PENICILLINS		2			ew		
Interaction	20208 20207		LYCOSIDES/PENICILLINS LYCOSIDES/PENICILLINS - Test 1		9			ew oproved		
Drug Pa	irs									
		DIFIED	REVIEWED	APPRO	/ED	[	DELETE REV	1EWED		
NEW				APPRO     APPRO     Severity     Level     Level     Descriptio	Interaction	n Corresponding FDB Interaction ID	g Request	IEWED Request Assigned To	Action Perform	
NEW	Routed Generic #	1 Routed Generic #2	Interaction Description	Severity Level	Interaction n ID 2020738	Corresponding n FDB Interaction ID	g Request Submitted By	Request	Ву	
NEW     Action     Status     New	MO     Routed Generic #     Description     ACACIA ORAL     G STREPTOMYCIN     SULFATE	Routed Generic #2     Description     ABOBOTULINUMTOXINA     INTRAMUSCULAR     NAFCILLIN SODIUM     INTRAVENOUS	Interaction Description VA Custom AMINOGLYCOSIDES/PENICILLINS	Severity Level Code 2 Severe	Interaction n ID 2020738 2020738	n Corresponding FDB Interaction ID 45	g Request Submitted By	Request Assigned To FIVE_APPROVER	Ву	
NEW	MO     Routed Generic #     Description     ACACIA ORAL     G STREPTONYCIN     SULFATE     INTRAMUSCULAF     1.2-     PENTANEDIOL	ABOBOTULINUMTOXINA INTRAMUSCULAR NAFOLLIN SODIUM INTRAVENOUS 1,3-BUTANEDIOL MISCELLANEOUS	Interaction Description VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom	Severity Level Code         Severity Level Descriptio           2         Severe Interaction           2         Severe	Interaction 1D 2020738 2020738 2020738	n Corresponding FDB Interaction ID 45 45	9 Request Submitted By FIVE_APPROVER	Request Assigned To FIVE_APPROVER	By FIVE_APPROVI ONE_APPROV	
NEW     Action     Status     New     Approve     New	MO     Routed Generic #     Description     ACACIA ORAL     STREPTOMYCIN     SULFATE     INTRAMUSCULAF     1.2-	Routed Generic #2     Description     ABOBOTULINUMTOXINA     INTRAMUSCULAR     NAFCILLIN SODIUM     INTRAVENOUS     1,3-BUTANEDIOL     MISCELLANEOUS     NAFCILLIN     SODIUM/DEXTROSE     5%-WATER	Interaction Description VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom	Severity Level Code 2 Severe Interaction 2 Severe Interaction 2 Severe	Interaction 2020738 2020738 2020738 2020738 2020738	A Corresponding FDB Interaction ID 45 45 45	9 Request Submitted By FIVE_APPROVER	Request Assigned To FIVE_APPROVER	By FIVE_APPROVI ONE_APPROV	
Action Status New Approve	MO     Routed Generic #     Description     ACACIA ORAL     ACACIA ORAL     STREPTOMYCIN     SULFATE     I.2-     PENTANEDIOL     MISCELLANEOUS     d STREPTOMYCIN     SULFATE	Routed Generic #2     Description     ABOBOTULINUMTOXINA INTRAMUSCULAR NAFCILLIN SODIUM INTRAVENOUS     1.3-BUTANEDIOL MISCELLANEOUS NAFCILLIN SODIUMDEXTROSE     5%-WATER NAFCILLIN SODIUMDEXTROSE     5%-UATER	Interaction Description AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS	Severity Level Descriptio 2 Severe Interaction 2 Severe Interaction 2 Severe Interaction 2 Severe Interaction 2 Severe	Interaction ID 2020738 2020738 2020738 2020738 2020738	Corresponding FDB Interaction ID 45 45 45 45	9 Request Submitted By FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER	Request Assigned To FIVE_APPROVER	By FIVE_APPROVI ONE_APPROVI FIVE_APPROVI	
NEW	Routed Generic # Description     ACACIA ORAL     ACACIA ORAL     STREPTOMYCIN     SULFATE     INTRAMUSCULAF     1.2-     PENTANEDIOL     MISCELLANEOUS     STREPTOMYCIN     SULFATE     INTRAMUSCULAF     STREPTOMYCIN     STREPTOMYCIN     STREPTOMYCIN     SULFATE	ABOBOTULINUMTOXINA INTRAMUSCULAR INTRAMUSCULAR INTRAMUSCULAR INTRAVENOUS I,3-BUTANEDIOL MISCELLANEOUS NAFCILLIN SODIUMDEXTROSE 5%-WATER INTRAVENOUS NAFCILLIN SODIUMDEXTROSE	Interaction Description AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom	Severity         Severity           Level         Descriptio           Code         Descriptio           2         Severe           Interaction         Severe           2         Severe           Interaction         Severe           2         Severe           Interaction         Severe           Interaction         Severe           2         Severe           Interaction         Severe           2         Severe	Interaction ID 2020738 2020738 2020738 2020738 2020738	ACOrresponding FDB Interaction ID 45 45 45 45 45 45	9 Request Submitted By FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER	Request Assigned To FIVE_APPROVER FIVE_APPROVER	By FIVE_APPROVI ONE_APPROVI FIVE_APPROVI ONE_APPROVI	
<ul> <li>Z NEW</li> <li>ect Action Status</li> <li>New</li> <li>Approve</li> <li>Mew</li> <li>Approve</li> <li>New</li> <li>New</li> <li>New</li> <li>New</li> <li>New</li> </ul>	MO     Routed Generic #     Description     ACACIA ORAL     ACACIA ORAL     STREPTOMYCIN     SULFATE     INTRAMUSCULAF     INTRAMUSCULAF     SULFATE     MISCELLANEOUS     STREPTOMYCIN     SULFATE     MISCELLANEOUS     PAROMOMYCIN	ABOBOTULINUMTOXINA INTRANUSCULAR NAFCILLIN SODIUM INTRAVENOUS 1,3-BUTANEDIOL MISCELLANEOUS NAFCILLIN SODIUMDEXTROSE 5%-WATER INTRAVENOUS NAFCILLIN SODIUMDEXTROSE 5%-WATER INTRAVENOUS	Interaction Description VA Custom AMINOGLYCOSIDES/PENICILLINS	Severity Level         Severity Descriptio           2         Severe Interaction           2         Severe	102020738 2020738 2020738 2020738 2020738 2020738	Corresponding FDB Interaction ID 45 45 45 45 45 45 45	9 Request Submitted By FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER	Request Assigned To FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER	By FIVE_APPROVI ONE_APPROVI ONE_APPROVI FIVE_APPROVI SIX APPROVE	
NEW     Action     Status     New     Approve     New     New     New     New	Control Contro Control Control Control Control Control Control Control Control Co	ABOBOTULINUMTOXINA INTRANUSCULAR INTRANUSCULAR INTRAVENOUS 1,3-BUTANEDIOL MISCELLANEOUS NAFCILLIN SODIUMDEXTROSE 5%-WATER INTRAVENOUS NAFCILLIN SODIUMIDEXTROSE 5%-WATER INTRAVENOUS PIPERACII IN	Interaction Description VA Custom AMINOGLYCOSIDES/PENICILLINS	Severity Level         Severity Descriptio           2         Severe Interaction           2         Severe	102020738 2020738 2020738 2020738 2020738 2020738 2020738	Corresponding FDB Interaction ID 45 45 45 45 45 45 45	9 Request Submitted By FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER SIX APPROVER	Request Assigned To FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER SIX APPROVER	By FIVE_APPROVI ONE_APPROVI ONE_APPROVI FIVE_APPROVI SIX APPROVE	
NEW	Routed Generic # Description     ACACIA ORAL     ACACIA ORAL     STREPTOMYCIN     SULFATE     INTRAMUSCULAF     1.2-     PENTANEDIOL     MISCELLANEOUS     STREPTOMYCIN     SULFATE     INTRAMUSCULAF     STREPTOMYCIN     SULFATE     MISCELLANEOUS     PAROMOMYCIN Select/Deselect All II Required)	ABOBOTULINUMTOXINA INTRANUSCULAR INTRANUSCULAR INTRAVENOUS 1,3-BUTANEDIOL MISCELLANEOUS INSCELLANEOUS INSCELLANEOUS INSCELLANEOUS INTRAVENOUS INAFCILIN SODIUM/DEXTROSE 5%-WATER INTRAVENOUS PIPERACII IN	Interaction Description VA Custom AMINOGLYCOSIDES/PENICILLINS	Severity Level         Severity Descriptio           2         Severe Interaction           2         Severe	102020738 2020738 2020738 2020738 2020738 2020738 2020738	Corresponding FDB Interaction ID 45 45 45 45 45 45 45	9 Request Submitted By FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER SIX APPROVER	Request Assigned To FIVE_APPROVER FIVE_APPROVER FIVE_APPROVER SIX APPROVER	By FIVE_APPROVI ONE_APPROVI ONE_APPROVI FIVE_APPROVI SIX APPROVE	

Figure 27: List of Drug Pairs You Can Act On

When you add new drug pairs, they are by default assigned to the same User ID as the associated DDI, but an Approver can reassign the drug pairs.

Home Advanced Query/Customization Easy Search Drug Pair Lookup Reports Help	WITED STATES DEPARTMENT OF VETERANS AFFAIRS		
Cancel Edit       Interaction Type       Interaction ID       Interaction Description       Interaction Severity       Interaction Action Status         FDB Interaction       12025221       PIMO2DE/TRICYCLIC COMPOUNDS       1       Interaction Action Status         FDB Interaction       1202       PIMO2DE/TRICYCLIC COMPOUNDS       1       Interaction Action Status         FDB Interaction       1202       PIMO2DE/TRICYCLIC COMPOUNDS       1       Interaction Action Status         Select Drug Paris 10 add to the above VA Custom Interaction       Select Drug Paris 10 add to the above VA Custom Interaction         Select Drug Paris 10 add to the above VA Custom Interaction       Select Drug Paris 10 add to the above VA Custom Interaction         Select Tom Iist of Generic drug pairs - note that a drug pair must be chosen before clicking the Customize button, Routed Generic #2 fields cannot be the same values. Route Generic #2 mas Nolvo the same order as the interaction Description.       Routed Generic #2 Description         Routed Generic drug pairs - note that a drug pair must be chosen before clicking the Customize button, Routed Generic #2 Description       Routed Generic #2 Description         Routed Generic drug pairs - onte that a drug pair to above balance clicking the Customize button, Routed Generic #2 Description       Routed Generic #2 Description         Routed Generic #1 and Routed Generic #2 mast Nolve be same order as the interaction Description.       Routed Generic #2 Description       Routed Generic #2 Description	PECS PHARMACY EN CUSTOMIZATIO	TERPRISE IN SYSTEM	Welcome, FIVE_APPROVER   Logout
Cancel Edit            Miteraction Type         Interaction ID         Interaction Action Status         Interaction Action Status         Interaction ID         Interaction         Interaction         Interaction ID         Interaction ID         Interaction ID         Interaction         Interactid	Home Advanced Query/Customization E	asy Search Drug Pair Lookup Reports Help	
Interaction Type         Interaction ID         Interaction Description         Interaction Seventy         Interaction Action Status           A Interaction         253         PRIOZDE/FINICYCLIC COMPOUNDS         1         NA             O Select Drug Pairs to add to the above VA Custom Interaction             Be interaction         0         Difference         NA             Select Drug Pairs to add to the above VA Custom Interaction             etcol Drug Pairs to corresponding FDB Interaction <ul> <li>Existing customized Drug Pairs for this FDB Drug-Drug Interaction are not displayed.</li> </ul> <td>Drug Pair Customization</td> <td></td> <td>Page Help</td>	Drug Pair Customization		Page Help
All Interaction       2020221       PINO2DEFTRICYCLUC COMPOUNDS       1       Approved         DBB Interaction       328       PINO2DEFTRICYCLUC COMPOUNDS       1       NA	Cancel Edit		
DB Interaction       328       PINO2DEFINICYCLIC COMPOUNDS       1       NA <ul> <li>Select Drug Pairs to add to the above VA Custom Interaction</li> <li>Select Drug Pairs from corresponding FDB Interaction</li> <li>Existing customized Drug Pairs for this FDB Drug-Drug Interaction are not displayed.</li> <li>Drug pair from Routed Generic Pairs note that a drug pair must be chosen before clicking the Customize button. Routed Generic #1 and Routed Generic #2 fields cannot be the same value. Route encir #1 and Routed Generic #2 fields cannot be the same value. Route encir #1 and Routed Generic #2 Description</li></ul>			
elect Drug Pair(s) Source Vary pairs from corresponding FDB Interaction Drug pairs from Routed Generic Drug lists elect from list of Generic Drug pairs - note that a drug pair must be chosen before clicking the Customize button. Routed Generic #1 and Routed Generic #2 fields cannot be the same value. Route eneric #1 and Routed Generic #2 must follow the same order as the Interaction Description. Routed Generic #2 Description Routed G			
Prup pairs from corresponding FDB Interaction     Drup pairs from Routed Generic Trug pairs - note that a drug pair must be chosen before clicking the Customize button. Routed Generic #2 must holivo the same order as the Interaction Description    elect from list of Generic Trug pairs - note that a drug pair must be chosen before clicking the Customize button. Routed Generic #2 fields cannot be the same value. Route eneric #1 and Routed Generic #2 Description    Routed Generic Trug pairs - note that a drug pair must be chosen before clicking the Customize button. Routed Generic #2 Description    Routed Generic Trug pairs - note that a drug pair must be chosen before clicking the Customize button. Routed Generic #2 Description    Routed Generic #2 Description   Routed Generic #2 Description   Routed Generic #2 Description                                                         Enter values in text boxes below and click 'Customize' to add drug pairs to interaction.    Reference Text (drug pair reference text):		Custom Interaction	
elect from list of Generic drug pairs - note that a drug pair must be chosen before clicking the Customize button. Routed Generic #2 fields cannot be the same value. Route eneric #1 and Routed Generic #2 Description Routed Generic #2 Description 0.225 % SODIUM CHLORIDE INJECTION Customize' to add drug pairs to interaction. Reference Text (drug pair reference laxt): Current Action Reason (for drug pair creation): (Required) FVE_APPROVER Customize' D Drug Pairs		Existing customized Drug Pairs for this FDB Drug-Drug Interactive	on are not displayed.
eneric #1 and Routed Generic #2 must follow the same order as the Interaction Description.          Routed Generic #1 Description       0.225 % SODIUM CHLORIDE INJECTION         0.225 % SODIUM CHLORIDE INJECTION       0         Inter values in text boxes below and click "Customize" to add drug pairs to interaction.         Reference Text (drug pair reference text):         Vou can change the assignee for the new drug pair when assigning a new drug pair to an approved DDI, as the default is the same user who is assigned the DDI.         Rurrent Action Reason (for drug pair creation): (Required)         Keigneed To(Required)         FVE_APPROVER         Customize	Prug pair from Routed Generic Drug lists		
Reference Text (drug pair reference text):	Routed Generic	#1 Description	
Reference Text (drug pair reference text):  Current Action Reason (for drug pair creation): (Required)  Securent Action Reason (for drug pair creation): (Required)  Secure 10  Secure 20  Customize		Enter values in text boxes below and click 'Customize' to add drug u	pairs to interaction.
Surrent Action Reason (for drug pair creation): (Required)  Segment To(Required)  FVE_APPROVER  Customize  D Orug Pairs	Reference Text (drug pair reference text):		
current Action Reason (for drug pair creation): (Required)  Customize  Drug Pairs  drug pair when assigning a new drug pair to an approved DDI, as the default is the same user who is assigned the DDI.  Five_Approvement  Drug Pairs			<u></u>
Current Action Reason (for drug pair creation): (Required) to an approved DDI, as the default is the same user who is assigned the DDI. Isological To(Required) FIVE_APPROVER Customize Drug Pairs			
Surrent Action Reason (for drug pair creation): (Required) Second To(Required) FVE_APPROVER Customize Drug Pairs			
Customize Drug Pairs	Current Action Reason (for drug pair creation): (I	tequired)	
Every Customize			
Customize Drug Pairs	seigned To(Required)		
Drug Pairs	FIVE_APPROVER		
	Customize		
Home Advanced Query/Customization Easy Search Drug Pair Lookup Reports Help	Drug Pairs		
	Home	Advanced Query/Customization Easy Search Drug Pair	Lookup Reports Help

Figure 28: Assigned To Drop-Down When Adding a Drug Pair

When you are working with the Drug Pair customization window and handling the pending drug pairs, you can use the drop-down to assign the Drug Pairs to a different user. The default is the Approver who is assigned to the DDI, but you can change that.

Home	e Adva	anced Query/Custo	mization Easy Search	h Drug Pair Lookup Reports	i Help							
rug	Pair Cu	stomization									<u>Pa</u>	<u>qe Hel</u>
ance	el Edit											
	teraction raction	Type Inter 2020738	raction ID	Interaction Descrip AMINOGLYCOSIDES/PENICILLINS	tion			Interaction 2	on Severity	Interaction Approved	Action Status	
	teraction	45		COSIDES/PENICILLINS				3		N/A		
ner E	xisting VA	Custom Record(s)										
	nteraction raction	Type Int 202073	eraction ID	Interaction Descript YCOSIDES/PENICILLINS	tion		1	Interaction		Interaction pproved	Action Status	
Inte	raction	202078	35 AMINOGL	YCOSIDES/PENICILLINS			3		N	lew		
	raction	202073	39 AMINOGL	YCOSIDES/PENICILLINS			2			pproved		
	raction raction	202088 202074		YCOSIDES/PENICILLINS YCOSIDES/PENICILLINS - Test 1			9			lew pproved		
~	NEW	MOE	DIFIED	REVIEWED		APPRO\	/ED		DELETE RE	/IEWED		
						Severity						
lect	Action Status	Routed Generic #1 Description	Routed Generic #2 Description	Interaction Description	Severity Level Code	Level Description	Interaction n ID	n Corresponding FDB Interaction ID	Request Submitted By	Request Assigned To	Action Perform By	
		Description   1,2- PENTANEDIOL	Description 1,3-BUTANEDIOL MISCELLANEOUS	Interaction Description	Level Code	Level	n ID 2020738	Interaction ID	Submitted By		Ву	
]	Status	Description  A 1,2-	Description 1,3-BUTANEDIOL MISCELLANEOUS	VA Custom AMINOGLYCOSIDES/PENICILLINS	Level Code 2	Level Description Severe	n ID 2020738 2020738	Interaction ID 45	Submitted By	Assigned To	By R FIVE_APPROV	I
2	Status . New	Description  1,2- PENTANEDIOL MISCELLANEOUS	Description 1,3-BUTANEDIOL MISCELLANEOUS ABOBOTULINUMTOXINA	VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom	Level Code 2 2 2	Level Description Severe Interaction Severe	n ID 2020738 2020738 2020738	Interaction ID 45 45	Submitted By FIVE_APPROVEF	Assigned To	By R FIVE_APPROV	
2	Status New New New Approved	Description - 1.2- PENTANEDIOL MISCELLANEOUS ACACIA ORAL PAROMOMYCIN SULFATE ORAL STREPTOMYCIN SULFATE INTRAMUSCULAR	Description 1,3-BUTANEDIOL MISCELLANEOUS ABOBOTULINUMTOXINA INTRAVENCULAR PIPERACILLIN SODIUMDEXTROSE 5%-WATER INTRAVENOUS NAFCILLIN SODIUMDEXTROSE 5%-WATER INTRAVENOUS	VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS	Level Code 2 2 2 2 2 2	Level Description Severe Interaction Severe Interaction Severe Interaction Severe Interaction	n ID 2020738 2020738 2020738 2020738	Interaction ID           45           45           45           45           45	Submitted By FIVE_APPROVEF FIVE_APPROVER SIX_APPROVER FIVE_APPROVEF	Assigned To R FIVE_APPROVER R FIVE_APPROVER SIX_APPROVER	By R FIVE_APPROV R FIVE_APPROV SIX_APPROVE ONE_APPROV	
	Status New New New Approved	Description - 1.2- PENTANEDIOL MISCELLANEOUS ACACIA ORAL PAROMOMYCIN SULFATE ORAL STREPTOMYCIN SULFATE INTRAMUSCULAR	Description 1,3-BUTANEDIOL MISCELLANEOUS ABOBOTULINUMTOXINA INTRAMUSCULAR PIPERACILLIN SODIUMDEXTROSE 5%-WATER INTRAVENOUS NAFCILLIN SODIUMDEXTROSE 5%-WATER INTRAVENOUS NAFCILLIN SODIUM INTRAVENOUS	VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom VA Custom	Level Code 2 2 2 2 2 2 2	Level Description Severe Interaction Severe Interaction Severe Interaction Severe	n ID 2020738 2020738 2020738 2020738	Interaction ID           45           45           45           45           45	Submitted By FIVE_APPROVER FIVE_APPROVER SIX_APPROVER	Assigned To R FIVE_APPROVER R FIVE_APPROVER SIX_APPROVER	By R FIVE_APPROVI R FIVE_APPROVI SIX_APPROVE	
	Status New New Approved Approved	Description    1,2- PENTANEDIOL MISCELLANEOUS ACACIA ORAL PAROMOMYCIN SULFATE ORAL STREPTOMYCIN SULFATE INTRAMUSCULAR STREPTOMYCIN SULFATE SUL	Description 1.3-BUTANEDIOL MISCELLANEOUS ABOBOTULINUMTOXINA INTRAMUSCULAR PIPERACILLIN SODIUMDEXTROSE 5%-WATER INTRAVENOUS NAFGILLIN SODIUMDEXTROSE 5%-WATER INTRAVENOUS NAFGILLIN SODIUM INTRAVENOUS	VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom	Level Code 2 2 2 2 2 2 2	Level Description Severe Interaction Severe Interaction Severe Interaction Severe Interaction	n ID 2020738 2020738 2020738 2020738	Interaction ID           45           45           45           45           45           45           45           45	Submitted By FIVE_APPROVEF FIVE_APPROVER SIX_APPROVER FIVE_APPROVEF	Assigned To R FIVE_APPROVER R FIVE_APPROVER SIX_APPROVER	By R FIVE_APPROVI R FIVE_APPROVI SIX_APPROVE ONE_APPROV ONE_APPROV	
	Status New New New Approved New	Description - 1.2- PENTANEDIOL MISCELLANEOUS ACACIA ORAL PAROMOMYCIN SULFATE ORAL STREPTOMYCIN SULFATE INTRAMUSCULAR STREPTOMYCIN SULFATE INTRAMUSCULAR	Description 1.3-BUTANEDIOL MISCELLANEOUS ABOBOTULINUMTOXINA INTRAMUSCULAR PIPERACILLIN SODIUMDEXTROSE 5%-WATER INTRAVENOUS NAFGILLIN SODIUMDEXTROSE 5%-WATER INTRAVENOUS NAFGILLIN SODIUM INTRAVENOUS	VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom AMINOGLYCOSIDES/PENICILLINS VA Custom	Level Code 2 2 2 2 2 2 2	Level Description Severe Interaction Severe Interaction Severe Interaction Severe Interaction Severe	<ul> <li>ID</li> <li>2020738</li> <li>2020738</li> <li>2020738</li> <li>2020738</li> <li>2020738</li> </ul>	Interaction ID 45 45 45 45 45 45 45 45	Submitted By FIVE_APPROVEF FIVE_APPROVER SIX_APPROVER FIVE_APPROVEF	Assigned To R FIVE_APPROVER R FIVE_APPROVER SIX_APPROVER R R FIVE APPROVER R R FIVE APPROVER	By R FIVE_APPROV R FIVE_APPROVE SIX_APPROVE ONE_APPROV ONE_APPROV R FIVE APPROV 2	

Figure 29: Assigned To Drop Down When Editing Drug Pairs


**Note:** If you change the state of the drug pairs to Submit as Reviewed or Submit for Delete, the drug pairs are automatically reassigned to the "Unassigned" category.

Also note: If you wish to put a Drug-Drug Interaction (DDI) into the Delete_Reviewed state, the Drug Pairs associated with the DDI must be in either a "Delete Reviewed," "Rejected" or "Deleted" state.

## **Record Locking Feature**

All five concepts available in PECS, Drug-Drug Interaction, Drug Pairs, Professional Monograph, Dose Range, and Duplicate Therapy all have a record locking feature, which means that only a single user can edit a PECS record. Multiple users can no longer simultaneously edit a record. This feature eliminates the possibility that users can overwrite each others' changes and/or omit changes made by another.

For instance, if a user is editing a Drug-Drug Interaction and another user tries to edit the same record, here is the message that is displayed:



Here is the scenario:

- 1. User 1 logs in (e.g., Approver 1).
- 2. User 1 opens an active (not historical) record (in this sample, a Drug-Drug Interaction, but could be any concept) from either their own list or from building a query:




3. User 1 determines they need to make a change to this record. They click the Edit button and the following window displays:

	mization Easy Search Drug Pair Lookup Reports Help	_
ug-Drug Interaction	Ês	ge His
incel Edit		
Interaction Type Int B Interaction 112	nteraction ID Interaction Description Interaction Severity Interaction Action Status ANTIDUABETICS, ORAUSALICITLATES 3 NIA	
eraction Description (Required)	ANTIDIABETICS, ORAL/SAUCHATES	
mograph IQ.	Antidiabetics, Oral/Salicylates - 112	*
tion Status presponding FDB Interaction ID.	New	
eraction ID	112 2020881	
everity Level Code (Required)	3 - Moderate Interaction	-
tion Date	2012-03-14 06 42 08	
tion Performed By	FOUR_APPROVER	
equest Submitted By	FOUR_APPROVER	
tion Effective Date	UNASSIGNED	*
inical Effect Code 1 (Required)	Increased effect of the former drug	~
inical Effect Code 2		*
3i Number		*
Di Text		
		8
Facts Number		9
I Facts Onset		*
Facts Severity		×
Facts Documentation		*
I Facts Text		0
		R
icromedex Seventy		*
icromedex Onset icromedex Substantiation		*
icromedex Text		2
edline Hits		109
edline Text		*
ackage Insert		2
ackage Insert Text		-
3M Criteria		100
BM Criteria Text		
DS Guidelines		-
DS Guidelines Text		*
eraction Source		122
teraction Type		* *
ighest Level of Evidence		~
oup Discussion		0
		19
ton Reason History	2012/07/14 10-42:00 CME_APPROVEN: test NMC 2012/07/14 4:01:05 TFOGT NHEAPPROVEN: test squain mmc 2012/07/14 4:01:01:07 FOGT APPROVEN: testing 2012/07/14 4:01:01:01 FOGT APPROVEN: testing	6 D
rrent Action Reason (Reguired)		10
		-9
ancel Edit Submit As Revie	ewed Reject Modify	

4. At the same time User 2 (e.g., Approver 3) signs into the same record:

	MACY ENTERPRISE OMIZATION SYSTEM			Welcome, THREE	_APPROVER   Logout
Home Advanced Query/Custom	ization Easy Search Drug Pair Lookup R	Reports Help			Page Help
	hutten helew				Page Help
dit Drug Pairs	Julion below.				Print Page
formational Messages:					
The associated drug pairs are not a rug pairs.	all approved as yet. To approve the interaction, you mu	st approve all the associ	ated drug pairs first. Click on the Drug	g Pairs button to view and ap	prove the associated
	eraction ID Interaction De	escription	Interaction Severity	Interaction	Action Status
DB Interaction <u>112</u>	ANTIDIABETICS, ORAL/SALICYLATE	.S	3	N/A	
teraction Description ( <mark>Required)</mark>	ANTIDIABETICS, ORAL/SALICYLATES				
onograph ID	Antidiabetics, Oral/Salicylates - 112				
ction Status	New				
orresponding FDB Interaction ID	112				
teraction ID	2020881				
everity Level Code <mark>(Required)</mark>	3 - Moderate Interaction				
tion Date	2012-03-14 06:49:24				
tion Performed By	FOUR_APPROVER				
equest Submitted By	FOUR_APPROVER				
tion Effective Date					
equest Assigned To	UNASSIGNED				
linical Effect Code 1 (Required)	increased effect of the former drug				
inical Effect Code 2					
01 Number					
DI Text					
Facts Number					
Facts Onset					
Facts Severity					
I Facts Documentation					
I Facts Text					
icromedex Severity					
icromedex Onset					
icromedex Substantiation					
icromedex Text					
edline Hits					
edline Text					
ackage Insert					
ackage Insert Text					
3M Criteria					
3M Criteria Text					
DS Guidelines					
DS Guidelines Text					
eraction Source					
teraction Type					
ighest Level of Evidence					
roup Discussion					
ction Reason History	2012/03/14 18:49:24 ONE_APPROVER: Test 1 2012/03/14 18:42:08 ONE_APPROVER: test 1 2012/03/14 16:27:06 THREE_APPROVER: Test 2012/03/14 14:01:22 FOUR_APPROVER: test: 2012/03/14 14:00:34 FOUR_APPROVER: creat	MMC t again mmc ing			
urrent Action Reason (Required)					
Edit Drug Pairs					Print Page
	Home Advanced Query/Customization	Easy Search	Drug Pair Lookup Reports	<u>s Help</u>	

5. User 2 clicks Edit, and the following message displays:



- 6. User 1 makes changes and clicks the Modify button. The record is returned in read-only mode with the changes:
- 7. User 2 waits a few minutes and clicks the Edit button again. They receive this message:

Window	s Internet Explorer 🛛 🛛
1	This Record was recently modified by another user and is no longer current. Click OK to open the current record.
	ОК

User 2 and all users will now be able to access the latest changes that have been made to a customization.

The Record Locking feature has safeguards that prevent a user from keeping a record locked too long; also, if the user leaves the record for any reason without completing the modification, the user is warned that they will lose their changes if they continue to navigate away from the record.

If the user does choose to leave the record without completing and saving their changes, the record is unlocked so others may work on it. If the user does not respond to the warning message, the

Here is another scenario:

- 1. You sign on and run a query for the concept for a customized record you want to modify.
- 2. You find the record and click the Modify button. The record opens in Edit mode and is locked for other users.
- 3. You begin to edit the record and for whatever reason, decide to do any one of the following: click any link on the page (except the help link), click any of the top navigation buttons, or close the browser. You see this message:

Windows	s Internet Explorer 🛛 🔀
⚠	Are you sure you want to navigate away from this page?
	Press OK to continue, or Cancel to stay on the current page.
	OK Cancel

What this message means is that if you click OK, you will be taken to whatever link you clicked, your changes will be lost, and the record will be unlocked so others may edit it. If you click Cancel, you remain on the record you were editing, in Edit mode and the record remains locked for other users.

4. You continue to edit the record, but end up having to answer several instant messages for 19 minutes. You hear a beep and go back to the PECS window, and see this message:

Window	rs Internet Explorer 🛛 🔀
1	Your editing session on this page will end in one minute. To avoid losing your changes click OK to extend your editing session
	ОК

5. You click OK and continue to edit the record, but are called away. You are called away for 30 minutes. When you return, you see the same message as in Step 4, but this time if you click OK, you are returned to the read-only record, and any changes you made will have been lost.

**Note:** The same is true if you do not respond to the message that is displayed in Step 3 within 19 minutes. The editing expiration message shown in Step 4 displays, and if you do not click OK within one minute, the record is unlocked. When you return, you must click OK and you are returned to the read-only record.

# Creating Multiple VA Custom Drug-Drug Interactions to One FDB Record

You can create multiple VA Custom Drug-Drug Interactions (DDIs) from one corresponding FDB Record. If you open an FDB DDI record on the Advanced Query/Customization page, the DDI Detail page will open. If there are any VA custom records for this FDB DDI, you'll see a message stating that "The following VA custom record(s) already exist for this FDB Drug-Drug Interaction," and a table and a link to any interactions displays. See below:

Reput decide of the set buttor buttor         Reput decide of the set buttor         Reput dec		AIRS ENTERPRISE TION SYSTEM Easy Search Drug Pair Lookup Reports	Help		Welcome, SIX_	APPROVER   Logout
<text></text>	Drug-Drug Interaction					Page Help
		low.				
Instantion therease in the space of th		(	<ul> <li>Here are the Cus FDB record. You of</li> </ul>	tom Records for this can create more. Note		Print Page
Anderson models       Unit of the sub of the SDD Drug Drug Drug Drug Drug Drug Drug Dr			that the interaction	on severity levels are		
Image: Description of the stand product o						
Numeradion         Absorbation Numeration         Approved         Approved           Numeradion         Nonconstruction         Nonconst						
Management       Resultation (VPH 24 Multions - 2105         Corresponding OPD Interaction       2105         Sourcity Level Code (Regiment)       3-Moderate Interaction         Resultation Code (Regiment)       increased effect of the former drug         Clinical Effect Code 1 (Regiment)       increased effect of the former drug         Clinical Effect Code 1 (Regiment)       increased effect of the former drug         Clinical Effect Code 1 (Regiment)       increased effect of the former drug         Clinical Effect Code 1 (Regiment)       increased effect of the former drug         Clinical Effect Code 1 (Regiment)       increased effect of the former drug         Clinical Effect Code 1 (Regiment)       increased effect of the former drug         Clinical Effect Code 1 (Regiment)       increased effect of the former drug         D Facts Number       increased effect of the former drug         D Facts Number       increased effect of the former drug         D Facts Number       increased effect of the former drug         D Facts Number       increased effect of the former drug         D Facts Number       increased effect of the former drug         D Facts Number       increased effect of the former drug         D Facts Number       increased effect of the former drug         D Facts Number       increased effect of the former drug      <	VA Interaction 2020334 VA Interaction 2020957	RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS	1 9	Interaction Severity	Approved New	ction Status
Classing Globing Law 20102010Soweig Voor Cook (Regins O)	Interaction Description (Required) RASA	GILINE/CYP1A2 INHIBITORS				•
Seventy Levo Cole (Reginal)       2 should intention         Trade Stripped To       Interset offet former drug         Chical Effet Code (Reginal)       Interset offet former drug         Chical Effet Code (Reginal)       Interset offet former drug         ED Humber       Interset offet former drug         ED Fach Stravelly       Interset offet former drug         Ed Fach Stravelly       Interset offet former drug         Ed Fach Stravelly       Interset offet former drug         Morender Grad       Interset offet former drug         Morender Grad       Interset offet former drug         Morender Grad       Interset offet former drug         Package Institution       Interset offet former drug         Package Insting       Interset offet former drug <t< td=""><td>Monograph ID. Rasa</td><td>giline/CYP1A2 Inhibitors - 2105</td><td></td><td></td><td></td><td>1</td></t<>	Monograph ID. Rasa	giline/CYP1A2 Inhibitors - 2105				1
Russet Asignet 70       Increased effect of the former dug         Clinical Effect Code 2       Increased effect of the former dug         EOI Number       Increased effect of the former dug         EOI Ted       Increased effect of the former dug         En Stat Number       Increased effect of the former dug         En Stat Number       Increased effect of the former dug         En Stat Number       Increased effect of the former dug         En Stat Number       Increased effect of the former dug         Increased Substantiation       Increased effect of the former dug         Micromoter Ted       Increased effect of the former dug         Micromoter Ted       Increased effect of the former dug         Package Insert Ted       Increased effect of the former dug         Package Insert Ted       Increased effect of the former dug         Package Insert Ted       Increased effect of the former dug         Package Insert Ted       Increased effect of the former dug         Package Insert Ted       Increased effect of the former dug         Package Ted       Increa	Corresponding FDB Interaction ID 2105					
Clickal Effect Code 1 (Regined )       Increased effect of the former dug         Clickal Effect Code 2       Increased effect of the former dug         ED Number       Increased effect of the former dug         Di Tada Sumber       Increased effect of the former dug         Di Facts Onnou       Increased effect of the former dug         Di Facts Onnou       Increased effect of the former dug         Di Facts Onnou       Increased effect of the former dug         Di Facts Onnou       Increased effect of the former dug         Di Facts Onnou       Increased effect of the former dug         Di Facts Onnou       Increased effect of the former dug         Di Facts Onnou       Increased effect of the former dug         Micromeder Statistical       Increased effect of the former dug         Micromeder Statistical       Increased effect of the former dug         Micromeder Statistical       Increased effect of the former dug         Padage Instatistical       Increased effect of the	Severity Level Code (Required) 3 - Mo	derate Interaction				
Cikical Effet Code 2         EDi Number         EDi Ted         Di Facto Number         Di Facto Number         Di Facto Source Antono         Micromedere Soutca Antono         Micromedere Toxi         Pacto Rest         Pacto Rest         Micromedere Toxi         Pacto Rest         Micromedere Toxi         Pacto Rest         Micromedere Toxi         Pacto Rest         Micromedere Toxi         Micromedere Toxi         Micromedere Toxi         Micromedere Toxi	Request Assigned To					
EVI wurder   EVI wurder   EVI wurder   Di Fasts Number   Di Fasts Number   Di Fasts Overlettation   Di Fasts Documentation   Di Fasts Documentation   Micromeder Severity   Micromeder Severity   Meinler Sd   Meinler Sd   Meinler Sd   Beild St   So Sudielines Text   Micromeder Severity   Micromeder Severity<		ised effect of the former drug				
Elorad         Di Facts Number         Di Facts Nomed         Di Facts Nomed         Di Facts Soventho         Di Facts Tolumentation         Di Facts Tolumentation         Micromoders Soventhy         Micromoders Soventhy         Micromoders Solution         Postage Insert Solution         Postage Insert Solution         Micromoders Fasi         Interactor Source         Micromoders Fasi         Interactor Source         Highers Level of Evidence         Orup Discussion         Current Actor Resource         Micromoders Response         Micromoders Response						
D Facts Number       D Facts Soverity         D Facts Soverity       D Facts Soverity         D Facts Soverity       D Facts Soverity         Micromeders Soverity       Micromeders Soverity         Package Insert Cont       Micromeders Soverity         Package Insert Cont       Micromeders Soverity         Polity Create Soverity       Micromeders Soverity         Polity Create Soverity       Micromeders Soverity         Interaction Sovere       Micromeders Soverity         Interaction Sovere       Micromeders Soverity         Courd Discussion       Micromeders Soverity         Enter Construct (Required)       Micromeders Soverity         Enter Construct (Required)       Micromeders Soverity         Micromeders Soverity       <						
D Facts Onset       U Facts Severity         D Facts Documentation       U Facts Total         D Facts Total       U Facts Total         Micromedox Severity       U Facts Onset         Micromedox Onset       U Facts Onset         Micromedox Total       U Facts Onset         Package Inset       U Facts Onset         Package Inset       U Facts Onset         Package Inset       U Facts Onset         Package Inset Total       U Facts Onset         Package Inset Total       U Facts Onset         Interaction Source       U Facts Onset         Interaction Source       U Facts Onset         Interaction Source       U Facts Onset         U Facts						
DiFats Seventy DiFats Tot DiFats Tot DiFats Tot DiFats Tot Micromedar Seventy Micromedar Seventy Micromedar Seventy Micromedar Substitution Micromedar Substitution Micromedar Tot Micromedar Tot Micromedar Tot Micromedar Tot Package Insert Tot Package Insert Tot Package Insert Tot PBM Criteria Tox ADD Guidelines Tot Micromedar Set Micromedar Tot Micromedar Tot Micromedar Tot Micromedar Tot Micromedar Tot Micromedar Tot Differe Tot Micromedar Tot Differe Tot D						
D Facts Documentation       U Facts Text         Micromedox Seventy       Micromedox Onset         Micromedox Onset       Micromedox Onset         Micromedox Text       Micromedox Text         Medine Text       Micromedox Onset         Medine Text       Micromedox Onset         Medine Text       Micromedox Onset         Medine Text       Micromedox Onset         Package Insert Text       Micromedox Onset         PDB Criteria Text       Micromedox Onset         ADS Guidelines Text       Micromedox Onset         Interaction Source       Micromedox Onset         Interaction Type       Micromedox Onset         Highest Level of Evidence       Corrent Action Reason (Required)         Corrent Action Reason (Required)       Pint Presic						,
Di Facts Text Micromedex Severity Micromedex Text Micromedex Text Micr	·					
Micromedex Severity       Micromedex Conset         Micromedex Substantiation       Micromedex Text         Micromedex Text       Micromedex Text         Medline Hits       Micromedia Text         Medline Text       Micromedia Text         Package Insert Text       Micromedia Text         PID Criteria Text       Micromedia Text         ADS Outdelines Text       Micromedia Text         Highest Level of Evidence       Micromedia Text         Origo Discussion       Micromedia Text         Ett       Pint Page						
Micromedex Substantiation       Incromedex Substantiation         Micromedex Text       Incromedex Text         Medline Hits       Incromedia Text         Medline Text       Incromedia Text         Package Insert Text       Incromedia Text         PBM Criteria       Incromedia Text         PBM Criteria Text       Incromedia Text         AIDS Guidelines Text       Incromedia Text         Interaction Source       Incromedia Text         Interaction Type       Incromedia Text         Interaction Type       Incromedia Text         Group Discussion       Incremedia Text         Edit       Print Page						
Micromedex Substantiation       Micromedex Text         Medline Hits       Medline Text         Medline Text       Medline Text         Package Insert Text       Medline Text         PBM Criteria Text       Medline Text         ADS Guidelines Text       Medline Text         Interaction Source       Medline Text         Highest Level of Evidence       Group Discussion         Corup Discussion       Entre Medline Text						1
Micromedex Text Medine His Medine Text Package Insert Package Insert Package Insert Package Insert PBM Criteria PBM Criteria PBM Criteria Text ADS Guidelines Catole Guidelines ADS Guidelines PExt Package Insert Package PBM Criteria PBM Cri						-
Medine Hits         Medine Ted         Package Inset         Package Inset         Package Inset Text         PBM Criteria         PBM Criteria Text         ADS Guidelines         ADS Guidelines Text         Interaction Source         Interaction Type         Highest Level of Evidence         Oroup Discussion         Edit						
Medline Text         Package Insert Text         PBM Criteria         PBM Criteria Text         ADDS Guidelines         ADDS Guidelines Text         Interaction Source         Interaction Type         Highest Level of Evidence         Oroup Discussion         Edit						i
Pakage Insert         Pakage Insert Text         PBM Criteria         PBM Criteria Text         ADDS Guidelines         ADDS Guidelines Text         Interaction Source         Interaction Type         Highest Level of Evidence         Group Discussion         Edit						
Package Insert Text         PBM Criteria         PBM Criteria Text         ADDS Guidelines         ADDS Guidelines Text         Interaction Source         Interaction Type         Highest Level of Evidence         Group Discussion         Edit						•
PBM Criteria         PBM Criteria Text         ADS Guidelines         ADS Guidelines Text         Interaction Source         Interaction Type         Highest Level of Evidence         Group Discussion         Edit						
ADS Guidelines ADS Guidelines ADS Guidelines Text Interaction Source Interaction Type Highest Level of Evidence Group Discussion Current Action Reagon (Required)  Edit Print Page						
AIDS Guidelines Text Interaction Source Interaction Type Highest Level of Evidence Group Discussion Current Action Reason (Required)  Edit Print Page	PBM Criteria Text					
Interaction Source Interaction Type Highest Level of Evidence Group Discussion Current Action Reason (Required) Edit Print Page	AIDS Guidelines					1
Interaction Type Highest Level of Evidence Group Discussion Current Action Reason (Required) Edit Print Page	AIDS Guidelines Text					
Highest Level of Evidence Group Discussion Current Action Reason (Required) Edit Print Page	Interaction Source					
Group Discussion Current Action Reason (Required) Edit Print Page	Interaction Type					•
Current Action Reason (Required) Edit Print Page	Highest Level of Evidence					1
Edit Print Page						1
	Current Action Reason (Required)					
Home Advanced Query/Customization Easy Search Drug Pair Lookup Reports Help	Edit					Print Page
	Home	Advanced Query/Customization Eas	y Search Drug Pai	r Lookup <u>Reports</u>	Help	

Z

From here, you can create another custom record if you wish. Checks exist in the system so that the same user cannot make duplicate DDIs *or* another user cannot come in and make the same DDI that another user just made.

#### **Create Multiple DDIs per One FDB Record**

- 1. Log on and go to the Advanced Query/Customization tab.
- 2. Choose Drug-Drug Interaction for the Concept.
- 3. Select FDB Records.
- 4. Build the query as follows: Fields=Interaction ID; Filter=Contains; Value= for user guide purposes, let's say 2105.
- 5. Click Query.
- 6. Open Interaction ID 2105 from the list that displays.
- 7. Click Edit.
- 8. Create the custom record by changing something.

9. Your new record is created. The record ID is displayed on the Interaction ID field. If you have any duplicates or other discrepancies, you will see a warning message (such as an identical interaction severity, as shown below):

Very and the second dick on the edit button below.  It Drug Pairs Print Pag Pairs Pairs Print Pag Pairs P		HARMACY E	NTERPRISE ON SYSTEM			Welcome, SIX_APPROVER	Logo
de la	Home Advanced Query/Co	ustomization	Easy Search Drug Pair Lookup	Reports Help			
Imp alor         Decision           Restaur         Second Se	rug-Drug Interaction						Page H
man presence of the second a lease set of the RABACE RECYPT 42 BHERTORS with eaverly 1. Set belies for the depicted 4 Acutemine cond datases. The accord to depice of the second accord to depice accord to depic	update this record click on the	e edit button below	ι.				
Audion interaction allowed; exists for RABADLINECOPP142 RHEBTORS with severity 12, set below for the danglaca V Austion interaction back appropriate data in the comparison of the	dit Drug Pairs					Print	nt Page
Set as as not all where off. To submit the interaction is an extension all associated dup pars. First dict on the Dop Dap bug batter.           Set as a model of the operation back plane. First dict on the Dop Dap bug batter.           Set as a model of the operation back plane.           Interaction Dop Dap batter.           Notable Dop Dap batter.           Notable Dop Dap batter.           Interaction Dop Dap batter.           Data Data Data Data Data Data Data Data	arning Messages:						
Table Second upday builts are real reviewed upday that the later took upday are field in the appropriate adday that the appropriate adday adday approx field in the appropriate adday adday approx field in the appropriate adday a	A VA Custom interaction alrea	dy exists for 'RAS	AGILINE/CYP1A2 INHIBITORS' with sever	ity '3'. See below for the duplicate	VA custom record details.		
Enclose         Enclose         Enclose         Enclose         Enclose           Interaction         Text Color         Resolution Color         Network	ormational Messages:						
Interaction (ppu         Interaction (ppu)         Interaction Action Selection (ppu)         Interaction Action Selection (ppu)           Interaction 2020221         RASADLAPECYTVA2 INTERTORS         0         New           Interaction 20202202         RASADLAPECYTVA2 INTERTORS         0         New           Interaction 2020202         RASADLAPECYTVA2 INTERTORS         0         New           Interaction 202020         RASADLAPECYTVA2 INTERTORS         0         Dethin Releveed           Interaction CDD Interaction CD         202080         Dethin Releveed         Interaction CDD Interaction CD           Interaction CDD Interaction CD         202080         Interaction CDD Interaction CD         Interaction CDD Interaction CD           Interaction CDD Interaction CD         202080         Interaction CDD	The associated drug pairs an	e not all reviewed	yet. To submit this interaction as reviewe	d, you must review all associated	I drug pairs. First click on the Dru	ug Pairs button then take appropriate acti	ion.
Interaction         202223         RAAGULIPE/CVP142 RHHRTORS         1         Reproved           Interaction         202222         RAAGULIPE/CVP142 RHHRTORS         2         Defent Reviewed           Interaction         202222         RAAGULIPE/CVP142 RHHRTORS         2         Defent Reviewed           Interaction         Respective/PV2 RHHRTORS         2         Defent Reviewed           Interaction         Site Provide/PV2 RHHRTORS         2         Defent Reviewed           Interaction         Site Provide/PV2 RHHRTORS         2         Defent Reviewed           Interaction         Site Provide/PV2 RHHRTORS         2         Defent Reviewed           Interaction         Site Provide/Provide/PV2 RHRTORS         2         Defent Reviewed           Interaction         Site Provide/Provide/Provide/Provide/Provide/Provide/Provide/Provide/Provid							
Interaction         2026/2         RRADULABEORY 2 2018/10705         9         New           Interaction         2026/2         RADULABEORY 2 2018/10705         2         Devise Reviewed           Interaction         2026/2         RADULABEORY 2 2018/10705         2         Devise Reviewed           Interaction         RESONATION 2 2018/10705         2         Devise Reviewed           Interaction         RESONATION 2 2018/10705         2         Devise Reviewed           Interaction         Resonation 2018/1000         Resonation 2018/1000         2         Devise Reviewed           Interaction         Resonation 2018/1000         Resonation 2018/1000         Resonation 2018/1000         2         Devise Reviewed           Interaction         Resonation 2018/1000         Resonation 2018/10000         2         Devise Reviewed         2         Devise Reviewed           Interaction         Resonation 2018/10000         Resonation 2018/10000         2         Devise Reviewed         2         Devise Reviewed           Interaction         Resonation 2018/10000         Resonation 2018/10000         2         Resonation 2018/10000         2         Resonation 2018/10000         2         Devise Reviewed 2018/10000         2         Devise Reviewed 2018/10000         E         E         E <td< th=""><th>A Interaction 2</th><th>020334</th><th>RASAGILINE/CYP1A2 INHIBITORS</th><th>3 1</th><th></th><th>Approved</th><th></th></td<>	A Interaction 2	020334	RASAGILINE/CYP1A2 INHIBITORS	3 1		Approved	
inderación     RASAGUINECOPPIAZ RAHEBORS       researcion EFGE Interestion     RASAGUINECOPPIAZ RAHEBORS       researcion EFGE Interestion     RASAGUINECOPPIAZ RAHEBORS       researcina EFGE Interestion     RASAGUINECOPIAZ       researcina EFGE Interestion     RASAGUINECOPIAZ       researcina EFGE Interestion     RASAGUINECOPIAZ       researcina EFGE Interestion     RASAGUINECOPIAZ       researcina EFGE Interesting Interest	A Interaction 2	020957	RASAGILINE/CYP1A2 INHIBITORS	9			
decision of the second o	Interaction	020660	RASAGILINE/CYP1A2 INHIBITORS	2			
decision of the second o							
name of the second sec	rresponding FDB Interaction I	D 2105					
in shais         New           in station Dic         202989           in a bolicab life indicab         31040480420000000000000000000000000000000	eraction Description (Requir	ed) RASAGIL	INE/CYP1A2 INHIBITORS				
nation Di200999and Local Structure9. Hoderate Herentionkin Dela9. Hoderate Herentionkin Dela9. KePROVERand Local Structure9. KePROVERand Local Structure1. KepRoVER <tr< td=""><td>nograph ID</td><td>Rasagili</td><td>ne/CYP1A2 Inhibitors - 2105</td><td></td><td></td><td></td><td></td></tr<>	nograph ID	Rasagili	ne/CYP1A2 Inhibitors - 2105				
	ion Status	New					
on Date 2012-04-00 04/20.47 on Performed By SQLAPPROVER on Effective Date 300 (APPROVER) conficiente Date 300 (APPROVER) confi	raction ID	2020958					
der formed 9y         SL_APPROVER	verity Level Code (Required)	3 - Mode	rate Interaction				
	on Date	2012-04	06 04:26:47				
defacted Date         quel Assigned To         QuASSIQNED         Increased affect of the former drug	on Performed By	SIX_APP	ROVER				
aviel Assign of To UNSIGNED UNSIGNED UNSIGNED UNSIGNED UNSIGNED UNSIGNED UNSIGNED UNSIGNED UNSIGNED US UNSIGNED US UNSIGNED US UNSIGNED US UNSIGNED US US UNSIGNED US	quest Submitted By	SIX_APP	ROVER				
Add Effect Code 1 (Require)         Increased effect of the former drug           Instal Effect Code 2         Increased effect of the former drug           Instal Effect Code 2         Increased effect of the former drug           Instal Effect Code 2         Increased effect of the former drug           Instal Effect Code 2         Increased effect of the former drug           Instal Effect Code 2         Increased effect of the former drug           Instal Effect Code 2         Increased effect of the former drug           Instal Effect Code 2         Increased effect of the former drug           Instal Effect Code 2         Increased effect of the former drug           Instal Effect Code 2         Increased effect of the former drug           Instal Effect Code 2         Increased effect of the former drug           Instal Effect Code 2         Increased effect of the former drug           Instal Effect Code 2         Increased effect of the former drug           Instal Effect Code 2         Increased effect of the former drug           Instal Effect Code 2         Increased effect of the former drug           Instal Effect Code 2         Increased effect of the former drug           Instal Effect Text         Increased effect of the former drug           Instal Effect Text         Increased effect of the former drug           Instal Effect Text         Incr	ion Effective Date						
Haie Effect Code 2 Number Tod	quest Assigned To	UNASSI	3NED				
Number Ted Ted Unber Facts Number Facts Severity Facts Severity Facts Severity Facts Ted Tormedex Substantiation Facts Ted Unber Fact Substantiation Greeder Ted Greeder Ted	nical Effect Code 1 (Required	l) Increase	d effect of the former drug				
Ted         acts Number         acts Number         acts Soventy         acts Documentation         acts Ted         romedex Soventy         stage Insert         (romedex Soventy         stage Insert Ted         (rottraits Goventy         Sovent Ted         Sovevent Ted	nical Effect Code 2						
Facts Number         Facts Onset         Facts Onset         Facts Sourcentation         Facts Toot         Facts Toot         romedex Onset         romedex Substantiation	l Number						
ards onset ards Soverity ards Soverity ards Soverity aromedex Sove	I Text						
ada Saventy ada Sa	Facts Number						
acts Documentation acts Test acts Oscienteration acts Severity actionedex Severity actionedex Substantiation actionedex Su	Facts Onset						
Facts Text romedex Sevently romedex Conset romedex	Facts Severity						
romedex Seventy romedex Sonset romedex Substantiation romedex Substa	Facts Documentation						
ramedex Onset romedex Substantiation romedex	acts Text						
romedex Substantiation romedex Ted innerHis innerHis isage Insert Text isage Insert	romedex Severity						
romedex Text dime Hits dime Text dime Text Acade Insert Text Ordenia M Criteria Text S Guidelines S Guidel	romedex Onset						
dine Hts dine Test dine Test kage insert Test Catherin Test Of Chrief Test So Guidelines	romedex Substantiation						
dine Text	romedex Text						
kkage insert kkage insert Text Kkage insert Text M Criteria Text S Guidelines Text S	dline Hits						
Age Inset Text 4 Criteria Text 4 Criteria Text 5 Guidelines 5 Guidel							
ا در اللع التع 4 در اللع التع 5 در اللغ اللع اللع اللع اللع اللع اللع اللع							
M Criteria Text S Guidelines S Guidelines Text raction Source raction Type Hest Level of Evidence up Discussion on Reason History 2012/04/06 16:26:47 SIX_APPROVER: Testing NMC read Action Reason (Required)							
S Ouidelines Text S Ouidelines Text Taction Source Taction Type Level of Evidence Up Discussion on Reason History 2012/04/06 16:26:47 SIX_APPROVER: Testing MMC text Action Reason (Required)							
S Guidelines Text raction Source raction Type hest Level of Evidence up Discussion on Reason History 2012/04/06 16:26:47 SIX_AFFROVER: Testing MMC rent Action Reason (Required)							
raction Source raction Type hest Level of Evidence up Discussion on Reason History 2012/04/06 16:26:47 SIX_AFFROVER: Testing MMC rent Action Reason (Required)							
raction Type hest Level of Evidence up Discussion on Reason History 2012/04/06 16:26:47 3IX_APPROVER: Testing MMC tent Action Reason (Required)							
hest Level of Evidence up Discussion on Reason History 2012/04/06 16:26:47 SIX_APPROVER: Testing MMC tent Action Reason (Required)							
up Discussion on Reason History 2012/04/06 16:26:47 SIX_APPROVER: Testing MMC tent Action Reason (Required)							
on Reason History 2012/04/06 16:26:47 SIX_APPROVER: Testing MMC rent Action Reason (Required)							
rent Action Reason (Required)		1000					
	,		/06 16:26:47 SIX_APPROVER: Test:	ng MMC			
It Drug Pairs Print Pag	rent Action Reason (Require	ed)					
	it Drug Pairs					Prin	nt Pag
Home Advanced Query/Customization Easy Search Drug Pair Lookup Reports Help							

#### Prevention of Two Users Adding Identical Drug Pairs to the Same DDI

1. After you have created a new DDI or added new drug pairs to an existing DDI, a second user can come in and attempt to add the same drug pairs. If so, they see a message similar to the one circled below:

PECS	VETERANS AFFAIRS PHARMACY EN CUSTOMIZATIO ry/Customization Ea		Help		Welcome, FIVE_APPROVER   Logo	ut
Drug Pair Customizati	on				Page H	lelp
Cancel Edit Error Messages: Unable to perform the sat	ve operation on the custo	mization. (Attempt to create duplicate drug pair.	RASAGILINE MESYLATE ORAL	MEXILETINE HCL MISCI	ELLANEOUS	
Interaction Type	Interaction ID	Interaction Descriptio	n Ir	teraction Severity	Interaction Action Status	
VA Interaction	2020958	RASAGILINE/CYP1A2 INHIBITORS	3		New	
FDB Interaction	2105	RASAGILINE/CYP1A2 INHIBITORS	3		N/A	1
Other Existing VA Custom Re Interaction Type VA Interaction VA Interaction	ecord(s) Interaction ID 2020334 2020957	Interaction Description RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS	n In 1 9	teraction Severity	Interaction Action Status Approved New	
VA Interaction	2020660	RASAGILINE/CYP1A2 INHIBITORS	2		Delete Reviewed	
<ul><li>Select Drug Pairs to</li><li>Drug Pairs</li></ul>	add to the above VA	Custom Interaction				
	Home	Advanced Query/Customization East	<u>y Search Drug Pair Loc</u>	<u>kup Reports</u>	Help	

2. The second user will also receive an error if they attempt to customize drugs that exist for an interaction in reverse order. Note the error messages.

	ery/Customization Ea	sy Search Drug Pair Lookup Reports	Help		
Drug Pair Customizat	tion				Page He
Cancel Edit		Attempt to add same drugs in reverse order message	message. [	reate duplicate drug   Does not sve Drug Pa ustomization.	
rror Messages:			<u> </u>		
Another Drug Pair exists					
	ave operation on the custo	omization. (Attempt to create duplicate drug pair: M	EXILETINE HCL MISCELLANEOUS/RASAG	ILINE MESYLATE OR/	AL)
	Interaction ID	Interaction Description	Interaction Se	verity	Interaction Action Status
Interaction Type					
A Interaction DB Interaction	2020958 2105	RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS	3 3	New N/A	
A Interaction DB Interaction	2020958 2105		3	New N/A	Interaction Action Status
A Interaction DB Interaction ther Existing VA Custom F Interaction Type	2020958 2105 Record(s) 1010000000000000000000000000000000000	RASAGILINE/CYP1A2 INHIBITORS	3	New N/A	
A Interaction DB Interaction ther Existing VA Custom F Interaction Type A Interaction	2020958 2105 Record(s)	RASAGILINE/CYP1A2 INHIBITORS	3 3 Interaction Se	New N/A	
/A Interaction DB Interaction Interaction VA Custom F Interaction Type /A Interaction /A Interaction	2020958 2105 Record(s) 1000000000000000000000000000000000000	RASAGILINE/CYP1A2 INHIBITORS Interaction Description RASAGILINE/CYP1A2 INHIBITORS	3 3 Interaction Se	New N/A verity Approve New	
(A Interaction DB Interaction ther Existing VA Custom F Interaction Type (A Interaction (A Interaction	2020958 2105 Record(s) 1010 2020334 2020957	RASAGILINE/CYP1A2 INHIBITORS Interaction Description RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS	3 3 Interaction Se 1 9	New N/A verity Approve New	ed
A Interaction DB Interaction ther Existing VA Custom F Interaction Type A Interaction A Interaction	2020958 2105 Record(s) 1010 2020334 2020957	RASAGILINE/CYP1A2 INHIBITORS Interaction Description RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS	3 3 Interaction Se 1 9	New N/A verity Approve New	ed
A Interaction DB Interaction ther Existing VA Custom F Interaction Type A Interaction A Interaction A Interaction	2020958 2105 Record(s) Interaction ID 2020334 2020957 2020957 2020660	RASAGILINE/CYP1A2 INHIBITORS Interaction Description RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS	3 3 Interaction Se 1 9	New N/A verity Approve New	ed
A Interaction DB Interaction ther Existing VA Custom F Interaction Type A Interaction A Interaction A Interaction	2020958 2105 Record(s) Interaction ID 2020334 2020957 2020957 2020660	RASAGILINE/CYP1A2 INHIBITORS Interaction Description RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS	3 3 Interaction Se 1 9	New N/A verity Approve New	ed
A Interaction DB Interaction ther Existing VA Custom F Interaction Type A Interaction A Interaction A Interaction B Select Drug Pairs to	2020958 2105 Record(s) Interaction ID 2020334 2020957 2020957 2020660	RASAGILINE/CYP1A2 INHIBITORS Interaction Description RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS	3 3 Interaction Se 1 9	New N/A verity Approve New	ed
A Interaction DB Interaction ther Existing VA Custom F Interaction Type A Interaction A Interaction A Interaction A Interaction	2020958 2105 Record(s) Interaction ID 2020334 2020957 2020957 2020660	RASAGILINE/CYP1A2 INHIBITORS Interaction Description RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS	3 3 Interaction Se 1 9	New N/A verity Approve New	ed
A Interaction DB Interaction Interaction Type A Interaction Type A Interaction A Interaction A Interaction A Interaction Select Drug Pairs to	2020958 2105 Record(s) Interaction ID 2020334 2020957 2020957 2020660	RASAGILINE/CYP1A2 INHIBITORS Interaction Description RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS RASAGILINE/CYP1A2 INHIBITORS	3 3 Interaction Se 1 9	New N/A verity Approve New	ed

## **Quick Selection of Drug Pairs from the Selection List**

When adding FDB Drug Pairs to an interaction on the Batch Customization page, you may select single drug pairs, groups of consecutive drug pairs, or a combination of both.

To select single drug pairs, simply click on the corresponding checkboxes of the drug pairs you want to select.

	ct Drug Pair(s) Source				
Drug	g pairs from corresponding FDB Interaction	۲	Existing customized Drug Pairs	for this FDB Drug-Drug Interaction are not displayed.	
Drug	g pair from Routed Generic Drug lists	0			
selec	ct from list of FDB drug pairs - note that at lea	ast one dru	g pair must be chosen before clic	king the Customize button.	
	Routed Generic #1 Description			Routed Generic #2 Description	
	BISACODYL/SODIUM PHOS,M-BASIC-D-BA	SIC MISCEL	LANEOUS	TRANDOLAPRIL/VERAPAMIL HCL ORAL	
	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	SIC MISCEL	LANEOUS	ENALAPRIL MALEATE/FELODIPINE ORAL	
~	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	SIC MISCEL	LANEOUS	PERINDOPRIL ERBUMINE ORAL	
	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	SIC MISCEL	LANEOUS	MOEXIPRIL HCL/HYDROCHLOROTHIAZIDE ORAL	
-	BISACODYL/SODIUM PHOS,M-BASIC-D-BA	SIC MISCEL	LANEOUS	TELMISARTAN ORAL	
	BISACODYL/SODIUM PHOS,M-BASIC-D-BA	SIC MISCEL	LANEOUS	IRBESARTAN/HYDROCHLOROTHIAZIDE ORAL	
	BISACODYL/SODIUM PHOS.M-BASIC-D-BAS	SIC MISCEL	LANEOUS	QUINAPRIL HCL/HYDROCHLOROTHIAZIDE/MAGNESIUM CARBONATE ORAL	

Figure 30: Select Single Drug Pairs

To select groups of consecutive drug pairs, click on the first checkbox in the group and then shift/click on the last checkbox in the group. All drug pairs between the first and last checkboxes will be selected. If you wish to add another group to your selection, simply click on the first checkbox in the second group and shift/click on the last checkbox in the group. You will now have two groups of drug pairs selected. To add other non-consecutive drug pairs, click on the corresponding checkbox.

	ct Drug Pair(s) Source		Eviation evotomized Drug Daire f	insthis EDD David David Internation are not displayed
-	g pairs from corresponding FDB Interaction	۲	Existing customized Drug Pairs in	for this FDB Drug-Drug Interaction are not displayed.
	g pair from Routed Generic Drug lists ct from list of FDB drug pairs - note that at lea	©	a pair must be abasan before alial	king the Customize button
elec		ast one uru	y pair must be chosen before click	-
	Routed Generic #1 Description			Routed Generic #2 Description
	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	SIC MISCEL	LANEOUS	TRANDOLAPRIL/VERAPAMIL HCL ORAL
✓	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	SIC MISCEL	LANEOUS	ENALAPRIL MALEATE/FELODIPINE ORAL
1	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	SIC MISCEL	LANEOUS	PERINDOPRIL ERBUMINE ORAL
✓	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	SIC MISCEL	LANEOUS	MOEXIPRIL HCL/HYDROCHLOROTHIAZIDE ORAL
✓	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	SIC MISCEL	LANEOUS	TELMISARTAN ORAL
✓	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	SIC MISCEL	LANEOUS	IRBESARTAN/HYDROCHLOROTHIAZIDE ORAL
✓	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	SIC MISCEL	LANEOUS	QUINAPRIL HCL/HYDROCHLOROTHIAZIDE/MAGNESIUM CARBONATE ORAL
	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	SIC MISCEL	LANEOUS	OLMESARTAN MEDOXOMIL ORAL
	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	SIC MISCEL	LANEOUS	EPROSARTAN MESYLATE/HYDROCHLOROTHIAZIDE ORAL
1	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	SIC MISCEL	LANEOUS	AMLODIPINE BESYLATE/VALSARTAN ORAL
✓	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	SIC MISCEL	LANEOUS	AMLODIPINE BESYLATE/VALSARTAN/HYDROCHLOROTHIAZIDE ORAL
1	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	SIC MISCEL	LANEOUS	QUINAPRIL HCL ORAL
	BISACODYL/SODIUM PHOS,M-BASIC-D-BAS	SIC MISCEL		QUINAPRIL HCL/HYDROCHLOROTHIAZIDE ORAL

Figure 31: Range of Drug Pairs Selected with Shift Key

# Forward and Reverse Professional Monograph

A single VA Custom Drug-Drug Interaction could be associated with a separate custom Professional Monograph for the forward and reverse interactions. An interaction described as Drug A and Drug B would have a different Custom Monograph from an interaction described as Drug B and Drug A. These different monographs may be necessary because there could be a different Clinical Effect Code between forward and reverse interactions (DrugA+DrugB: Clinical Effect Code = Adverse effects of the former drug; DrugB+DrugA: Clinical Effect Code = Adverse effects of the latter drug).

The following VA Custom Professional Monograph pairs will be associated with each other. This means that when a Monograph is assigned to a VA Custom Drug-Drug Interaction, the corresponding Monograph will be automatically assigned to the reverse Drug-Drug Interaction (DDI1 = DrugA + DrugB; DDI2 = DrugB+DrugA).

Monograph ID and Title	Paired Monograph ID and Title
150022 VA Customized: Adverse Effects of Former	150024 VA Customized: Adverse Effects of Latter Drug
Drug (Critical) (ARF1)	(Critical) (ARL1)
150023 VA Customized: Adverse Effects of the Former	150025 VA Customized: Adverse Effects of the Latter
Drug (Significant) (ARF2)	Drug (Significant) (ARL2)
150030 VA Customized: Decreased Effects (Critical)	150032 VA Customized: Decreased Effects (Critical)
(DEF1)	(DEL1)
150031 VA Customized: Decreased Effects (Significant)	150033 VA Customized: Decreased Effects (Significant)
(DEF2)	(DEL2)
150034 VA Customized: Increased Effects (Critical)	150036 VA Customized: Increased Effects (Critical)
(INF1)	(INL1)
150035 VA Customized: Increased Effects (Significant)	150037 VA Customized: Increased Effects (Significant)
(INF2)	(INL2)
150040 VA Customized: Mixed Effects of Former Drug	150103 VA Customized: Mixed Effects of Latter Drug
(Critical) (MXF1)	(Critical) (MXL1)
150041 VA Customized: Mixed Effects of the Former	150104 VA Customized: Mixed Effects of the
Drug (Significant) (MXF2)	LatterDrug (Significant) (MXL2)

When viewing a Drug-Drug Interaction, the PECS user interface will display only the Professional Monograph associated with the Forward interaction. The associated Reverse Professional Monograph will be visible only in the custom updates file created by the Release Manager. A sample is on the next page.




Figure 32: Forward/Reverse DDIs with Professional Monographs, Custom Update File Created by Release Manager

# **Easy Search Query Page**

This page allows you to easily query for any Drug-Drug Interactions (and associated Professional Monographs) that may exist within PECS for at least two and up to 10 drugs. This page also allows you to search for Duplicate Therapy information for any drug you select. The example shown is for Drug-Drug Interaction with Professional Monograph and/or Duplicate Therapy.

WINTED STATES DEPARTMENT OF VETERANS AFFAIRS PECS PHARMACY ENTER CUSTOMIZATION S	RPRISE SYSTEM	Welcome, ONE_APPROVER   Logout
Home Advanced Query/Customization Easy	Search Drug Pair Lookup Reports Help	
Easy Search		2
Select Search Type	×	Page Help
Drug-Drug Interaction with Profes	ssional Monograph and/or Duplicate Therapy	

Figure 33: Initial Easy Search Window


To begin an Easy Search:

1. From the "Select Search Type" drop-down list, select Drug-Drug Interaction with Professional Monograph and/or Duplicate Therapy.' After you select these values, you see the "Select Information Type", "Search and Select Drugs", "Search Results" and "Drugs to Check" panels:

Welcome, ONE_APPROVER   Logout
Page Help

Figure 34: Select Drug-Drug Interaction with Professional Monograph and Duplicate Therapy

- 2. Select either the 'Drug-Drug Interaction with Professional Monograph' checkbox, or the 'Duplicate Therapy' checkbox, or both.
  - If you have selected the 'Drug-Drug Interaction with Professional Monograph' checkbox, you must select one of the options provided, Display Severity Levels 1 (contraindicated) and 2 (severe)' or 'Display All Severity Levels'.



- 3. Enter a partial string or whole drug name into the "Search and Select Drugs" field. Note that you can enter multiple partial strings, and the system returns drugs that match on both strings -- the order of the strings and case are ignored.
- 4. Click the "Search" button. The system returns all drugs that contain the partial string/whole drug name entered.

WINTED STATES         DEPARTMENT OF VETERANS AFFAIRS         PECS       PHARMACY ENTERPRISE         CUSTOMIZATION SYSTEM         Home       Advanced Query/Customization         Easy Search       Drug Pair Lookup       Reports         Help	Welcome, ONE_APPROVER   Locout
Easy Search	
Select Search Type Drug-Drug Interaction with Professional Monograph and/or Duplicate Therapy 💌	Page Help
Select Information Type	
Drug-Drug Interaction with Professional Monograph	
O Display Severity Levels 1 (contraindicated) and 2 (severe)	
O Display All Severity Levels	
Duplicate Therapy	
Search and Select Drugs	
Drug Metyrapone oral	
Search	
Search Results	Care-Care-Care-Care-Care-Care-Care-Care-

Figure 35: Severity Levels 1 and 2 Selected, and Drug Name to Search

- 5. Within the Search Results box, you can select up to ten drugs to run the Easy Search query for. You can click one drug at a time to select it for inclusion (highlighted). Alternately, you can click one drug, hold down the 'shift' key, and click as many drugs above or below you want to select, or you can click one drug, hold down the 'Ctrl' key to select additional drugs.
- 6. After you have selected all desired drugs, click the "Add to Drugs to Check" button. The selected drugs are moved down to the "Drugs to Check" panel.

- 7. You may perform additional searches to select more drugs, but only ten drugs can be submitted for a query. If you select more than ten, only the first ten drugs are added to the "Drugs to Check" panel and you receive an error message. Note that you can remove a drug from the "Drugs to Check" listing by highlighting it and clicking the 'Remove from Drugs to Check' button. To remove all drugs at once from the "Drugs to Check" listing, click the 'Remove All Drugs to Check".
- 8. When the drugs in the "Drugs to Check" are finalized, click the "Submit" button to run the query.

Here is a sample return:

WINTED STATES	
PECS PHARMACY ENTERPRISE CUSTOMIZATION SYSTEM	Welcome, FIVE_APPROVER   Logout
Home Advanced Query/Customization Easy Search Drug Pair Lookup Reports	
asy Search Results	Return to Search
igs Checked:	
pirin 300 mg Rectal Suppository (GCN: 4371) Therapeutic Class: Non-Steroidal Anti-Inflarmatory (NSAID) & Salicylates Therapeutic Class: Antiplatelet and Antithrombotic Drugs pirin 500 mg Tab, Delayed Release (GCN: 4383) Therapeutic Class: Non-Steroidal Anti-Inflarmatory (NSAID) & Salicylates Therapeutic Class: Antiplatelet and Antithrombotic Drugs pirin, 500 mg Tab, Delayed Release (GCN: 4383) Therapeutic Class: Antiplatelet and Antithrombotic Drugs pirin, 501 mg Tab, Delayed Release (GCN: 439787) Therapeutic Class: Antiplatelet and Antithrombotic Drugs pirin, 501 mg Tab, Delayed Release (GCN: 439787) Therapeutic Class: Low dose Aspinin (81 mg or less) profen 200 mg Cap (GCN: 1356) Therapeutic Class: Non-Steroidal Anti-Inflammatory (NSAID) & Salicylates Non-Steroidal Anti-Inflammatory (NSAID) & Salicylates Therapeutic Class: Narcotic Analgesics- IR (with non-analgesic opiates)	
rug - Drug Interaction	
ug - Drug Interaction - VA spirin 300 mg Rectal Suppository (GCN: 4371) uprofen-oxycodone 400 mg-5 mg Tab (GCN: 58402)	
teraction Description: ASPIRIN/IBUPROFEN everity: 2 - Severe Interaction inical Effects: The antiplatelet and cardioprotective effect of aspirin may be decreased if ibuprofen if administered before aspirin.	
Professional Monograph	

#### Figure 36: Partial Easy Search Results - Drug-Drug Interaction

Monograph Title:	Aspirin/Ibuprofen
Clinical Effects:	The antiplatelet and cardioprotective effect of aspirin may be decreased if ibuprofen if administered before aspirin.
Severity Level:	3-Moderate Interaction: Assess the risk to the patient and take action as needed.
Mechanism Of Act	
	te, which will result in a lack of effect.
Predisposing Fac	
Patient Managem	
	ne cardioprotective effect from aspirin is based on the antiplatelet effects. The irreversible inhibition of cyclooxygenase mediates the antiplatelet effects. Administration of
	sible inhibitor or cyclooxygenase, blocks the irreversible effect of aspirin on the platelets.
References:	
	1 Drug Administration Center for Drug Evaluations and Research - FDA Science Paper. Concomitant Use of Ibuprofen and Aspirin Potential for Attenuation of the Anti-Platelet Effect
	ble at: http://www.fda.gov/cder/drug/infopage/ibuprofen/science_paper.htm September 8, 2006.
	Should people on aspirin avoid lbuprofen? A review of the literature. Cardiol Rev 2004 May-Jun;12(3):174-6.
20:345(25):1809	son F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001 De
	n RG. Cooper SA. Hsu C. Wason S. Double-blind, randomized, parallel, placebo-controlled study of ibuprofen effects on thromboxane B2 concentrations in aspirin-treated healthy
	In Ro, Cooper S., Insu C., Vassori S. Dobletoninu, fandomizeu, parane, pracebo-contoried study of bupfolen enects on anomoosane b2 concentrations in aspinimeteated nearing. Clin Ther 2005 Feb 27(2):185-91.
	and Y. Portnay EL, Masoudi FA, Havranek EP, Krumholz HM. Aspirin, ibuprofen, and mortality after myocardial infarction: retrospective cohort study. BMJ 2003 Dec 6;327
(7427):1322-3.	ing r, romay EE, meddad r X, haranek Er, raannoizhin, Approion, and morany and mydaratal marciner readybeare constrated. Die 2000 Dec 9,021
	Idberg KC. Use of aspirin and ibuprofen compared with aspirin alone and the risk of myocardial infarction. Arch Intern Med 2004 Apr 26; 164(8):852-6.
	TM. Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003 Feb 15:361(9357):573-4.
	n RJ, Walker AM, Chan KA, Buring JE, Hennekens CH, Gaziano JM, Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs.
Circulation 2003	) Sep 9; 108(10);1191-5.

Figure 37: Partial Easy Search Results: Professional Monograph

Professional Monograph initially displays as collapsed; you can expand it by clicking the plus sign. Note that some drugs do NOT have a professional monograph to display (this is rare).

Duplicate Therapy Results						
Duplicate Therapy - FDB						
ibuprofen 200mg Cap (GCN: 135 aspirin 300mg Rectal Suppositor, aspirin 500mg Tab, Delayed Rele ibuprofen-oxycodone 400mg-5mg	(GCN: 4371) ase (GCN: 4383)					
Duplicate Allowance: 0 Use of ib	dal Anti-Inflammatory (NSAID) & S uprofen 200 mg Cap, aspirin 300 ion to the therapeutic drug class N	mg Rectal Suppository, aspi			-oxycodone 400 mg-5 mg T	ab may represent a duplication
Link to record in PECS						
Duplicate Therapy - FDB						
aspirin 300 mg Rectal Suppository aspirin 500 mg Tab, Delayed Rele						
Therapeutic Class: Antiplatelet Duplicate Allowance: 0 Use of a: Antiplatelet Drug-excluding antiplat			layed Release may repre	esent a duplication in the	rapy based on their associa	ation to the therapeutic drug clas
Link to record in PECS						
Duplicate Therapy - FDB						
aspirin 300 mg Rectal Suppositor, aspirin 500 mg Tab, Delayed Rele						
Therapeutic Class: Antiplatelet Duplicate Allowance: 0 Use of a: Antiplatelet and Antithrombotic Dru	spirin 300 mg Rectal Suppository	and aspirin 500 mg Tab, Del	layed Release may repre	esent a duplication in the	rapy based on their associa	ation to the therapeutic drug clas
Link to record in PECS						N
						N
	Home Advanc	ed Query/Customization	Easy Search	Drug Pair Lookup	Reports	

Figure 38: Partial Easy Search Results - Duplicate Therapy

9. Duplicate Therapy results only display those results that fall outside the value established by the duplicate allowance indicator. In Figure 27, the duplicate allowance indicator for each therapeutic class is 0, indicating that no duplicate drugs in each therapeutic class are allowed. Note that if the duplicate allowance indicator for a therapeutic class had been set to 1, the Duplicate Therapy results for that therapeutic class would no longer display, since they would be within the acceptable duplicate allowance.

# Potential Discrepancy Between Easy Search Results and PECS Records

The custom detail pages in PECS (e.g., Figure 20: Dose Range Panel, Figure 21: Professional Monograph Panel, and Figure 22: Duplicate Therapy Panel) show the custom record as it exists in PECS. These detail pages are accessed through either the Advanced Query/Customization tab, or by clicking the "Link to record in PECS" link found on the Easy Search Results screens.

When you use Easy Search to look up Drug-Drug Interactions or Duplicate Therapy, in the background you are searching a different database table than the one used to store the actual PECS record. The Easy Search results page shows only data from custom records in an Approved state that have been exported in a custom update and processed by an external process named DATUP. If a custom record hasn't gone through these steps, you will see the FDB record and there will be a discrepancy.

Also, if a previously approved/exported custom record is updated, Easy Search will not show the updated data in the results page until the record is approved, exported, and processed by DATUP. Instead, Easy Search will show the custom record results that were last uploaded to DATUP.

Here is an example. Do the following:

- 1. Click the Easy Search tab from the home page.
- 2. Select Drug-Drug Interaction with Professional Monograph and/or Duplicate Therapy from the drop-down.
- 3. Select the Drug-Drug Interaction with Professional Monograph check box.
- 4. Select the Display All Severity Levels radio button.
- 5. Enter "fluti" in the search box,
- 6. From the list of drugs, select fluticasone furoate 27.5 mcg/Actuation Nasal Spray, Susp (GCN: 62658) to be included in the search.
- 7. Enter "lopinavir" in the search box.
- 8. From the list of drugs, select lopinavir-ritonavir 133.3 mg-33.3 mg Cap (GCN: 46600) to be included in the search.
- 9. Click Submit.

Here is a sample of the Easy Search screen you see:

Home Advanced Query/Customization Easy Search Drug Pair Lookup Reports Help	
Easy Search Results	Return to Search
rugs Checked:	Page Help
uticasone furoate 27.5 mcg/Aduation Nasal Spray, Susp (GCN: 62658) Therapeutic Class: Nasal Steroids opinavir-ritionavir 133.3 mg-33.3 mg Cap (GCN: 46600) Therapeutic Class: Antiviral-HIV (Antiretroviral) Protease Inhibitor Therapeutic Class: Selected Antivral-HIV Protease Inhibitors Therapeutic Class: Ritonavir	
Drug - Drug Interaction	
)rug - Drug Interaction - VA	
uticasone furoate 27.5 mcg/Actuation Nasal Spray, Susp (GCN: 62658) opinavir-ritonavir 133.3 mg-33.3 mg Cap (GCN: 46600)	
nteraction Description: SELECTED INHALED CORTICOSTEROIDS/PROTEASE INHIBITORS evently: 3 - Moderate Interaction Jinical Effects: No Professional Monograph is associated to this Drug-Drug Interaction <u>ink to record in PECS</u>	
hrug - Drug Interaction - VA uticasone furoate 27.5 mcg/Actuation Nasal Spray, Susp (GCN: 62658) Note Interaction Description Name opinavir-ritonavir 133.3 mg-33.3 mg Cap (GCN: 46600)	
Iteraction Description FLUTICASONE/RITONAVIR evently: 1 - Contraindicated Drug Combination Ultinical Effects: Concurrent use of ritonavir may result in increased systemic exposure to and effects from budesonide, dexame ushing's syndrome and adremal suppression.	sthasone, fluticasone, prednisolone, and triamcinolone, including
ink to record in PECS	
Professional Monograph	

Figure 39: Easy Search DDI Record

Note the second Interaction Description Name, as is shown above (FLUTICASONE/RITONAVIR) Now, click the "Link to record in PECS" link as is shown above. The next picture displays the name discrepancy.

WINTED STATES DEPARTMENT OF VETERAN PECS PHARM CUSTO Home Advanced Query/Customiz	AACY ENTERPRISE MIZATION SYSTEM	Welcome, <b>FIVE_APPROVER</b>   <u>Logout</u>
Drug-Drug Interaction		
Drug Pairs		Print Page
Interaction Description (Required)	SELECTED CORTICOSTEROIDS/RITONAVIR	he State Sta
Monograph ID	Selected Corticosteroids/Ritonavir - 1333	<b>~</b>
Action Status	Approved	
Corresponding FDB Interaction ID	1333	
Interaction ID (Required)	2013331	
Severity Level Code (Required)	1 - Contraindicated Drug Combination	<b>V</b>

Figure 40: Referenced PECS Record with Name Discrepancy

This potential discrepancy applies to Drug-Drug Interaction, Professional Monograph, Duplicate Therapy, and Dose Range concepts.

## **Easy Search Dose Range**

This page allows you to easily query the appropriate dosage information based on the patient and dose particulars entered for a selected drug. The results of this query allows you to ensure the amount being prescribed is an acceptable amount.

To begin a Dose Range Easy Search:

- 1. From the "Select Search Type" drop-down list, select 'Dose Range.'
- 2. Enter a partial string or whole drug name into the "Drug" field. Note that you can enter multiple partial strings, and the system returns drugs that match on both strings -- the order of the strings and case are ignored.
- 3. Click the "Search" button. The system returns all drugs that contain the partial string/whole drug name entered.
- 4. Within the Search Results box, you can select a single drug to run the Easy Search query for by clicking the drug to select it for inclusion (highlighted). Note that if the drug does not have a defined dose route and/or a defined dose unit, the query will not be able to be performed. (Query on aspartame and select aspartame Powder (GCN: 48696) for an example)
- 5. After you have selected the desired drug, the Selected Drug box is populated with drug information for the selected drug and Dose Type and Dose Route drop downs are populated.
- 6. Patient demographic information defaults, and if the Add Default BSA checkbox remains checked, the body surface area value displays. Note that as the fields are updated to match the patient specifics, the body surface area is automatically recalculated.
- 7. The Single Dose and Frequency fields in the Dosing Information default to 1. The Dose Unit dropdown only contains values associated with the selected drug. Note that a blank option exists in the Does Rate Unit dropdown because this field is not required for oral doses.
- 8. When the fields in the Demographic Information and Dosing Information, are finalized, click the "Submit" button to run the query.

## **User Roles**

### Requestor

The Requestor's role is to create customization requests, modify their own requests, and run, save, and export queries.

## Approver

The Approver's role is to create, review, approve, modify, delete or reject customization requests. They also run, save, and export queries, and run reports. An approver can review but cannot approve their own requests.

## **Release Manager Role**

The Release Manager's role is to handle custom updates. Custom updates can be run at any time, but not more than once per day. The custom update will contain any custom records that have been APPROVED or DELETED since the previous custom update and can be for any of the five main PECS concepts (Dose Range, Drug Pairs, Drug-Drug Interaction, Duplicate Therapy, and Professional Monograph).

Release Managers can search for and view records but they are not allowed to create or approve customizations. They run custom updates at the instruction of the PECS Administrator and/or the National Drug File (NDF) Support Group. They will send an Outlook email to the PECS Administrators after the update has been created.

Here are the steps a Release Manager takes to run a custom update:

- 1. Log in to PECS.
- 2. Click the Custom Update tab:

DEPARTMENT OF VETERANS AN DECS PHARMAG CUSTOMIZ OME Advanced Query/Customizatio			telease Manager's home lick Custom Updates tat to run updates		Welcome, THREE_CUSTOM   LogoL
elcome THREE_CUSTOM st update to First DataBank DIF database st customization update file creation occu		version: 3.2			<u>Page H</u>
	Home	Advanced Query/Customiz	ation <u>Custom Update</u>	<u>s Help</u>	

#### 3. Click Create New Update button:

PEC	PHARMAC	Y ENTERPRISE ATION SYSTEM	Welcome, THREE_CUSTOM   Logou
Home Adva	anced Query/Customization	Custom Updates Help	
Customization	n Update Files		Page He
Create New U	Ipdate		
JEIELL	Created Date	Version Comment	
Download	04-11-2012	Incremental Update File Version: 3.2.710, Created by: THREE_CUSTOM	
ownload	04-11-2012	Full Update File Version: 3.2.711, Created by: THREE_CUSTOM	
ownload	04-04-2012	Full Update File Version: 3.2.693, Created by: THREE_CUSTOM	
ownload	04-04-2012	Incremental Update File Version: 3.2.692, Created by: THREE_CUSTOM	
ownload	04-03-2012	Incremental Update File Version: 3.2.690, Created by: THREE_CUSTOM	
lownload	04-03-2012	Full Update File Version: 3.2.691, Created by: THREE_CUSTOM	
ownload	03-29-2012	Incremental Update File Version: 3.2.670, Created by: THREE_CUSTOM	
lownload	03-29-2012	Full Update File Version: 3.2.671, Created by: THREE_CUSTOM	
lownload	03-21-2012	Full Update File Version: 3.2.653, Created by: THREE_CUSTOM	
lownload	03-21-2012	Incremental Update File Version: 3.2.652, Created by: THREE_CUSTOM	
lownload	03-21-2012	Incremental Update File Version: 3.2.650, Created by: THREE_CUSTOM	
lownload	03-21-2012	Full Update File Version: 3.2.651, Created by: THREE_CUSTOM	
ownload	03-16-2012	Full Update File Version: 3.2.631, Created by: THREE_CUSTOM	
lownload	03-16-2012	Incremental Update File Version: 3.2.630, Created by: THREE_CUSTOM	
lownload	03-13-2012	Full Update File Version: 3.2.613, Created by: PBMSUPER_USER	
lownload	03-13-2012	Incremental Update File Version: 3.2.612, Created by: PBMSUPER_USER	
lownload	03-12-2012	Incremental Update File Version: 3.2.610, Created by: THREE_CUSTOM	
lownload	03-12-2012	Full Update File Version: 3.2.611, Created by: THREE_CUSTOM	
lownload	03-09-2012	Incremental Update File Version: 3.2.594, Created by: THREE_CUSTOM	
lownload	03-09-2012	Full Update File Version: 3.2.595, Created by: THREE_CUSTOM	
lownload Iownload	03-08-2012 03-08-2012	Full Update File Version: 3.2.593, Created by: THREE_CUSTOM	
iownioad	03-08-2012	Incremental Update File Version: 3.2.592, Created by: THREE_CUSTOM Full Update File Version: 3.2.591, Created by: THREE_CUSTOM	
lownload	03-07-2012	Incremental Update File Version: 3.2.590, Created by: THREE_CUSTOM	
ownload	02-29-2012	Full Update File Version: 3.2.571, Created by: THREE_CUSTOM	
ownload	02-29-2012	Incremental Update File Version: 3.2.570, Created by: THREE_CUSTOM	
ownload	02-29-2012	Full Update File Version: 3.2.554, Created by: THREE_CUSTOM	
lownload	02-22-2012	Incremental Update File Version: 3.2.553, Created by: THREE_CUSTOM	
lownload	02-21-2012	Full Update File Version: 3.2.551, Created by: THREE_CUSTOM	
lownload	02-21-2012	Incremental Update File Version: 3.2.550, Created by: THREE_CUSTOM	
ownload	01-24-2012	Full Update File Version: 3.2.547, Created by: THREE_CUSTOM	
lownload	01-24-2012	Incremental Update File Version: 3.2.548, Created by: THREE_CUSTOM	
lownload	01-24-2012	Incremental Update File Version: 3.2.546, Created by: THREE_CUSTOM	
		Full Update File Version: 3.2.549, Created by: THREE_CUSTOM	
Download	01-24-2012		

- 4. Verify today's date in Created Date column.
- 5. If an error message is received, report it to PECS Administrator.

#### **Update Files Explained**

The custom update files that are run include both a full update and an incremental update. It is rare that a Release Manager will ever have to view these files, but if they do, here is an explanation.

A Custom Update file will always follow the same file naming standard. This standard is:

CstmUpdFile_{FDB Version}.{PECS Generated Version Number}_{Date/Time Stamp}.zip

So a file with the name CstmUpdFile_3.2.751_20120503154622.zip has an FDB Version number of "3.2," a PECS Generated Version Number of "751," and was created on May 3, 2012 at 15:46:22 (military time). The contents of the zip file will determine if this is an Incremental or a Full update.

Name 🔺	Туре	Packe	Has	Size	R	Date	$\rightarrow$
FDBCUSTOMDDIM.UPD	UPD File	1 KB	No	1 KB	39%	4/13/2012 10:34 AM	
FDBCUSTOMDDIMINTERACTION.UPD	UPD File	1 KB	No	1 KB	4%	4/13/2012 10:34 AM	- 2
FDBCUSTOMDDIMSTRINGS.UPD	UPD File	1 KB	No	1 KB	4%	4/13/2012 10:34 AM	
FDBCUSTOMDOSERANGE.UPD	UPD File	1 KB	No	1 KB	5%	4/13/2012 10:34 AM	
FDBCUSTOMDUPLICATETHERAPY.UPD	UPD File	1 KB	No	1 KB	5%	4/13/2012 10:34 AM	٦
FDBCUSTOMMONOGRAPH.UPD	UPD File	1 KB	No	1 KB	5%	4/13/2012 10:34 AM	
FDBUPDCONTROL.DAT	DAT File	1 KB	No	1 KB	46%	4/13/2012 10:34 AM	
🔮 proddefinition.×ml	XML Document	2 KB	No	13 KB	90%	4/13/2012 10:34 AM	
							- 1

The custom zip file contains a proddefinition.xml, FDBPRODCONTROL.DAT and several data files that have an extension of UPD. Here is a picture:

Figure 41: Custom Update Zip File

The proddefinition.xml file is a file from FDB that defines the table structures for the FDB tables in an XML format. The FDBUPDCONTROL.DAT file contains control information used by the FDB Data Updater software when determining if this Incremental update should be applied to a database. The UPD files contain data updates for a particular FDB table in the database.

Here is a sample: Note that the "D", "C", and "A" in the left column mean Delete, Change, and Add, respectively.

H fdb_custom_ddim 26 4 40 3.2 W 20120416 USA
F 10 1 rtgenid1 2 rtgenid2 3 interactionid 4 seqno 5 uicategory1 6 uicategory2 7 uicategory3 8 uicateg
ory4 9 uicategory5 10 uicategory6
P 4 1 2 3 4
D 1052533 1050026 2020134 1
D 1050026 1052533 2020134 2
D 10489717 1050028 2020134 1
D 1050028 10489717 2020134 2
D 1052533 1050027 2020134 1
D 1050027 1052533 2020134 2

Figure 42: Custom Update Text File

#### The full update contains text files.

Name 🔺	Туре	Packe	Has .	Size	R	Date
CTVERSION.TXT	Text Document	1 KB	No	1 KB	0%	5/3/2012 3:46 PM
FDBCUSTOMDDIM.TXT	Text Document	523 KB	No	4,25	88%	5/3/2012 3:46 PM
FDBCUSTOMDDIMINTERACTION.TXT	Text Document	20 KB	No	95 KB	80%	5/3/2012 3:46 PM
FDBCUSTOMDDIMSTRINGS.TXT	Text Document	4 KB	No	18 KB	78%	5/3/2012 3:46 PM
FDBCUSTOMDOSERANGE.TXT	Text Document	2 KB	No	10 KB	85%	5/3/2012 3:46 PM
FDBCUSTOMDUPLICATETHERAPY.TXT	Text Document	1 KB	No	1 KB	42%	5/3/2012 3:46 PM
FDBCUSTOMMONOGRAPH.TXT	Text Document	24 KB	No	115 KB	80%	5/3/2012 3:46 PM
🖬 FILECOUNTS.DAT	DAT File	1 KB	No	1 KB	55%	5/3/2012 3:46 PM
proddefinition.xml	XML Document	2 KB	No	13 KB	90%	5/3/2012 3:46 PM

< >

Figure 43: Full Update File

Here is a sample of the full update of Drug-Drug Interactions:

1048627 1050000 2004892 1 VA	
1050000 1048627 2004892 2 VA	
1048627 1050001 2004892 1 VA	
1050001 1048627 2004892 2 VA	
1048627 1050014 2004892 1 VA	
1050014 1048627 2004892 2 VA	
1048627 1050015 2004892 1 VA	
1050015 1048627 2004892 2 VA	
1048627 1052651 2004892 1 VA	
1052651 1048627 2004892 2 VA	
1048627 23070090 2004892 1 VA	
23070090 1048627 2004892 2 VA	

Figure 44: Custom Drug-Drug Interaction Full Update File

## **Administrator Role**

A PECS Administrator specific maintenance tasks grouped on the Administration tab that are not available to the other User Roles in the application.

The Administrator can

- Advanced Query/Customization
- Customize Settings
- Run Reports
- Initiate the process to remove drug pairs containing a null routed generic drug

### **Customize Settings**

Use Customize Setting to change the way data appears in various ways related to a specific concept.

Cu	Customize Settings					
	Drug Pair					
	Drug-Drug Interaction					
	Dose Range					
	Duplicate Therapy					
	Professional Monograph					

Customize Settings allows you to change the label name for the Field (Display Name), whether the field should appear in Queries, Detail Pages, and Reports. It also allows you to change the order the individual fields are displayed on their respective pages.

Warning: Changes made on the Settings page will affect all PECS users. Please proceed cautiously.

Customize Drug Pair Settings Page								
Name	Display Name	Display In Query	Display In Details	Include In Reports	Display Order			
RTGENID1_DESC	Routed Generic #1 Des	True (O) False (O)	True 🔘 False 🖲	True 🔘 False 🖲	1			
RTGENID2_DESC	Routed Generic #2 Des	True (O) False (O)	True 🔘 False 🖲	True 🔘 False 🖲	2			
NTERACTIONID_DESC	Interaction Description	True 🔍 False 🔘	True False 🔿	True 🔘 False 🖲	3			
SEVERITYLEVELCODE	Severity Level Code	True 🔍 False 🔿	True O False O	True 🔘 False 🖲	5			
ACTION_STATUS	Action Status	True 🔍 False 🔘	True 💿 False 🔘	True False 🔘	6			

#### **Change Field Display Name**

To change how the name of a field is displayed on the page, modify the contents of the Display Name field.


- 1. In the Customize <Concept> List, find the name of the database field you want to change.
- 2. Modify the contents of the field in the Display Name column.
- 3. Repeat the process as necessary.

4. Click Save to save your changes; click Cancel to abandon the changes and return to the Settings page. NOTE: Cancel is immediate; you will not be warned that you are about to lose your changes.

#### Add/Remove Field from Query Options

To add (or remove) a field from Query options

- 1. In the Customize <Concept> List, find the name of the database field you want to change.
- 2. In the Display in Query column, select True to display the field in Query options, select False to prevent the field from displaying in Query options. NOTE: Display in Query options are not available for all fields; some fields are explicitly required to be displayed in the Query options while others are forbidden from being displayed. In these cases, the required display option (True or False) will be the only options displayed and cannot be changed.



- 3. Repeat the process as necessary.
- 4. Click Save to save your changes; click Cancel to abandon the changes and return to the Settings page. NOTE: Cancel is immediate; you will not be warned that you are about to lose your changes.

#### Add/Remove Field from Detail Pages

To add (or remove) a field from Detail pages

1. In the Customize <Concept> List, find the name of the database field you want to change.

2. In the Display in Detail column, select True to display the field on the concept Detail page, select False to prevent the field from displaying on the concept Detail page.

Di	splay In Details	
True	۲	
False	$\odot$	
True	0	
False	•	
True	۲	
False	$\odot$	

- 3. Repeat the process as necessary.
- 4. Click Save to save your changes; click Cancel to abandon the changes and return to the Settings page. NOTE: Cancel is immediate; you will not be warned that you are about to lose your changes.

#### Add/Remove Field from Reports

To add (or remove) a field from Reports

- 1. In the Customize <Concept> List, find the name of the database field you want to change.
- 2. In the Include in Reports column, select True to display the field on concept-related reports, select False to prevent the field from displaying on the concept-related reports.

In	clude In Reports
True	۲
False	$\odot$
True	0
False	•
True	۲
False	

- 3. Repeat the process as necessary.
- 4. Click Save to save your changes; click Cancel to abandon the changes and return to the Settings page. NOTE: Cancel is immediate; you will not be warned that you are about to lose your changes.

#### **Change Field Display Order**

To change the order that the fields appear in Detail pages and drop-down lists, change the adjacent number in the Display Order field. Note that changing the Display Order is an entirely manual process; each field must be changed individually and the order is not validated in any way. Multiple fields can have the same display order.

When all changes are complete, click Save; click Cancel to abandon the changes and return to the Settings page.

	Display Order	
1		
2		
3		
4		
5		
6		
7		

## **Approver User Settings**

The Approver User Settings allow you to add or delete a user with the Approver role.

#### **Delete an Approver**

To Delete an Approver User

1. From the Settings tab, click Update User Settings.

Approver User Settings				
Update User Settings				

2. Select one or more users from the Approver User Name list.

Home Advanced Query/Customizati	on Admi	nistration	Reports
Approver User Settings			
Approver User Name	Delete		
APPROVER_ONE	V		
APPROVER_TWO			
APPROVER_THREE	~		
*Add an Approver User: Save Cancel			

3. Click Save.

4. Click OK to delete the user(s); click Cancel to abandon the delete user operation and return to the Settings page.



#### Add an Approver

To add a user with the Approver role

- 1. From the Settings tab, click Update User Settings.
- 2. In the Add an Approver User field, type in the name of the person you want to add.
- 3. The name must be in ALL CAPS and include both the first and last name (in that order) separated by an underscore . Examples: FIRSTNAME_LASTNAME, ERIC_SHINSEKI, JOHN_DOE.
- 4. Click Save.
- 5. Click OK to add the approver user; click Cancel to abandon the add user operation.

Are you sure you want to save User Settings?
OK Cancel

## **Null Drug Pair Removal Process**

The purpose of the Null Drug Pair Removal process is to change the status of any VA Drug Pair that contains a null Routed Generic to "Deleted", and to remove the null drug pairs from their associated VA Drug-Drug Interactions. VA Drug Pairs end up with null Routed Generics because one or both of the Routed Generics that make up the Drug Pair has been deleted by FDB. PECS applies the FDB Routed Generic deletes as part of the weekly FDB-DIF update, so it is recommended that the Null Drug Pair Removal process be run weekly, after the FDB-DIF update completes.

The Administrator may initiate this process at any time by clicking the "Null Drug Pair Removal" button on the following window:

WITTED STATES DEPARTMENT OF VETERANS AFFAIRS
PECS PHARMACY ENTERPRISE CUSTOMIZATION SYSTEM
Home         Advanced Query/Customization         Administration         Reports         Help           Administration         Administradministration         Administration
Customize Settings
Drug Pair Drug-Drug Interaction Dose Range Duplicate Therapy Professional Monograph
Approver User Settings
Update User Settings
Remove Null Drug Pairs Click the button below to initiate the Null Drug Pair Removal process.
Null Drug Pair Removal

When the process is complete, a message will appear at the top of the page to indicate that the process has completed.

#### Administration

#### Informational Messages:

Null Drug Pair Removal processing has completed.

Figure 45: Null Drug Pair Removal Process Complete

**Note:** The Null Drug Pairs Customization Report can be used to identify *approved* VA Drug-Drug Interactions that contain null Drug Pairs. However, the Null Drug Pair Removal Process removes null drug pairs from *any* VA Drug-Drug Interaction, regardless of status. All VA Custom drug pairs that contain a null routed generic drug are updated as follows: the action status of the drug pair is changed to "Deleted" and the current action reason is "FDB Deleted," with the value of the FDB issue date when the custom drug pair was deleted. The FDB issue date is the date associated with the FDB update file that includes the deletion.

# **Sample Modification Scenarios**

The following scenarios are examples of the types of modifications a typical user may perform. It is not a step-by-step guide in instructing users how to perform actual modifications. Sample steps are given, but these could differ based on the customizations being modified.

## **Duplicate Therapy Modification**

### **Process Steps**

Edit duplicate therapy allowance:

- 1. From the Home Page, click the Advanced Query/Customization tab.
- 2. Select "Duplicate Therapy" from the *Select a Concept* drop-down and select 'FDB' from the *Select VA, FDB, or Both* drop-down.
- 3. Build the query as follows: Fields=Description; Constraints=contains; Value=Tar.
- 4. Click the Query button.
- 5. Look at the query results at the bottom of the page.
- 6. Click the Open link for the desired class of drug.

7. You see the following:

Iome Advanced Query/Custom	MACY ENTERPRISE MIZATION SYSTEM zation Easy Search Drug Pair Lookup Reports Help	
uplicate Therapy		
		Page H
		Print Page
id	1026	
stom Dup Allowance <mark>(Required)</mark>	0	×
scription (Required)	Coal Tar Products	
quest Assigned To		×
erence Text		
		~
rent Action Reason (Required)		
		~
Customize		Print Page

- 8. Click the drop down arrow on Custom Dup Allowance (required).
- 9. Enter a Description (required).
- 10. Enter the Current Action Reason (required).
- 11. Add any reference text you think is needed (optional).
- 12. Click the Customize button.

## **Duplicate Therapy Approval**

Sample Case: After the duplication allowance has been edited for the above situation, you need to submit the request for approval. Assign this request to FOUR_APPROVER.

### **Process Steps**

- 1. From the Home page, look at My Request History.
- 2. Click the link to the NEW Duplicate Therapy requests.
- 3. Look at the query results at the bottom of the page.
- 4. Click the link for the desired class of drug (Topical Pine Tar).
- 5. Review the information.
- 6. Select the next business reviewer's name in Request Assigned To (optional) field.
- 7. Indicate the action reason in Current Action Reason (optional) field.
- 8. Click the Submit As Reviewed button.

## **Drug Interaction Research**

Sample Case: The chief of urology has been told by the Pfizer sales rep that the VA has no drug-drug interaction between sildenafil and tamsulosin. The chief insists that a significant (severity level 2) interaction be added to the system.

### **Process Steps for Severity Check, Case 1**

- 1. Check severity of an existing drug-drug interaction.
- 2. From the Home page, click the Drug Pair Lookup tab.
- 3. Fill in known information (Drug A: Sildenafil; Drug B: Tamsulosin).
- 4. Click the Query button.
- 5. Review the VA custom records and FDB record.
- 6. Note existing VA custom interaction between sildenafil and tamsulosin with severity level 2 and FDB interaction with severity level 3.
- 7. No action needed.

## **Drug Interaction Severity Change**

Sample Case: The FDA recently issued a black box warning stating that cyclosporine and tolterodine should never be used together due to risk of renal toxicity. This interaction is considered severity level 3 (moderate) by First Data Bank. Based on the issuance of this black box warning, the NDF support group is recommending the severity level be changed to 1 (critical). Create custom drug-drug pairs for this new VA custom drug-drug interaction.

## **Process Steps for Editing Case 1**

Edit the severity of an existing FDB drug interaction

- 1. From Home page, choose the Advanced Query/Customization tab.
- 2. Select "Drug-Drug Interaction" from the *Select a Concept* drop-down and select 'FDB' from the *Select VA, FDB, or Both* drop-down.
- 3. Build the Query: Column=Interaction Description; Constraints=contains; Value=cyclosporine.
- 4. Click the And button.
- 5. Build Query: Column=Interaction Description; Constraints=contains; Value=tolterodine.
- 6. Click the And button.
- 7. Click the Query button.
- 8. Look at the query results at the bottom of the page.
- 9. Click the Open link for desired Interaction Description.
- 10. Click the drop down arrow on Severity Level Code (required).
- 11. Select the new desired severity level code (1).
- 12. Indicate the action reason in the free text Current Action Reason (optional) field.
- 13. Click the Customize button.
- 14. Click Drug Pairs button.
- 15. Click plus sign on Select Drug Pairs to add to the above VA Custom interaction bar.
- 16. Click the radio button for "Drug Pairs from Corresponding FDB Interaction."
- 17. Select desired drug pairs to add to the custom interaction
- 18. Indicate the action reason in the free text Current Action Reason (optional) field.
- 19. Click the Customize button.

#### To Submit as Reviewed:

- 1. From the home page, look at My Assigned Requests for Review.
- 2. Click Drug-Drug Interaction.
- 3. Look at the query results at the bottom of the page.
- 4. Click the link for the desired interaction description (tolterodine/cyclosporine).
- 5. Click the Modify button.
- 6. Review the information.
- 7. Indicate the Action Reason in the free text Current Action Reason (optional) field.
- 8. Click the Submit For Review button.
- 9. Choose the Customization tab.
- 10. Click 'VA' under 'Drug-Drug Interaction.'
- 11. Build the Query: Column=Interaction Description; Constraints=contains; Value=tolterodine.

- 12. Click the And button.
- 13. Build the Query: Column=Interaction Description; Constraints=contains; Value=cyclosporine.
- 14. Click the And button.
- 15. Click the Query button.
- 16. Look at the query results at the bottom of the page.
- 17. Select the link for the desired Interaction Description.
- 18. Click the Modify button.
- 19. Indicate the Action Reason in the free text Current Action Reason (optional) field.
- 20. Click the Drug Pairs button at the bottom of the page.
- 21. Click the plus sign before 'Select Drug Pairs to add to the above VA Custom Interaction.'
- 22. Click the radio button for 'Select/Deselect all drug pairs from corresponding FDB interaction.'
- 23. Indicate the Action Reason in the free text Current Action Reason (optional) field.
- 24. Click the Submit for review button.

## **Drug Interaction Severity Change**

Sample Case: Over the past six months, several local VA facilities have reported adverse reactions (ADRs) involving the use of digoxin and metoclopramide resulting in digoxin toxicity requiring hospital admissions for management. This interaction is classified as severity level 3 (moderate) by FDB and therefore does not create an alert in the physician order entry process. The NDF support group has approved the change of the severity level from 3 to 2 (severe) to provide for order alerts and has assigned you to perform this task. Create custom drug-drug pairs for this new VA custom drug-drug interaction. Then submit the new interaction and drug pairs as reviewed.

## **Process Steps for Editing Case 2**

Edit the severity of an existing FDB drug interaction

- 1. From the Home page, choose the Advanced Query/Customization tab.
- 2. Select "Drug-Drug Interaction" from the *Select a Concept* drop-down and select 'FDB' from the *Select VA, FDB, or Both* drop-down.
- 3. Build the Query: Column=Interaction Description; Constraints=contains; Value=digoxin.
- 4. Click the And button.
- 5. Build the Query: Column=Interaction Description; Constraints=contains; Value=metoclopramide.
- 6. Click the And button.
- 7. Click the Query button.
- 8. Look at the query results at the bottom of the page.
- 9. Click the Active link for the desired Interaction Description.
- 10. Click the drop down arrow on Severity Level Code (required).
- 11. Select the desired new severity level code (2).

- 12. Indicate the action reason in the free text Current Action Reason (optional) field.
- 13. Click the Customize button.
- 14. Click Drug Pairs button.
- 15. Click the plus sign on Select Drug Pairs to add to the above VA Custom interaction bar.
- 16. Click the radio button for 'drug pairs from corresponding FDB interaction.'
- 17. Click the checkbox for 'Select/Deselect all drug Pairs from corresponding FDB interaction.'
- 18. Indicate the action reason in the free text Current Action Reason (optional) box
- 19. Click the Customize button.
- 20. From the Home page, look at My Request History.
- 21. Click the NEW Drug-Drug Interactions link.
- 22. Look at the query results at the bottom of the page.
- 23. Click on the Active link for the desired interaction description (digoxin/metoclopramide).
- 24. Click Drug Pairs button (Drug pairs should be submitted as reviewed prior to submitting the interaction for review)
- 25. Click the plus sign on Drug Pairs Bar
- 26. Click the checkbox for 'Select/Deselect All Drug Pairs Displayed from VA Custom Interaction'
- 27. Click the Submit as Reviewed button.
- 28. Click on the VA Interaction ID at top of page to navigate to Drug Interaction Detail page
- 29. Click the Submit as Reviewed button.

## **Remove Drug Pair from Interaction**

Sample Case: You have been asked to remove the drug pair SUMATRIPTAN NASAL/TRANYLCYPROMINE SULFATE ORAL from the existing VA custom drug-drug interaction SELECTED 5HT-1D AGONISTS/MAO INHIBITORS.

## **Process Steps**

Remove or add a drug pair from an existing VA custom drug-drug interaction.

- 1. Choose the Advanced Query/Customization tab.
- 2. Select "Drug-Drug Interaction" from the *Select a Concept* drop-down and select 'VA' from the *Select VA, FDB, or Both* drop-down.
- 3. Build the Query: Column=Interaction Description; Constraints=contains; Value=SELECTED 5HT.
- 4. Click the And button.
- 5. Click the Query button.
- 6. Look at the query results at the bottom of the page.
- 7. Select the Active link for the desired Interaction Description.

- 8. Click the Drug Pairs button at the bottom of page.
- 9. Click the plus sign on 'Drug Pairs' bar.
- 10. Click on the checkbox associated with Sumatriptan Nasal and Tranylcypromine Sulfate Oral.
- 11. Click the Submit for Delete button.
- 12. Alert another Approver that the drug pair needs to be deleted.

## **Create Professional Monograph**

Sample Case: Create a new VA custom monograph using the current FDB interaction monograph created for cyclosporine and tolterodine as the guide. Modify the FDB monograph severity level from level 3 to level 1 – contraindication.

## **Process Steps**

- 1. Choose the Advanced Query/Customization tab.
- 2. Select "Professional Monograph" from the *Select a Concept* drop-down and select 'FDB' from the *Select VA*, *FDB*, *or Both* drop-down.
- 3. Build the Query: Column=Monograph Title; Constraints=contains; Value=cyclosporine.
- 4. Select "And" from the drop-down.
- 5. Build the Query: Column=Monograph Title; Constraints=contains; Value=tolterodine.
- 6. Click the Query button.
- 7. Look at the results at the bottom of the page.

8. Click the link for the desired monograph title in the FDB table results. The Monograph is displayed, as shown.

	nization Easy Search Drug Pair Lookup Reports Help	
Professional Monograph		<u>ae Help</u>
	Print Page	
lonograph Title <mark>(Required)</mark>	Tolterodine/Cyclosporine	< >
equest Assigned To		*
everity Level <mark>(Required)</mark>	3-Moderate Interaction: Assess the risk to the patient and take action as needed.	~
echanism Of Action	Cyclosporine may inhibit the metabolism of tolterodine by CYP P-450-314.(1,2)	< >
inical Effects (Required)	The concurrent administration of tolterodine with cyclosporine may result in elevated levels of tolterodine and signs of toxicity.(1,2)	~
edisposing Factors	None determined.	~
atient Management	The manufacturer of tolterodine recommends that a maximum tolterodine dosage of 1 mg twice daily of the non extended release dosage form(1) or 2 mg once daily of the extended release dosage form(2) be used in patients receiving concurrent therapy with cyclosporine.	~
iscussion	In a study in eight subjects who were deficient in CYP P-450-2D6, the concurrent administration of tolterodine (2 mg) with ketoconazole (200 mg once daily for four days), another inhibitor of CYP P-450-3A4, resulted in a 60% decrease in tolterodine clearance.(3) Tolterodine AUC and Cmax increased 2.5-fold and 2-fold, respectively.(2)	
eference	<ol> <li>Detrol (tolterodine tartrate) US prescribing information. Pharmacia &amp; Upjohn Company April, 2009.</li> <li>Detrol LA (tolterodine tartrate) US prescribing information. Pharmacia &amp; Upjohn Company September, 2008.</li> <li>Brynne N, Forslund C, Hallen B, Gustafsson LL, Bertilsson L. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. Br J Clin Pharmacol 1999 Oct;48(4):564-72.</li> </ol>	< >
aference Text		
urrent Action Reason <mark>(Required)</mark>		
Customize	Print Page	

- 9. Change the Severity level to 1 Critical.
- 10. Indicate the action reason in the free text Current Action Reason (optional) field.
- 11. Click the Customize button.

# Reports

The Reports page displays a list of available reports in PECS. PECS Reports are essentially exported Excel spreadsheets that can be manipulated and formatted as the user sees fit.

Note, the Reports page is not visible to Requestor role users.

To run a report, click the link associated with it. You will be provided the option of opening the file directly or saving it to copy of the file to a location on your workstation (or accessible network location).

## **Customization Reports**

### **FDB Custom Dose Range Report**

The FDB Custom Dose Range Report contains active VA custom Dose Range records in an Approved status along with their corresponding FDB record data. The default file name is Dosing_Total_Customization_Report.xlsx.

## **FDB Custom Drug-Drug Interaction Report**

The FDB Custom Drug-Drug Interaction Report contains active VA custom Drug-Drug interaction records in an Approved status along with their corresponding FDB record data.

To Run the FDB Custom Drug-Drug Interaction Report

- 3. Click the Reports tab on the PECS Application Window.
- 4. Select the FDB Custom Drug-Drug Interaction Report radio button and click the Export button.
- 5. Select Open to view the exported file in Excel; select Save to save a copy of the file to a location on your workstation (or accessible network location). The file name is Ddiminteraction_Total_Customization_Report.xlsx.
- 6. If you selected Open, the report will automatically appear in the Excel application.

## **FDB Custom Duplicate Therapy Report**

The FDB Custom Duplicate Therapy Report contains active VA custom Duplicate Therapy records in an Approved status along with their corresponding FDB record data.

To Run the FDB Custom Duplicate Therapy Report

- 1. Click the Reports tab on the PECS Application Window.
- 2. Select the FDB Custom Duplicate Therapy Report radio button and click the Export button.
- 3. Select Open to view the exported file in Excel; select Save to save a copy of the file to a location on your workstation (or accessible network location). By default, the file name is Dtcat_Total_Customization_Report.xlsx.
- 4. If you selected Open, the report will automatically appear in the Excel application.

## **FDB Custom Professional Monograph Report**

The FDB Custom Professional Monograph Report contains active VA custom Professional Monograph records in an Approved status along with their corresponding FDB record data.

To run the FDB Custom Professional Monograph Report

- 1. Click the Reports tab on the PECS Application Window.
- 2. Select the FDB Custom Professional Monograph Report radio button and click the Export button.
- 3. Select Open to view the exported file in Excel; select Save to save a copy of the file to a location on your workstation (or accessible network location). By default, the file name is Monograph_Total_Customization_Report.xlsx.
- 4. If you selected Open, the report will automatically appear in the Excel application.

### **Deleted Monograph Customization Report**

The Deleted Monograph Customization Report contains active VA custom Drug-Drug interaction records in an Approved status that are associated with a deleted FDB Professional Monograph.

To Run the Deleted Monograph Customization Report

- 1. Click the Reports tab on the PECS Application Window.
- 2. Click the Deleted Monograph Customization Report link.
- 3. Select Open to view the exported file in Excel; select Save to save a copy of the file to a location on your workstation (or accessible network location). By default, the file name is Deleted_Monograph_Report.xlsx.
- 4. If you selected Open, the report will automatically appear in the Excel application.

### **Null Drug Pairs Customization Report**

The Null Drug Pairs Customization Report contains approved VA custom Drug-Drug Interactions that contain Drug Pairs with null Routed Generic #1 or Routed Generic #2 fields. If this report contains any entries, it is recommended that a user in the Administrator role initiate the Null Drug pair Removal Process.

To Run the Null Drug Pairs Customization Report

- 1. Click the Reports tab on the PECS Application Window.
- 2. Click the Null Drug Pairs Customization Report link.
- 3. Select Open to view the exported file in Excel; select Save to save a copy of the file to a location on your workstation (or accessible network location). By default, the file name is Deleted_Monograph_Report.xlsx.
- 4. If you selected Open, the report will automatically appear in the Excel application.

March 2013

## **FDB Comparison Reports**

The FDB Comparison Reports display the changes to existing data included in the Incremental FDB updates. They inform an approver or administrator of the latest FDB changes for the Duplicate Therapy, Drug-Drug Interaction, and Drug Pair concepts and provide data that helps them decide whether to change a custom record. The FDB Comparison Reports help an approver or administrator keep PECS customizations in sync with FDB changes.

FDB Comparison Reports display:

- Customized records in all action statuses that have differences between the PECS FDB data and the data in the Incremental FDB Update file.
- Un-customized records that have differences between the PECS FDB data and the data in the Incremental FDB Update file.
- Indications that an FDB record is scheduled to be deleted by DATUP.
- Lists of the drug pairs that will be added or deleted by DATUP.
- A "no data found" message if the Incremental FDB Update file has no changes to the FDB data.

### Structure of the FDB Comparison Report

DTReport.xlsx					-		-	23
A	В	С	D	E	F	G	н	1
FDB Update Received	20111202					Note: * indicates changed FDB data		
2	Action Status	Action Date	DATUP will delete	DTCID	Dup Allowance	Description		
3 VA Custom	Reviewed	2012-02-17		1210		0 Fat Absorption Decreasing Agents		
4 FDB After Update				1210	2*	Fat Absorption Decreasing Agents		
5 FDB Before Update				1210	0 *	Fat Absorption Decreasing Agents		
7 VA Custom	Modified	2012-02-17		1211		1 Procarbazine		
8 FDB After Update				1211		0 Procarbazine test *		
9 FDB Before Update				1211		0 Procarbazine *		
1 VA Custom	New	2012-02-17		1206		0 Manganese		
2 FDB After Update				1206	2*	Manganesee *		
3 FDB Before Update				1206	0*	Manganese *		
	Delete							
5 VA Custom	Reviewed	2012-02-17		1204	. (	0 Agents to Treat Resistant Gram Positive Organisms		
FDB After Update				1204	1*	Agents to Treat Resistant Gram Positive Organisms		
7 FDB Before Update				1204	0 *	Agents to Treat Resistant Gram Positive Organisms		
VA Custom	Deleted	2012-02-17		1202		0 Antiparkinson wh Ropinirole Formulations		
FDB After Update				1202		0 Antiparkinsonian Ropinirole Formulations test22 *		
FDB Before Update				1202		0 Antiparkinsonian Ropinirole Formulations *		
3								
◆ ▶ ▶ DT FDB Compa	rison Report 🥂 🐮	1/						•

Figure 46: Sample FDB Comparison Report - Duplicate Therapy

Each FDB Comparison Report lists the "FDB Update Received" date, which is the date listed in the Incremental FDB Update file.

Each report lists comparison sets of VA and FDB data. Each comparison set consists of at least three rows separated by a blue line. The three rows are:

VA Custom	Data in the Custom VA record. If the corresponding FDB record has
	not been customized, a "Not customized" message will be in the Action
	Status column and the rest of the row will be blank.
FDB After Update	Data in the Incremental FDB Update File. This data will be in the PECS
	database shortly after the incremental FDB update is done via DATUP.
FDB Before	Data in the PECS FDB record. This data will be replaced by the 'FDB
Update	After Update' data. If the FDB After Update and FDB Before Update
	data of the same type are different, they are marked with an asterisk (*)
	and colored red. Records that do not have any differences between the
	FDB Before Update and FDB After Update data of the same type are
	not listed in the report.

Each FDB Comparison Report has the following columns:

Action Status	The state of the associated VA record based on the most recent action performed. PECS compares FDB data with VA customizations in any Action Status, including Rejected or Deleted.						
Action Date	The date the current action (Action Status) was taken.						
DATUP will delete	YES in this column Indicates the associated FDB record will be deleted by DATUP. If the column is blank, the associated FDB record will not be deleted by DATUP. If the FDB record will be deleted by DATUP, only the FDB Interaction ID and DATUP will delete columns will be filled out in the FDB After						
	Update row. All the other columns will be blank.						

The reports are organized by type and the date of the FDB Incremental Update. Links to the reports are kept for eight weeks on the Reports page.

To run an FDB Comparison report, click the appropriate FDB Incremental Update date under the appropriate Report Heading.

		_	
)rug-Drug l	nteraction/	Drug Pairs	1
2012-05-31	2012-05-16	2012-05-09	2012-05-08
2012-05-07	2012-05-04	2012-04-27	
uplicate T	herapy		
2012-05-31	2012-05-16	2012-05-09	2012-05-08
	2012-05-04		

If there are no differences between the FDB After Update and FDB Before Update data of the same type in any of the records, a "No Data Found" message is printed on the FDB Comparison Report.

	DTReport.xlsx										23
	А	В	С	D	E	F	G	Н	I.	J	ĸ
1	Latest FDB Update:	20111202					Note: * indicates updated information				
2		Action Status	Action Date	DATUP will delete	DTCID	Dup Allowance	Description				
3	NO DATA FOUND										
4											
5											
6											
7											
8											
9											1
10											
11											
11 12 13 14											
13											
14											
15											
16											
17											
18											
19 20											
20											
21	DT FDB Comp	arison Report 🖉	2								► .

## **Drug-Drug Interaction/Drug Pair Report**

렌	DDIReport.xlsx							- 6	3 23
1	А	В	С	D	E	F	G		
1	FDB Update Received:	20111202					Note: * indicates changed FDB data		
2		Action Status	Action Date	DATUP will delete	VA Interaction ID	FDB Interaction ID	Interaction Description		
28	VA Custom	Rejected	2010-05-11		2002371	237	ERGOT ALKALOIDS/NITRATES		
29	FDB After Update			Yes		237			
30	FDB Before Update					237	ERGOT ALKALOIDS/NITRATES		
37 31	VA Custom	Deleted	2010-05-05		2012742	1274	STEROIDAL CONTRACEPTIVES/APREPITANT		
	FDB After Update	Deleteu	2010 00 00	Yes	2012/42	1274			
				105			STEROIDAL CONTRACEPTIVES/APREPITANT		
55							,		
36	VA Custom	Not customized							
37	FDB After Update			Yes		451			
38	FDB Before Update					451	THEOPHYLLINES/TACRINE		
40	VA Custom	Not customized							
41	FDB After Update			Yes		452			
42	FDB Before Update					452	CYCLOSPORINE/BARBITURATES		
	VA Custom	Not customized							
45	FDB After Update					1623	POSACONAZOLE/CIMETIDINE-HI *		
46	FDB Before Update					1623	POSACONAZOLE/CIMETIDINE *		
	VA Custom	Rejected	2010-05-17		2015651	1565	RANOLAZINE/QT PROLONGING AGENTS		
49	VA Custom	Rejected	2010-05-17		2015652	1565	RANOLAZINE/QT PROLONGING AGENTS		
14 4	DDI-DP FDB Com	parison Report /	FDB Interactio	on ID 16-DP / FDB I	Interaction ID 81-DP	FDB 4			►

The FDB Comparison Drug-Drug Interaction/Drug Pairs Report displays the changes to existing Drug-Drug Interactions included in the Incremental FDB updates. All Action Statuses are compared and are included in the report. The following data points are compared between the FDB update and the VA Drug-Drug Interaction records:

- Corresponding FDB Interaction ID
- Interaction Description
- Monograph ID
- Severity Level Code
- Clinical Effect 1
- Clinical Effect 2

- Deleted Drug Pairs
- Added Drug Pairs

The DDI-DP FDB Comparison Report contains two types of spreadsheets:

- The DDI-DP FDB Comparison Report gives information about the FDB comparisons and the associated VA custom records.
- FDB Interaction ID-DP gives information about the added or deleted drug pairs for a specific FDB record. Each FDB update record that has added or deleted drug pairs has its own FDB Interaction ID-DP spreadsheet.

r							
VA Interaction ID	A VA-assigned numerical identifier for the interaction.						
FDB Interaction ID	An FDB-assigned numerical identifier for the interaction.						
Interaction Description	A text description of the interaction.						
Monograph ID	A numerical identifier for the Professional Monograph associated with the interaction.						
Severity Level	A coded severity indicator. See Severity Level Codes for additional information.						
Clinical Effect 1	A three letter code describing the clinical effect. See Clinical Effect Codes for additional information.						
Clinical Effect 2	A three letter code describing the clinical effect. See Clinical Effect Codes.						
Drug Pairs	If a DDI has drug pairs scheduled to be added or deleted by DATUP, there will be a message, "See FDB Interaction ID <fdb Interaction ID number&gt;-DP." If a DDI record in the incremental FDB update file does not have added or drug pairs, this column will remain blank.</fdb 						

The following DDI-specific fields are included in the DDI-FDB Comparison Report spreadsheet:

Here are screen shots of a DDI Comparison Report with the "See FDB Interaction ID > DP" message and the tab that relates to it. Notice the highlighted row:

А	В	С	D	E	F	G
DB Update Received:	20111202					Note: * indicates changed FDB data
	Action Status	Action Date	DATUP will delete	VA Interaction ID	FDB Interaction ID	Interaction Description
A Custom	Modified	2012-03-09		2020866	1581	DROSPIRENONE/ACE INHIBITORS; ARBS
DB After Update					1581	DROSPIRENONE/ACE INHIBITORS; ARBS
DB Before Update					1581	DROSPIRENONE/ACE INHIBITORS; ARBS
/A Custom	New	2012-03-09		2020864	30786	SELECTED MACROLIDE ANTIBIOTICS/EPLERENONE (MONO DELETED)
/A Custom	New	2012-03-09		2020865	30786	SELECTED MACROLIDE ANTIBIOTICS/EPLERENONE (MONO DELETED)
DB After Update					30786	SELECTED MACROLIDE ANTIBIOTICS/EPLERENONE (MONO DELETED)
DB Before Update					30786	SELECTED MACROLIDE ANTIBIOTICS/EPLERENONE (MONO DELETED)
A Custom	New	2012-03-14		2020881	112	ANTIDIABETICS, ORAL/SALICYLATES
/A Custom	Modified	2012-03-15		2020882	112	ANTIDIABETICS, ORAL/SALICYLATES
DB After Update						ANTIDIABETICS, ORAL/SALICYLATES-Test *
DB Before Update					112	ANTIDIABETICS, ORAL/SALICYLATES *
/A Custom	Reviewed	2012-03-01		2020857	31809	QUINOLONES/THEOPHYLLINES
DB After Update					31809	QUINOLONES/THEOPHYLLINES
DB Before Update					31809	QUINOLONES/THEOPHYLLINES
/A Custom	Deleted	2012-01-23		2020502	250	CYCLOSPORINE/CALCIUM CHANNEL BLOCKERS
A Custom	Rejected	2012-01-23		2020502		CYCLOSPORINE/CALCIUM CHANNEL BLOCKERS
A Custom	Approved	2010-05-00		2002582		CYCLOSPORINE/CALCIUM CHANNEL BLOCKERS
DB After Update	Approved	2010-03-00		2002301		CYCLOSPORINE/CALCIUM CHANNEL BLOCKERS
DB Before Update						CYCLOSPORINE/CALCIUM CHANNEL BLOCKERS
ob before opdate					238	CICEOSPORINE/CAECIONI CHANNEE BEOCRERS
/A Custom	Delete Reviewed	2012-02-24		2020828	30120	CIPROFLOXACIN/AGOMELATINE
DB After Update		2012 02 21		2020020		CIPROFLOXACIN/AGOMELATINE-FUN *
DB Before Update						CIPROFLOXACIN/AGOMELATINE *
bb before opdate					50120	
DDI-DP FDB Con	nparison Report	FDB Interact	on ID 81-DP 🖌 FDB	Interaction ID 112-DP	FDB Interaction II	D 1565-DP 🖉

#### Figure 47: First Half of FDB Comparison Report for DDI

Aonograph ID	Severity Level	Clinical Effect 1	Clinical Effect 2	Drug Pairs
Drospirenone/Ace Inhibitors; ARBs - 1581	1	3 Decreased effect of the former drug		
Cyclosporine/Calcium Channel Blockers - 258 *	3	3 Additive side effects from both drugs		
Drospirenone/Ace Inhibitors; ARBs - 1581 *		3 Additive side effects from both drugs		
Eplerenone/Selected Macrolide Antibiotics (mono deleted03/01/2012) - 1214	1	3 Increased effect of the latter drug		
Eplerenone/Selected Macrolide Antibiotics (mono deleted03/01/2012) - 1214		2 Increased effect of the latter drug		
Eplerenone/Selected Macrolide Antibiotics (mono deleted03/01/2012) - 1214	1	3 Adverse reaction of the former drug *		
Eplerenone/Selected Macrolide Antibiotics (mono deleted03/01/2012) - 1214		3 Increased effect of the latter drug *		
Antidiabetics, Oral/Salicylates - 112		3 Increased effect of the former drug		
Antidiabetics, Oral/Salicylates - 112		2 Increased effect of the former drug	6	
Antidiabetics, Oral/Salicylates - 112	1*	Increased effect of the former drug	1	See FDB Interaction ID 112-DP
Antidiabetics, Oral/Salicylates - 112	3*	Increased effect of the former drug		
Theophyllines/Quinolones - 191		1 Increased effect of the latter drug	Adverse reaction of the former drug	7
Theophyllines/Quinolones - 191		2 Increased effect of the latter drug	Adverse reaction of the former drug *	
Theophyllines/Quinolones - 191		2 Increased effect of the latter drug	. /	
Cyclosporine/Calcium Channel Blockers - 258 Cyclosporine/Calcium Channel Blockers - 258 Cyclosporine/Calcium Channel Blockers - 258 Cyclosporine/Calcium Channel Blockers - 258 Cyclosporine/Calcium Channel Blockers - 258 VA customized: Decreased Effects (Significant) (DEL2) - 150033 (custom) Ranolazine/QT Prolongina Ageme - 5665 * Agemetaline/Ciprofloxacin - 1880 *	1* 3*	a Labeling conflicts between countries or products a Labeling conflicts between countries or products a Increased effect of the former drug a Adverse reaction of the former drug a Increased effect of the latter drug increased effect of the latter drug increased effect of the latter drug	Additive the effects from both drugs *	
	/			
DDI-DP FDR Comparison Report FD8 Interaction ID 81-DP FD8 Interact		DB Interaction ID 1565-DP	Charles - Charle	

Figure 48: Second Half of FDB Comparison Report for DDI

If the latest FDB update contains added or deleted drug pairs, these will be displayed on separate tabs titled "FDB Interaction ID <FDB Interaction ID number>-DP". Here are the contents of the FDB Interaction ID tab, i.e., the drug pairs that have been updated by FDB:

1	l	Note: * In	dicates new Routed Ger	eric 1 or 2 Descriptio	on		
2 Routed Generic 1 Description			eneric 2 Description			DATUP action	
							- 7
3 GLIPIZIDE ORAL		ASPIRIN/D	IPHENHYDRAMINE/SOD	IUM BICARBONATE/	CITRIC ACID ORAL	Delete	- 2
							- 1
4 FUROSEMIDE IN 0.9 % SODIUM CHI	LORIDE INTRAVENOUS	CAPTOPRI	L/HYDROCHLOROTHIAZI	DEORAL		Add	
5 FUROSEMIDE IN 0.9 % SODIUM CHI		CARTORN				Add	- 4
6	LONIDE INTRAVENOUS	CAFTOFIL	LONAL			Auu	-7
7							
8							
9							Ţ
10							
11							_}
12							
13							<b>-</b> X
14							-₹
15							
16							
17 18							-4
19							-4
20							-
21							-1
22							Ŧ
23							-4
24							
25							-7
26							T
27							٦.
28							
29							- (
30							
31							
32							
33							_₹
34							
35							
36							-9
DDI-DP FDB Comparison Rep	port 📝 FDB Interaction I	ID 81-DP	FDB Interaction ID 11	2-DP FDB Interacti	on ID 1565-DP		
Ready	and a second as		and the second second	at march	-	- and deal-	J

If an FDB record has been customized multiple times, all of the customizations will be listed in the report, as shown below:

	А	8	C	0	5	,	U	
1 F	DB Update Received:	20111202					Note: * indicates changed FDB data	
2		Action Status	Action Date	9	A Interaction ID	FDB Interaction ID	Interaction Description	Monograph ID
54 V	/A Custom	Approved	2010-05-04	Multiple VA custom updates and their various	2011561	1156	INTERLEUKIN-1 BLOCKER/TUMOR NECROSIS FACTOR (TNF) INHIBITORS	Interleukin-1 Blocker/Tumor Necrosis Factor (TNF)Inhibitors - 1156
55 F	DB After Update			action statuses		1156	INTERLEUKIN-1 BLOCKER/TUMOR NECROSIS FACTOR (TNF) INHIBITORS	Interleukin-1 Blocker/Tumor Necrosis Factor (TNF)Inhibitors - 1156
56 F	DB Before Update					1156	INTERLEUKIN-1 BLOCKER/TUMOR NECROSIS FACTOR (TNF) INHIBITORS	Interleukin-1 Blocker/Tumor Necrosis Factor (TNF)Inhibitors - 1156
58 V	A Custom	Modified	2012-03-05		2020866	1581	DROSPIRENONE/ACE INHIBITORS; ARBS	Drospirenone/Ace Inhibitors; ARBs - 1581
	DB After Update DB Before Update						DROSPIRENONE/ACE INHIBITORS; ARBS DROSPIRENONE/ACE INHIBITORS; ARBS	Cyclosporine/Calcium Channel Blockers - 258 * Drospirenone/Ace Inhibitors; ARBs - 1581 *
63 V 64 F	/A Custom /A Custom DB After Update DB Batore Update	New	012-03-09 2012-03-09		2020864 2020865	30786 30786	SELECTED MACROLIDE ANTIBIOTICS/EPLERENONE (MONO DELETED) SELECTED MACROLIDE ANTIBIOTICS/EPLERENONE (MONO DELETED) SELECTED MACROLIDE ANTIBIOTICS/EPLERENONE (MONO DELETED) SELECTED MACROLIDE ANTIBIOTICS/EPLERENONE (MONO DELETED)	Eplerenone/Selected Macrolide Antibiotics (mono deleted03/01/2012) - Eplerenone/Selected Macrolide Antibiotics (mono deleted03/01/2012) - Eplerenone/Selected Macrolide Antibiotics (mono deleted03/01/2012) - Eplerenone/Selected Macrolide Antibiotics (mono deleted03/01/2012) -
68 V 69 F		New Modified	2012-03-14 2012-03-15		2020881 2020882	112	ANTIDIABETICS, ORAL/SALICYLATES ANTIDIABETICS, ORAL/SALICYLATES ANTIDIABETICS, ORAL/SALICYLATES-Test * ANTIDIABETICS, ORAL/SALICYLATES *	Antidiabetics, Oral/Salicylates - 112 Antidiabetics, Oral/Salicylates - 112 Antidiabetics, Oral/Salicylates - 112 Antidiabetics, Oral/Salicylates - 112
73 F	/A Custom DB After Update DB Before Update	Reviewed	2012-03-01		2020857	31809	QUINOLONES/THEOPHYLLINES QUINOLONES/THEOPHYLLINES QUINOLONES/THEOPHYLLINES	Theophyllines/Quinolones - 191 Theophyllines/Quinolones - 191 Theophyllines/Quinolones - 191
77 V 78 V	/A Custom	Deleted Rejected Approved	2012-01-23 2010-05-06 2010-05-06		2020502 2002582 2002581	258 258	CYCLOSPORINE/CALCIUM CHANNEL BLOCKERS CYCLOSPORINE/CALCIUM CHANNEL BLOCKERS CYCLOSPORINE/CALCIUM CHANNEL BLOCKERS CYCLOSPORINE/CALCIUM CHANNEL BLOCKERS	Cyclosporine/Calcium Channel Blockers - 256 Cyclosporine/Calcium Channel Blockers - 258 Cyclosporine/Calcium Channel Blockers - 258 Cyclosporine/Calcium Channel Blockers - 258
	DB Before Update						CYCLOSPORINE/CALCIUM CHANNEL BLOCKERS	Cyclosporine/Calcium Channel Blockers - 258

Routed Generic 1 Description	The Routed Generic Description of Drug 1 in the Drug Pair
Routed Generic 2 Description	The Routed Generic Description of Drug 2 in the Drug Pair
DATUP action	The action that DATUP will perform. DATUP will either add the drug pair to the PECS database or delete it from PECS.

The following fields are included in the FDB Interaction ID-DP spreadsheet:

**Note:** A DDI record that is not listed on the DDI-DT FDB Comparison Report spreadsheet can still have added or deleted drug pairs listed in the latest incremental FDB update file. In that case, the drug pair information is just listed on an FDB Interaction ID-DP spreadsheet.

## **Duplicate Therapy Report**

	А	В	С	D	E	F	G
L	FDB Update Received:	20120525					Note: * indicates changed FDB data
		Action Status	Action Date	DATUP will delete	DTCID	Dup Allowance	Description
	VA Custom	Approved	2012-05-07		1338	1	Antidiarrheal Formulations with Gut Flora Microorganisms
	FDB After Update			Yes	1338		
	FDB Before Update				1338	0	Antidiarrheal Formulations with Gut Flora Microorganisms
7	VA Custom	Approved	2012-04-16		376	1	Stimulant Laxatives
	FDB After Update			Yes	376		
	FDB Before Update				376	0	Stimulant Laxatives
1	VA Custom	Reviewed	2012-02-23		375	0	Steroids - Mouth
2	FDB After Update			Yes	375		
3	FDB Before Update				375	0	Steroids - Mouth
5	VA Custom	Modified	2012-02-23		378	1	Sulfonamides
6	FDB After Update			Yes	378		
7	FDB Before Update				378	0	Sulfonamides
9	VA Custom	Reviewed	2012-04-13		1132	0	Thrombin Inhibitors (Non-Heparinoid)
D	FDB After Update			Yes	1132		
1	FDB Before Update				1132	0	Thrombin Inhibitors (Non-Heparinoid)
3	VA Custom	Modified	2012-02-23		1213	1	Dantrolene
4	FDB After Update			Yes	1213		
5	FDB Before Update				1213	0	Dantrolene
7	VA Custom	Modified	2012-04-09		1456	1	Orotic Acid
8	FDB After Update			Yes	1456		
9	FDB Before Update				1456	0	Orotic Acid
	VA Custom	Reviewed	2012-02-23		1310	1	Lymphocyte Immune Globulin
2	FDB After Update			Yes	1310		
3	FDB Before Update				1310	0	Lymphocyte Immune Globulin
	VA Custom	Modified	2012-02-23		1319	2	Typhoid Vaccine
6	FDB After Update			Yes	1319		
7	FDB Before Update				1319	0	Typhoid Vaccine
-	VA Custom	Not customized					
0	FDB After Update			Yes	1564		
1	FDB Before Update				1564	0	Malic Acid
	VA Custom	New	2012-02-21		1131	0	Nasal Antihistamines
4	FDB After Update			Yes	1131		
5	FDB Before Update				1131	0	Nasal Antihistamines
-	► ► DT FDB Comparis	on Report 🏾 🐲	7			-	4

Figure 49: FDB Comparison Report - Duplicate Therapy

The Duplicate Therapy FDB Comparison Report displays the differences between the PECS FDB data and the data in the Incremental FDB Update file for the Duplicate Therapy (DT) concept. This report displays the following DT-specific data:

DTCID	Duplicate Therapy Control ID. A numerical identifier for the DT FDB and VA records.
Dup Allowance	Duplicate Allowance. The number of drugs performing the same function before a warning is issued.
Description	A description (name) of the drug that is the basis of the DT record.

## **Dose Range Report**

Not implemented in this release.

(This page left blank for two-sided copying.)